<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1405245285
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2001
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        RUMAFEN
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        DICLOFENAC SODIUM
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        36
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        21.05
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M02AA15
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Diclofenac sodium, the active ingredient in RUMAFEN, is one of a<br />group of medicines called non-steroidal anti-inflammatory drugs<br />(NSAIDs). NSAIDs reduce pain and inflammation. RUMAFEN<br />tablets relieve pain, reduce swelling and ease inflammation in<br />conditions affecting the joints , muscles and tendons including :<br />&bull; Rheumatoid arthritis, osteoarthritis, acute gout (painful<br />inflammation of the joints especially in the feet and hands),<br />ankylosing spondylitis (form of spinal arthritis).<br />&bull; Backache, sprains and strains, soft tissue sports injuries, frozen<br />shoulder, dislocations and fractures.<br />&bull; Conditions affecting the tendons for example, tendonitis,<br />tenosynovitis,bursitis.<br />They are also used to treat pain and inflammation associated with<br />dental and minor surgery.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; you are allergic (hypersensitive) to diclofenac sodium, aspirin,<br />ibuprofen or any other NSAID, or any of the other ingredients of<br />RUMAFEN tablets (these are listed under section 6 &quot;FURTHER<br />INFORMATION&quot; of the leaflet). Signs of a hypersensitivity<br />reaction include swelling of the face and mouth (angioedema),<br />breathing problems, Chest pain, runny nose , skin rash or any<br />other allergic type reaction<br />&bull; you have now, or have ever had, a stomach (gastric) or duodenal<br />(peptic) ulcer, or bleeding in the digestive tract (this can include<br />blood in vomit, bleeding when emptying bowels, fresh blood in<br />faeces or black, tarry faeces)<br />&bull; you have had stomach or bowel problems after you have taken<br />other NSAIDs.<br />&bull; you have severe heart, kidney or liver failure.<br />&bull; you have established heart disease and/or cerebrovascular<br />disease, e.g., if you have had a heart attack, stroke, mini-stroke<br />(TIA) or blockages to blood vessels to the heart or brain or an<br />operation to clear or bypass blockages.<br />&bull; you have or have had problems with your blood circulation<br />(peripheral arterial disease).<br />&bull; you are more than six months pregnant.<br />Warnings and precautions<br />Talk to your doctor or pharmacist before taking Rumafen 50<br />mg Tablets if:<br />&bull; you suffer from any stomach or bowel disorders including<br />ulcerative colitis or Crohn&rsquo;s disease.<br />&bull; you have kidney or liver problems, or you are elderly.<br />&bull; you have a condition called porphyria.<br />&bull; you suffer from any blood or bleeding disorder. If you do, your<br />doctor may ask you to go for regular check-ups while you are<br />taking these tablets.<br />&bull; you ever had asthma, seasonal allergic rhinitis, swelling of the<br />nasal mucosa (nasal polyps), chronic pulmonary diseases or<br />infections of the respiratory tract.<br />&bull; you are breast feeding.<br />&bull; you have angina, blood clots, high blood pressure, raised<br />cholesterol or raised triglycerides.<br />&bull; you have heart problems or if you had a stroke or you think you<br />might be at risk of these conditions (for example, if you have high<br />blood pressure, diabetes or high cholesterol or are a smoker)<br />&bull; you have diabetes.<br />&bull; you smoke.<br />&bull; you have Systemic Lupus Erythematosus SLE (inflammatory,<br />auto-immune disorder which causes symptoms such as joint<br />pain, joint inflammation, skin rashes, fever) or any similar<br />condition.<br />&bull; you have an intolerance to some sugars such as lactose (these<br />tablets contain lactose)<br />Tell your doctor if you recently had or you are going to have a<br />surgery of the stomach or intestinal tract before taking RUMAFEN<br />50mg tablets, as DICLOFENAC can sometimes worsen wound<br />healing in your gut after surgery.<br />Tell your doctor or pharmacist if you have any of these<br />conditions because Rumafen 50 mg tablets might not be the<br />right medicine for you.<br />Children<br />These tablets are not suitable for children aged under 12.<br />Other medicines and Rumafen 50 mg Tablets<br />Some medicines can interfere with your treatment. Please tell<br />your doctor or pharmacist if you are taking or have recently taken<br />any other medicines, including medicines obtained without a<br />prescription, especially any of the following:<br />&bull; Medicines to treat diabetes.<br />&bull; Anticoagulants (blood thinning tablets like warfarin)<br />&bull; Diuretics (water tablets)<br />&bull; Lithium (used to treat some mental problems)<br />&bull; Methotrexate (for treatment of some inflammatory diseases and<br />some cancers)<br />&bull; Ciclosporin and tacrolimus (used to treat some inflammatory<br />diseases and after transplants)<br />&bull; Trimethoprim (a medicine used to prevent or treat urinary tract<br />infections)<br />&bull; Quinolone antibiotics (for infections)<br />&bull; Any other NSAID or COX-2 (cyclo-oxygenase-2) inhibitor, for<br />example aspirin or ibuprofen<br />&bull; Mifepristone (a medicine used to terminate pregnancy)<br />&bull; Cardiac glycosides (for example digoxin), used to treat heart<br />problems.<br />&bull; Medicines known as SSRIs (used to treat depression)<br />&bull; Oral steroids (an anti-inflammatory drug)<br />&bull; Medicines used to treat heart conditions or high blood pressure,<br />for example beta blockers or ACE inhibitors.<br />&bull; Voriconazole (a medicine used to treat fungal infections).<br />&bull; Phenytoin (a medicine used to treat seizures)<br />&bull; Colestipol/cholestyramine (used to lower cholesterol)<br />Always tell your doctor or pharmacist about all the medicines you<br />are taking. This means medicines you have bought yourself as well<br />as medicines on prescription from your doctor.<br />Taking RUMAFEN 50 mg Tablets with food and drink<br />Take this medicine with or after food.<br />Pregnancy and breast-feeding<br />Do not take RUMAFEN if you are in the last 3 months of pregnancy<br />because it may harm your unborn baby or cause problems at birth.<br />It can cause kidney and heart problems for your unborn baby.<br />It may affect the tendency for you and your baby to bleed and<br />cause labor to be later or later than expected.<br />You should not take RUMAFEN during the first 6 months of<br />pregnancy unless absolutely necessary and advised by your<br />doctor. If you need treatment during this period or while you are<br />trying to get pregnant, the lowest dose should be used for the&nbsp;shortest possible time. If taken for more than a few days from<br />20 weeks of pregnancy onwards. RUMAFEN can cause kidney<br />problems in your unborn baby, which could lead to low levels<br />of the amniotic fluid that surrounds the baby (oligohydramnios)<br />or narrowing of the blood vessels (ductus arteriosus) in the<br />baby&#39;s heart. If you need treatment for longer than a few days,<br />your doctor may recommend additional monitoring.<br />Driving and using machines<br />Very occasionally people have reported that diclofenac sodium<br />tablets have made them feel dizzy, tired or sleepy. Problems with<br />eyesight have also been reported. If you are affected in this way,<br />you should not drive or operate machinery.<br />Other special warnings<br />&bull; You should take the lowest effective dose of Diclofenac Sodium<br />for the shortest possible time particularly if you are underweight<br />or elderly.<br />&bull; There is a small increased risk of heart attack or stroke when<br />you are taking any medicine like Diclofenac Sodium. The risk<br />is higher if you are taking high doses for a long time. Always<br />follow the doctor&rsquo;s instructions on how much to take and how<br />long to take it for.<br />&bull; If at any time while taking Diclofenac Sodium you experience any<br />signs or symptoms of problems with your heart or blood vessels<br />such as chest pain, shortness of breath, weakness or slurring of<br />speech, contact your doctor immediately.<br />&bull; Whilst you are taking these medicines your doctor may want to<br />give you a check-up from time to time.<br />&bull; If you have a history of stomach problems when you are taking<br />NSAIDs, particularly if you are elderly, you must tell your doctor<br />straight away if you notice any unusual symptoms.<br />&bull; Because it is an anti-inflammatory medicine, Diclofenac Sodium<br />tablets may reduce the symptoms of infection, for example,<br />headache, and high temperature. If you feel unwell and need<br />to see a doctor, remember to tell him or her that you are taking<br />Diclofenac Sodium tablets.<br />These tablets are not suitable for children aged under 12.<br />Rumafen tablets contains Lactose<br />Rumafen 50 mg contains lactose. If you have been told by your<br />doctor that you have an intolerance to some sugars, contact your<br />doctor before taking this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>when to take them. Always take RUMAFEN exactly as your doctor<br />has told you. You should check with your doctor or pharmacist if<br />you are not sure. Keep taking your tablets for as long as you have<br />been told, unless you have any problems. In that case, check with<br />your doctor. Take the tables with or after food.<br />Swallow the tablets whole with a glass of water. DO NOT crush<br />or chew the tablets.<br />The usual dose is:<br />Adults:<br />75 to 150 mg daily in two or three divided doses.<br />The number of tablets which you take will depend on the strength<br />the doctor has given you.<br />Elderly:<br />The lowest effective dose should be used. Your doctor may advise<br />you to take a dose that is lower than the usual adult dose if you<br />are elderly. Your doctor may also want to check closely that the<br />Diclofenac Sodium tablets are not affecting your stomach.<br />Children:<br />These tablets are not suitable for children aged under 12.<br />The doctor may also prescribe another drug to protect the<br />stomach to be taken at the same time, particularly if you have had<br />stomach problems before, or if you are elderly, or taking certain<br />other drugs as well.<br />If you take more RUMAFEN 50 mg Tablets than you should<br />If you, or anyone else, accidentally takes too much RUMAFEN,<br />tell your doctor or go to your nearest hospital casualty department<br />immediately. Take your medicine pack with you so that people can<br />see what you have taken.<br />Symptoms of an overdose can include: headache, nausea (feeling<br />sick), vomiting, abdominal pain, stomach or intestinal bleeding,<br />rarely diarrhea, disorientation, excitation, coma, drowsiness,<br />dizziness, ringing in the ears, fainting, or occasionally convulsions<br />(seizures, uncontrolled fits).<br />If you forget to take RUMAFEN 50 mg Tablets<br />It is important that you do not miss a dose. If you forget to take<br />a dose, take one as soon as you remember. If it is nearly time<br />for your next dose, just take the next dose and forget about the<br />one you missed. Do NOT take a double dose to make up for a<br />forgotten tablet. Do not take more than 150 mg in 24 hours. If you<br />have trouble remembering to take the tablets, tell your doctor or<br />pharmacist. If you have any further questions on the use of this<br />product, ask your doctor or pharmacist.<br />If you have any further questions on the use of this medicine,<br />ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, RUMAFEN can cause side effects, although not<br />everybody gets them.<br />Some side effects can be serious<br />STOP TAKING RUMAFEN and seek immediate medical help<br />if you notice :<br />&bull; Sudden and crushing chest pain (signs of myocardial infarction<br />or heart attack)<br />&bull; Breathlessness, difficulty breathing when lying down, swelling of<br />the feet or legs (signs of heart failure)<br />&bull; Sudden weakness or numbness in the face, arm or leg especially<br />on one side of the body, sudden loss or disturbance of vision;<br />sudden difficulty in speaking or ability to understand speech;<br />sudden migraine-like headaches which happen for the first time,<br />with or without disturbed vision. These symptoms can be an<br />early sign of a stroke.<br />&bull; Stomach pain, indigestion, heartburn, wind, nausea (feeling sick)<br />or vomiting (being sick)<br />&bull; Any sign of bleeding in the stomach or intestine, for example,<br />when emptying your bowels, blood in vomit or black, tarry<br />faeces<br />&bull; Allergic reactions which can include skin rash, itching, bruising,<br />painful red areas, peeling or Blistering<br />&bull; Wheezing or shortness of breath (bronchospasm)<br />&bull; Swollen face, lips, hands or fingers<br />&bull; Yellowing of your skin or the whites of your eyes<br />&bull; Persistent sore throat or high temperature<br />&bull; An unexpected change in the amount of urine produced and/<br />or its appearance.<br />&bull; Mild cramping and tenderness of the abdomen, starting shortly<br />after the start of the treatment with Diclofenac Sodium and<br />followed by rectal bleeding or bloody diarrhea usually within 24<br />hours of the onset of abdominal pain.<br />&bull; Stevens Johnson syndrome (serious illness with blistering of the<br />skin, mouth, eyes and genitals)<br />If you notice that you are bruising more easily than usual or have<br />frequent sore throats or infections, tell your doctor.<br />Tell your doctor immediately if you notice the following:<br />&bull; Chest pain, which can be a sign of a potentially serious allergic<br />reaction called Kounis syndrome.<br />The side effects listed below have also been reported.<br />Common side effects (These may affect between 1 and 1 in 10<br />in every 100 patients):<br />&bull; Stomach pain, heartburn, nausea, vomiting, diarrhea, indigestion,<br />wind, loss of appetite<br />&bull; Headache, dizziness, vertigo<br />&bull; Skin rash or spots<br />&bull; Raised levels of liver enzymes in the blood<br />Uncommon side effects (These may affect between 1 and 10<br />in every 1000 patients):<br />&bull; Fast or irregular heart beat (palpitations), chest pain, heart<br />disorders, including heart attack or breathlessness, difficulty<br />breathing when lying down, or swelling of the feet or legs (signs<br />of heart failure), especially if you have been taking a higher dose<br />(150 mg per day) for a long period of time.<br />Rare side effects (These may affect between 1 in every 1,000 to<br />1 in every 10,000 patients):<br />&bull; Stomach ulcers or bleeding (there have been very rare reported<br />cases resulting in death, particularly in the elderly)</p><p>Gastritis (inflammation, irritation or swelling of the stomach<br />lining)<br />&bull; Vomiting blood<br />&bull; Diarrhoea with blood in it or bleeding from the back passage<br />&bull; Black, tarry faeces or stools<br />&bull; Drowsiness, tiredness<br />&bull; Hypotension (low blood pressure, symptoms of which may<br />include faintness, giddiness or light headedness)<br />&bull; Skin rash and itching<br />&bull; Fluid retention, symptoms of which include swollen ankles<br />&bull; Liver function disorders, including hepatitis and jaundice<br />&bull; Asthma (symptoms may include wheezing, breathlessness,<br />coughing and a tightness across the chest)<br />Very rare side effects (These may affect less than 1 in every<br />10,000 patients):<br />Effects on the nervous system:<br />Inflammation of the lining of the brain (meningitis), tingling or<br />numbness in the fingers, tremor, visual disturbances such as<br />blurred or double vision, taste changes, hearing loss or impairment,<br />tinnitus (ringing in the ears), sleeplessness, nightmares, mood<br />changes, depression, anxiety, irritability, mental disorders,<br />disorientation and loss of memory, fits, headaches together with<br />a dislike of bright lights, fever and a stiff neck.<br />Effects on the stomach and digestive system:<br />Constipation, inflammation of the tongue, mouth ulcers,<br />inflammation of the inside of the mouth or lips, taste changes,<br />lower gut disorders (including inflammation of the colon or<br />worsening of ulcerative colitis or Crohn&rsquo;s disease), inflammation<br />of the pancreas.<br />Effects on the heart, chest or blood:<br />Hypertension (high blood pressure),<br />hypotension (low blood pressure, symptoms<br />of which may include faintness, giddiness<br />or light headedness), inflammation of blood<br />vessels (vasculitis), inflammation of the lung<br />(pneumonitis), blood disorders (including<br />anaemia).<br />Effects on the liver or kidneys:<br />Kidney or severe liver disorders including liver<br />failure, presence of blood or protein in the urine<br />Effects on skin or hair:<br />Facial swelling, serious skin rashes including<br />Stevens-Johnson syndrome, Lyell&rsquo;s syndrome<br />and other skin rashes which may be made<br />worse by exposure to sunlight. Hair loss.<br />Effects on the reproductive system:<br />Impotence.<br />Other side effects that have also been reported with unknown<br />frequency include:<br />Throat disorders, confusion, hallucinations, malaise<br />(generalfeeling of discomfort), inflammation of the nerves in the<br />eye,disturbances of sensation.<br />Medicines such as diclofenac may be associated with a small<br />increased risk of heart attack or stroke.<br />Do not be alarmed by this list - most people take Diclofenac<br />Sodium Tablets without any problems.<br />If any of the side effects becomes serious, or if you notice side<br />effects not listed in this leaflet, please tell your doctor.<br />He/she may want to give you a different medicine.<br />If any of the side effects becomes serious, or if you notice side<br />effects not listed in this leaflet, please tell your doctor or the<br />pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&bull; Keep out of the sight and reach of children.<br />&bull; Store in original package in order to protect from light.<br />&bull; Store below 30 &deg;C.<br />&bull; Do not use RUMAFEN 50 mg Tablets after the expiry date<br />printed on the pack. The expiry date refers to the last day of<br />that month.<br />&bull; Do not throw any medicines via wastewater or household waste.<br />Ask your pharmacist how to throw away medicines you no<br />longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>What RUMAFEN 50 mg Tablets contain<br />Each Enteric Coated tablet contains Diclofenac Sodium (BP) 50 mg.<br />Other ingredients: Microcrystalline Cellulose (PH101), Lactose,<br />Maize Starch, Povidone (K30), Magnesium Stearate and enteric<br />coating materials (Eudragit L30D-55, Triethyl Citrate, Titanium<br />Dioxide and Purified Talc).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Each Enteric Coated tablet looks White to off white, enteric
coated, biconvex, circular tablets with RP engraved on one side
and 2 on the other side.
Pack:
Packs contain (20) Enteric Coated tablets of RUMAFEN 50 mg.
Each (transparent PVC-PVDC film/ Alu) blister contains 10 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)<br />P.O.Box 442, Riyadh 11411<br />Fax: +966 11 265 0505<br />Email: contact@riyadhpharma.com<br />For any information about this medicinal product, please contact<br />the local representative of marketing authorisation holder:<br />Saudi Arabia<br />Marketing department<br />Riyadh<br />Tel: +966 11 265 0111<br />Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in (10/2022)
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ديكلوفيناك الصوديوم، هو المادة الفعالة في رومافن، وهو واحد من مجموعة من<br />الأدوية تسمى العقاقير غير الستيرويدية المضادة للالتهابات )المسكنات(. المسكنات<br />تقلل من الألم والالتهاب. أقراص رومافن تخفف الألم، تقلل التورم وتخفف الالتهاب<br />في الحالات التي تؤثر على المفاصل والعضلات و الأوتار و تشمل :<br />&bull;التهاب المفاصل الروماتويدي والتهاب المفاصل والنقرس الحاد )التهاب مؤلم في<br />المفاصل وخاصة في القدمين واليدين(، التهاب الفقار اللاصق )شكل من أشكال<br />التهاب المفاصل في العمود الفقري(<br />&bull;ألم الظهر، والالتواء والسلالات، والإصابات الرياضية في الأنسجة اللينة، الكتف<br />المتجمدة، الخلع والكسور.<br />&bull;الحالات التي تؤثر على الأوتار على سبيل المثال، التهاب الأوتار، التهاب غمد<br />الوتر، الالتهاب الكيسي.<br />كما أنه يستخدم لعلاج الألم والالتهابات المرتبطة بجراحة الأسنان والجراحات<br />البسيطة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول أقراص رومافن 50 ملجم إذا:<br />&bull;كان لديك حساسية )تحسس( لديكلوفيناك الصوديوم، والأسبرين والايبوبروفين<br />أو أي من المسكنات الأخرى، أو أي من المكونات الأخرى لأقراص رومافن )<br />المدرجة في القسم 6 &quot;معلومات إضافية&quot; من هذه النشرة(. علامات تفاعل فرط<br />الحساسية تشمل تورم الوجه والفم )الوذمة الوعائية( ، ومشاكل في التنفس ،و<br />ألم بالصدر ،و رشح الأنف ، والطفح الجلدي أو أي نوع آخر من الحساسية.<br />&bull;لديك الآن ، أوكان لديك في أي وقت مضى ، قرحة المعدة أو قرحة الاثني عشر<br />، أو نزيف في الجهاز الهضمي )وهذا يمكن أن يشمل دم في القيء ، ونزيف عند<br />إفراغ الأمعاء ، و دم جديد في البراز أو براز أسود )بلون القطران(.<br />&bull; كنت تعاني من مشاكل في المعدة أو الأمعاء بعد تناول مضادات<br />الالتهاب غير الستيرويدية الأخرى<br />&bull;كان لديك قصور شديد في القلب أو الكلى أو الكبد<br />&bull;كان لديك أمراض القلب و / أو الأمراض القلبية الوعائية ، على سبيل المثال ،<br />أو انسداد )TIA( إذا كنت تعاني من نوبة قلبية أو سكتة دماغية أو ضربة دماغية<br />في الأوعية الدموية إلى القلب أو المخ أو أجريت عملية لإزالة أو تخطي الانسداد.<br />&bull;لديك أو كان لديك مشاكل في الدورة الدموية )مرض الشرايين الطرفية(.<br />&bull;اذا كنتِ حامل لأكثر من ستة أشهر<br />الاحتياطات و التحذيرات<br />تحدث مع طبيبك او الصيدلي قبل تناول أقراص رومافن 50 ملجم اذا:<br />&bull;كنت تعاني من أي اضطرابات في المعدة أو الأمعاء بما في ذلك التهاب القولون<br />التقرحي أو داء كرون<br />&bull;كان لديك مشاكل في الكلى أو الكبد ، أو كنت من كبار السن<br />&bull;كان لديك حالة تسمى البورفيريا<br />&bull;كنت تعاني من أي اضطراب دموي أو نزيف. إذا قمت بذلك ، قد يطلب منك<br />الطبيب إجراء فحوصات منتظمة أثناء تناول هذه الأقراص.<br />&bull;سبق وأن أصبت بالربو ، التهاب الأنف التحسسي الموسمي ، تورم في الغشاء<br />المخاطي للأنف )أورام الأنف( ، أمراض رئوية مزمنة أو عدوى في الجهاز<br />التنفسي.<br />&bull;كنتِ ترضعين طفلك رضاعة طبيعية<br />&bull;كنت تعاني من الذبحة الصدرية ، أو جلطات الدم ، أو ارتفاع ضغط الدم ، أو<br />زيادة الكولسترول أو ارتفاع مستوى الدهون الثلاثية<br />&bull;كان لديك مشاكل في القلب أو إذا كنت تعاني من سكتة دماغية أو تعتقد أنك<br />معرض لخطر هذه الحالات )على سبيل المثال ، إذا كنت تعاني من ارتفاع ضغط<br />الدم أو مرض السكري أو ارتفاع نسبة الكوليسترول أو كنت مدخنًا(<br />&bull;كان لديك مرض السكري<br />&bull;كنت تدخن<br />الاضطراب الالتهابي التلقائي ( SLE &bull;كان لديك مرض الذئبة الحمامية الجهازية<br />المناعي الذي يسبب أعراض مثل آلام المفاصل ، التهاب المفاصل ، الطفح<br />الجلدي ، الحمى( أو أي حالة مشابهة<br />&bull;كان لديك عدم تحمل بعض السكريات مثل اللاكتوز )تحتوي هذه الأقراص<br />على اللاكتوز(<br />أخبر طبيبك إذا كنت قد أجريت مؤخرًا أو ستخضع لعملية جراحية في المعدة أو<br />الأمعاء قبل تناول أقراص رومافن 50 ملجم ، حيث يمكن أن يؤدي ديكلوفيناك أحيانًا<br />إلى سوء التئام الجروح في أمعائك بعد الجراحة.<br />أخبر طبيبك أو الصيدلي إذا كان لديك أي من هذه الحالات لأن أقراص رومافن 50<br />ملجم قد لا تكون الدواء المناسب لك.<br />الأطفال<br />هذه الأقراص ليست مناسبة للأطفال الذين تقل أعمارهم عن 12 سنة.<br />الأدوية الأخرى و أقراص رومافن 50 ملجم<br />يمكن لبعض الأدوية ان تتداخل مع العلاج. يرجى إخبار الطبيب أو الصيدلي إذا كنت<br />تتناول أو تناولت مؤخرا أي أدوية أخرى، بما في ذلك الأدوية التي تم الحصول عليها<br />دون وصفة طبية، وخاصة أي مما يلي:<br />&bull;أدوية علاج مرض السكري<br />&bull;مضادات التخثر )أقراص ترقق الدم مثل الوارفارين(<br />&bull;مدرات البول )أقراص الماء(<br />&bull;الليثيوم )يستخدم لعلاج بعض المشاكل العقلية(<br />&bull;ميثوتريكسات )لعلاج بعض الأمراض الالتهابية وبعض أنواع السرطان(<br />&bull;سيكلوسبورين و تاكروليماس )يستخدمان لعلاج بعض الأمراض الالتهابية وبعد<br />زراعة الأعضاء(<br />&bull;تريميثوبريم )دواء يستخدم لمنع أو علاج عدوى المسالك البولية(<br />&bull;المضادات الحيوية الكينولون )للعدوى(<br />سيكلو أوكسجيناز - 2( ، على سبيل المثال ( COX- أو مثبطات 2 NSAID &bull;أي<br />الأسبرين أو الأيبوبروفين<br />&bull;ميفيبريستون )دواء يستخدم لإنهاء الحمل(<br />&bull;جليكوسيدات قلبية )على سبيل المثال الديجوكسين( ، تستخدم لعلاج مشاكل القلب<br />المستخدمة لعلاج الاكتئاب( ( SSRIs &bull;الأدوية المعروفة باسم<br />&bull;الستيرويدات عن طريق الفم )دواء مضاد للالتهابات(<br />&bull;الأدوية المستخدمة لعلاج أمراض القلب أو ارتفاع ضغط الدم ، مثل حاصرات<br />بيتا أو مثبطات الإنزيم المحول للأنجيوتنسين<br />&bull;فوريكونازول )دواء يستخدم لعلاج الالتهابات الفطرية(<br />&bull;الفينيتوين )دواء يستخدم لعلاج النوبات(<br />&bull;كولستيبول / كوليسترامين )يستخدم لخفض الكولسترول(<br />دائما أخبر طبيبك أو الصيدلي عن جميع الأدوية التي تتناولها. هذا يعني الأدوية التي<br />قد اشتريتها بنفسك وكذلك الأدوية على وصفة طبية من طبيبك.<br />تناول أقراص رومافن 50 ملجم مع الطعام والشراب<br />تناول هذا الدواء مع أو بعد الطعام.<br />الحمل والرضاعة الطبيعية<br />لا تتناولين رومافن إذا كنت في الأشهر الثلاثة الأخيرة من الحمل لأنه قد يؤذي<br />الجنين أو يسبب مشاكل عند الولادة. يمكن أن يسبب مشاكل في الكلى والقلب<br />لجنينك الذي لم يولد بعد. قد يؤثر على ميلك أنت وطفلك للنزيف ويتسبب في تأخر&nbsp;المخاض أو تأخره عما هو متوقع.<br />لا يجب أن تتناولين رومافن خلال الأشهر الستة الأولى من الحمل ما لم تكن هناك<br />ضرورة قصوى ونصح به طبيبك. إذا كنت بحاجة إلى علاج خلال هذه الفترة أو<br />أثناء محاولتك للحمل، فيجب استخدام أقل جرعة لأقصر وقت ممكن. إذا تم تناوله<br />لأكثر من بضعة أيام من 20 أسبوعًا من الحمل فصاعدًا. يمكن أن يسبب دواء<br />رومافن مشاكل في الكلى لدى طفلك الذي لم يولد بعد، مما قد يؤدي إلى انخفاض<br />مستويات السائل الأمنيوسي الذي يحيط بالطفل )قلة السائل السلوى( أو تضيق<br />الأوعية الدموية )القناة الشريانية( في قلب الطفل. إذا كنت بحاجة إلى علاج لمدة<br />تزيد عن بضعة أيام، فقد يوصي طبيبك بمراقبة إضافية.<br />استخدام الآلات و القيادة<br />في كثير من الأحيان ابلغ الناس أن أقراص ديكلوفيناك الصوديوم تجعلهم يشعرون<br />بالدوار أو التعب أو النعاس. كما تم الإبلاغ عن مشاكل في البصر. إذا تأثرت بهذه<br />الطريقة، يجب أن لا تقوم بقيادة السيارة أو تقوم بتشغيل الآلات.<br />تحذيرات خاصة أخرى<br />&bull;يجب أن تتناول أقل جرعة فعالة من ديكلوفيناك الصوديوم لأقصر فترة زمنية<br />ممكنة خاصة إذا كنت ناقص الوزن أومن كبار السن.<br />&bull;هناك زيادة صغيرة في خطر الإصابة بنوبة قلبية أو سكتة دماغية عند تناول أي<br />دواء مثل ديكلوفيناك الصوديوم. الخطر أعلى إذا كنت تتناول جرعات عالية لفترة<br />طويلة. اتبع دائمًا إرشادات الطبيب حول مقدار ما يجب تناوله وطول مدة تناوله.<br />&bull;إذا شعرت في أي وقت أثناء تناول ديكلوفيناك الصوديوم بأي علامات أو<br />أعراض لمشاكل في القلب أو الأوعية الدموية مثل ألم في الصدر ، أو ضيق في<br />التنفس ، أو ضعف في الكلام ، فاتصل بطبيبك على الفور.<br />&bull;في الوقت الذي تتناول فيه هذه الأدوية ، قد يرغب طبيبك في عمل فحص لك<br />من وقت لآخر.<br />&bull;إذا كان لديك تاريخ من مشاكل المعدة عند تناول مضادات الالتهاب غير<br />الستيرويدية ، خاصة إذا كنت مسناً ، يجب أن تخبر طبيبك فوراً إذا لاحظت<br />أي أعراض غير عادية.<br />&bull;نظرًا لأنه دواء مضاد للالتهابات ، فقد تقلل أقراص ديكلوفيناك الصوديوم من<br />أعراض العدوى ، على سبيل المثال ، الصداع ، وارتفاع درجة الحرارة. إذا<br />شعرت بتوعك واحتجت لرؤية طبيب ، تذكر أن تخبره بأنك تتناول أقراص<br />ديكلوفيناك الصوديوم.<br />هذه الأقراص ليست مناسبة للأطفال الذين تقل أعمارهم عن 12 سنة.<br />تحتوي أقراص رومافن 50 ملجم على اللاكتوز<br />تحتوي أقراص رومافن 50 ملجم على اللاكتوز. إذا أخبرك طبيبك بأن لديك عدم<br />قدرة على تحمل بعض السكريات ، اتصل بطبيبك قبل تناول هذا المنتج الطبي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>سوف يخبرك الطبيب كم قرص رومافن يجب أن تتناول و اوقات تناولهم. تناول<br />رومافن دائما تماما كما اخبرك الطبيب. يجب عليك التحقق من طبيبك أو الصيدلي<br />إذا لم تكن متأكدا. استمر في تناول الاقراص كيفما قيل لك، إلا إذا كان لديك أي<br />مشاكل. في هذه الحالة، يجب مراجعة الطبيب. تناول الأقراص مع أو بعد الطعام.<br />ابتلع الأقراص كاملة مع كوب من الماء. لا تسحق أو تمضغ الأقراص.<br />الجرعة المعتادة هي:<br />البالغين:<br />150 ملجم يوميا مقسمة الى 2 او 3 جرعات. -75<br />يعتمد عدد الأقراص التي تتناولها على التركيز الذي وصفه لك الطبيب.<br />كبار السن:<br />يجب استخدام أقل جرعة فعالة. قد ينصح الطبيب لك أن تتناول جرعة أقل من جرعة<br />الكبار وهذا هو المعتاد إذا كنت من كبار السن. قد يرغب طبيبك أيضًا في التحقق من<br />أن أقراص ديكلوفيناك الصوديوم لا تؤثر على معدتك .<br />الأطفال:<br />هذه الأقراص ليست مناسبة للأطفال الذين تقل أعمارهم عن 12 سنة.<br />قد يصف الطبيب أيضًا دواء آخر في الوقت نفسه لحماية المعدة ، خاصة إذا كنت<br />تعاني من مشاكل في المعدة من قبل ، أو إذا كنت مسناً ، أو إذا كنت تتناول<br />أدوية أخرى .<br />إذا تناولت أقراص رومافن 50 ملجم أكثر مما يجب<br />إذا كنت، أو أي شخص آخر، تناول عن طريق الخطأ كثير من رومافن، أخبر طبيبك<br />أو اذهب إلى أقرب قسم طوارئ على الفور. اصطحب علبة الدواء معك حتى يتمكن<br />الاطباء من معرفة ما تناولت.<br />أعراض الجرعة الزائدة يمكن أن تشمل: صداع، غثيان )الشعور المرضي(، التقيؤ،<br />آلام في البطن والمعدة أو نزيف في الامعاء، ونادرا الإسهال، والارتباك، والإثارة،<br />والغيبوبة، والنعاس، والدوخة، وطنين في الأذنين، والاغماء، أو في بعض الأحيان<br />التشنجات )النوبات(<br />إذا نسيت تناول أقراص رومافن 50 ملجم<br />من المهم أن لا تنسى الجرعة . إذا نسيت تناول جرعة، تناول الجرعة بمجرد<br />التذكر. إذا اقترب وقت تناول الجرعة التالية، فقط تناول الجرعة القادمة وتغاضي<br />عن الجرعة التي فاتتك. لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. لا<br />تتناول أكثر من 150 ملجم خلال 24 ساعة. إذا كان لديك صعوبة في تذكر تناول<br />الاقراص، أخبر طبيبك أو الصيدلي.<br />إذا كان لديك أي أسئلة أخرى حول استخدام هذا الدواء ، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن أن يتسبب رومافن في آثار جانبية، على الرغم من ذلك<br />فأنها لا تحدث للجميع.<br />بعض الآثار الجانبية يمكن أن تكون خطيرة<br />توقف عن تناول رومافن واطلب المساعدة الطبية الفورية إذا لاحظت:<br />&bull;ألم مفاجئ وساحق في الصدر )علامات احتشاء عضلة القلب أو نوبة قلبية(<br />&bull;ضيق التنفس ، صعوبة التنفس عند الاستلقاء ، تورم القدمين أو الساقين )علامات<br />لقصور القلب(<br />&bull;ضعف مفاجئ أو تنميل في الوجه أو الذراع أو الساق خاصة في جانب واحد من<br />الجسم ، فقدان مفاجئ أو اضطراب في الرؤية. صعوبة مفاجئة في التحدث أو<br />القدرة على فهم الكلام ؛ صداع مفاجئ شبيه بالصداع النصفي يحدث لأول مرة<br />مع أو بدون اضطراب في الرؤية. يمكن أن تكون هذه الأعراض علامة مبكرة<br />على الإصابة بسكتة دماغية.<br />&bull;ألم المعدة ، وعسر الهضم ، وحرقة المعدة ، والرياح ، والغثيان )الشعور<br />بالمرض( أو القيء )المرض(<br />&bull;أي علامة نزيف في المعدة أو الأمعاء ، على سبيل المثال ، عند إفراغ أمعائك دم<br />بالقيء أو براز أسود بلون القطران<br />&bull;ردود الفعل التحسسية التي يمكن أن تشمل الطفح الجلدي ، الحكة ، الكدمات ،<br />مناطق حمراء مؤلمة ، التقشير أو تقرحات<br />&bull;صفير أو ضيق في التنفس )تشنج قصبي(<br />&bull;ﺗورم اﻟو ﻪﺟ أو اﻟش ﻩﺎﻔ أو اﻟيدﻳن أو ا ﻊﺑﺎﺻﻷ<br />&bull;اصفرار بشرتك أو بياض عينيك<br />&bull;التهاب الحلق المستمر أو ارتفاع درجة الحرارة<br />&bull;تغيير غير متوقع في كمية البول و / أو شكله.<br />&bull;التشنج الخفيف و ألم في البطن ، تبدأ بعد وقت قصير من بدء العلاج مع<br />ديكلوفيناك الصوديوم ويتبعه نزف مستقيمي أو إسهال دموي عادة خلال 24<br />ساعة من بداية الألم البطني.<br />&bull;متلازمة ستيفنز جونسون )مرض خطير مع تقرحات في الجلد والفم والعينين<br />والأعضاء التناسلية(<br />إذا لاحظت أنك تتعرض لكدمات أكثر سهولة من المعتاد أو لديك التهاب الحلق أو<br />الالتهابات المتكررة ، أخبر طبيبك.<br />تم الإبلاغ عن الآثار الجانبية المذكورة أدناه.<br />أعراض جانبية شائعة )قد تؤثر على ما بين 1 و 1 من كل 10 من كل 100<br />مريض(:<br />&bull;ألم المعدة وحرقة المعدة والغثيان والقيء والإسهال وعسر الهضم والريح وفقدان<br />الشهية<br />&bull;صداع ، دوار ، دوخة<br />&bull;طفح جلدي أو بقع<br />&bull;مستويات مرتفعة من إنزيمات الكبد في الدم<br />أعراض جانبية غير شائعة )قد تؤثر على ما بين 1 و 10 من كل 1000 مريض(:<br />&bull;سرعة ضربات القلب أو عدم انتظامها )خفقان القلب( ، وألم في الصدر ،<br />واضطرابات في القلب ، بما في ذلك النوبة القلبية أو ضيق التنفس ، وصعوبة<br />التنفس عند الاستلقاء ، أو تورم القدمين أو الساقين )علامات لفشل القلب( ،<br />خاصة إذا كنت تتناول جرعة عالية ) 150 مجم يوميا( لفترة طويلة من الزمن.<br />أعراض جانبية نادرة )قد تؤثر على ما بين 1 من كل 1000 إلى 1 من كل<br />10000 مريض(:<br />&bull;قرحة في المعدة أو نزيف )كانت هناك حالات نادرة جداً تم الإبلاغ عنها أدت إلى<br />الوفاة ، خاصة عند كبار السن(<br />&bull;التهاب المعدة )التهاب أو تهيج أو انتفاخ في بطانة المعدة(<br />&bull;قيء دموي<br />&bull;إسهال دموي أو النزف من المستقيم</p><p>&bull;براز أسود أو براز بلون القطران<br />&bull;النعاس والإرهاق<br />&bull;انخفاض ضغط الدم )انخفاض ضغط الدم ، قد تشمل أعراضه الضعف أو الدوخة<br />أو الدوار الخفيف(.<br />&bull;طفح جلدي وحكة<br />&bull;احتباس السوائل ، تشمل أعراضه كواحل منتفخة<br />&bull;اضطرابات وظائف الكبد ، بما في ذلك التهاب الكبد واليرقان<br />&bull;الربو )قد تشمل الأعراض أزيز وضيق في التنفس وسعال وضيق في الصدر(<br />أعراض جانبية نادرة جدًا )قد تؤثر على أقل من 1 من كل 10000 مريض(:<br />آثار على الجهاز العصبي:<br />التهاب بطانة الدماغ )التهاب السحايا(، وخز أو خدر في الأصابع أو الرعشة أو<br />اضطرابات بصرية مثل عدم وضوح الرؤية أو ازدواج الرؤية أوتغير الطعم أو<br />فقدان السمع أو ضعف السمع أو طنين الأذن )الرنين في الأذنين( أو الأرق أو<br />الكوابيس أو تغيرات المزاج أو الاكتئاب أو القلق أو التهيج أو الاضطرابات النفسية<br />أو الارتباك وفقدان الذاكرة أو النوبات أو الصداع جنبا إلى جنب مع كراهية الأضواء<br />الساطعة والحمى وتيبس الرقبة.<br />آثار على المعدة والجهاز الهضمي:<br />الإمساك ، التهاب اللسان ، قرحة الفم ، التهاب داخل الفم أو الشفتين ، تغيرات الذوق<br />، اضطرابات الأمعاء السفلى )بما في ذلك التهاب القولون أو تفاقم التهاب القولون<br />التقرحي أو مرض كرون(، التهاب البنكرياس.<br />آثار على القلب أو الصدر أو الدم:<br />ارتفاع ضغط الدم ، انخفاض ضغط الدم )انخفاض ضغط الدم ، وقد تشمل أعراضه<br />الإغماء ، والدوخة أو خفة الرأس( ، والتهاب الأوعية الدموية ، والتهاب الرئة<br />)التهاب رئوي( ، واضطرابات الدم )بما في ذلك فقر الدم(.<br />آثار على الكبد أو الكليتين:<br />أمراض الكلى أو الكبد الحاد بما في ذلك فشل الكبد أو وجود الدم أو البروتين<br />في البول<br />آثار على الجلد أو الشعر:<br />تورم الوجه والطفح الجلدي الخطير بما في ذلك متلازمة ستيفنز جونسون ومتلازمة<br />ليل و أنواع الطفح الجلدي الأخرى التي قد تتفاقم بسبب التعرض لأشعة الشمس.<br />تساقط الشعر.<br />التأثيرات على الجهاز التناسلي:<br />ضعف جنسى.<br />الآثار الجانبية الأخرى التي تم الإبلاغ عنها أيضًا بتكرار غير معروف تشتمل<br />على ما يلي:<br />إضطرابات الحلق ، إرتباك ، هلوسة ، توعك )شعور عام بعدم الراحة( ، إلتهاب<br />أعصاب العين ، إضطرابات في الإحساس.<br />قد تترافق الأدوية مثل ديكلوفيناك مع زيادة خطر الإصابة بنوبة قلبية أو سكتة<br />دماغية.<br />لا تنزعج من هذه القائمة - معظم الناس يتناولون أقراص ديكلوفيناك الصوديوم<br />دون أي مشاكل.<br />إذا أصبحت أي من الآثار الجانبية خطيرة ، أو إذا لاحظت آثارًا جانبية غير مدرجة<br />في هذه النشرة ، فيرجى إخبار طبيبك.<br />قد يرغب في إعطائك دواءً مختلفًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>&bull;يحفظ بعيدا عن متناول أيدي ونظر الأطفال.<br />&bull;يحفظ في العبوة الأصلية للحماية من الضوء.<br />&bull;يحفظ في درجة حرارة أقل من 30 درجة مئوية.<br />&bull;يجب عدم استعمال أقراص رومافن 50 ملجم بعد تاريخ انتهاء الصلاحية<br />المذكور على العبوة. تاريخ الانتهاء يشير الى أخر يوم في ذلك الشهر.<br />&bull;التخلص من الأدوية يجب ألا يكون عن طريق مياه الصرف الصحي أو النفايات<br />المنزليه. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبه. هذه<br />التدابير مساعده في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>على ماذا تحتوي أقراص رومافن 50 ملجم<br />يحتوي كل قرص مغلف تغليفاً معوياً على ديكلوفيناك الصوديوم )دستور الأدوية<br />البريطاني( 50 ملجم.<br />لاكتوز، نشا ذرة، بوفيدون ،pH المواد الإضافية: مايكروكريست سيليلوز 101<br />تراي إيثايل ،L30D- مغنيسيوم ستيريت ومواد مغلفة معوياً )إيودراجت 55 ،k30<br />سيتريت، تيتينيوم دايوكسايد و تالك نقي(</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p><strong>كل قرص مغلف تغليف معوي بلون أبيض الى أبيض داكن , مغلف ,دائري مع نقش<br />على جانب و رقم 2 على الجانب الأخر RP<br />العبوة:<br />تحتوي العبوة على ) 20 ( قرص مغلف تغليف معوي من أقراص رومافن 50 ملجم<br />يحتوي 10 أقراص )PVDC-PVC/Alu( كل شريط شفاف</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">شركة المنتجات الطبية والتجميلية المحدودة (الرياض فارما)</p><p dir="RTL">ص.ب. 442 الرياض 11411</p><p dir="RTL">فاكس: 966112650505+</p><p dir="RTL">البريد الإلكتروني: contact@riyadhpharma.com</p><p dir="RTL"><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على صاحب الترخيص والتسويق:</em></p><p dir="RTL">المملكة العربية السعودية</p><p dir="RTL">قسم التسويق</p><p dir="RTL">الرياض</p><p dir="RTL">تلفون: 966112650111+</p><p dir="RTL">البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            
تمت مراجعة هذه النشرة بتاريخ (10/2022) 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Rumafen tablets 50mg
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Diclofenac sodium 50 mg
For a full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
Enteric Coated tablet.
White to off white , enteric coated , biconvex, circular tablets with RP engraved on one side and 2 on the other
side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adults and elderly<br />Relief of all grades of pain and inflammation in a wide range of conditions, including:<br />(i) arthritic conditions: rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, acute gout,<br />(ii) acute musculo-skeletal disorders such as periarthritis (for example frozen shoulder), tendinitis,<br />tenosynovitis, bursitis,<br />(iii) other painful conditions resulting from trauma, including fracture, low back pain, sprains, strains,<br />dislocations,orthopaedic, dental and other minor surgery.<br />Children<br />Rumafen 50 mg tablets are not suitable for children.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Posology<br />Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to<br />controlsymptoms (see section 4.4).<br />Adults: 75 mg to 150 mg daily in two or three divided doses.<br />The recommended maximum daily dose of diclofenac sodium is 150mg.<br />Special populations<br />Elderly:<br />Although the pharmacokinetics of Diclofenac sodium are not impaired to any clinically relevant extent in<br />elderly patients, nonsteroidal anti-inflammatory drugs should be used with particular caution in such patients<br />who generally are more prone to adverse reactions. In particular it is recommended that the lowest effective<br />dosage be used in frail elderly patients or those with a low body weight (see also precautions) and the patient<br />should be monitored for GI bleeding during NSAID therapy.<br />Cardiovascular and significant cardiovascular risk factors<br />Diclofenac is contraindicated in patients with established congestive heart failure (NYHA II-IV), ischemic heart<br />disease, peripheral arterial disease and/or cerebrovascular disease (see section 4.3 Contraindications).<br />Patients with congestive heart failure (NYHA-I) or significant risk factors for cardiovascular disease should be<br />treated with diclofenac only after careful consideration. Since cardiovascular risks with diclofenac may increase<br />with dose andduration of exposure, the lowest effective daily dose should be used and for the shortest duration<br />possible (see section4.4 Special warnings and precautions for use).<br />Renal impairment: Diclofenac is contraindicated in patients with renal failure (see section 4.3<br />Contraindications). Nospecific studies have been carried out in patients with renal impairment, therefore, no<br />specific dose adjustmentrecommendations can be made. Caution is advised when administering diclofenac to<br />patients with mild to moderaterenal impairment (see section 4.4 Special warnings and precautions for use).<br />Hepatic impairment: Diclofenac is contraindicated in patients with hepatic failure (see section 4.3<br />Contraindications).<br />No specific studies have been carried out in patients with hepatic impairment, therefore, no specific dose<br />adjustment recommendations can be made. Caution is advised when administering diclofenac to patients with<br />mild to moderate hepatic impairment (see section 4.4 Special warnings and precautions for use).<br />Paediatric population:<br />Rumafen 50 mg tablets are not suitable for children.<br />Method of administration<br />For oral administration.<br />To be taken whole with liquid, preferably with or after food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                • Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
• Active, or gastric or intestinal ulcer, bleeding or perforation.
• History of gastrointestinal bleeding or perforation, relating to previous NSAIDs therapy.
• Active, or history of recurrent peptic ulcer/haemorrhage (two or more distinct episodes of proven
ulceration or bleeding).
• Last trimester of pregnancy (see section 4.6)
• Hepatic failure
• Renal failure
• Established congestive heart failure (NYHA-II-IV), ischemic heart disease, peripheral arterial disease
and/or cerebrovascular disease.
• Like other non-steroidal anti-inflammatory drugs (NSAIDs), diclofenac is also contraindicated in
patients in whom attacks of asthma, angiodema, urticaria.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General<br />Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to<br />control symptoms (see section 4.2, and GI and cardiovascular risks below).<br />The concomitant use of diclofenac with systemic NSAIDs including cyclooxygenase-2 selective inhibitors<br />should be avoided due to the absence of any evidence demonstrating synergistic benefits and the potential for<br />additive undesirable effects (see section 4.5).<br />Caution is indicated in the elderly on basic medical grounds. In particular, it is recommended that the lowest<br />effective dose be used in frail elderly patients or those with a low body weight (see section 4.2).<br />As with other nonsteroidal anti-inflammatory drugs including diclofenac, allergic reactions, including<br />anaphylactic/anaphylactoid reactions, can also occur without earlier exposure to the drug (see section<br />4.8).Hypersensitivity reactions can also progress to Kounis syndrome, a serious allergic reaction that can result<br />in myocardial infarction. Presenting symptoms of such reactions can include chest pain occurring in association<br />with an allergic reaction to diclofenac.<br />Like other NSAIDs, diclofenac may mask the signs and symptoms of infection due to its pharmacodynamic<br />properties.<br />This medicine contains lactose and therefore is not recommended for patients with rare hereditary problems of<br />galactose intolerance, severe lactase deficiency or glucose-galactose malabsorption.<br />Gastrointestinal effects<br />Gastrointestinal bleeding (haematemesis, melaena), ulceration or perforation, which can be fatal has been<br />reported with all NSAIDs including diclofenac, and may occur at any time during treatment, with or without<br />warning symptoms or a previous history of serious gastrointestinal (GI) events. They generally have more<br />serious consequences in the elderly. If gastrointestinal bleeding or ulceration occurs in patients receiving<br />diclofenac, the medicinal product should be withdrawn.<br />As with all NSAIDs, including diclofenac, close medical surveillance is imperative and particular caution<br />should be exercised when prescribing diclofenac in patients with symptoms indicative of gastrointestinal<br />disorders or with a history suggestive of gastric or intestinal ulceration, bleeding or perforation (see section 4.8).<br />The risk of GI bleeding, ulceration or perforation is higher with increasing NSAID doses including diclofenac<br />and in patients with a history of ulcer, particularly if complicated with haemorrhage or perforation.<br />The elderly have an increased frequency of adverse reactions to NSAIDs especially gastrointestinal bleeding<br />and perforation which may be fatal (see section 4.2).<br />To reduce the risk of GI toxicity in patients with a history of ulcer, particularly if complicated with<br />haemorrhage or perforation, and in the elderly, the treatment should be initiated and maintained at the lowest<br />effective dose.<br />Combination therapy with protective agents (e.g. misoprostol or proton pump inhibitors) should be considered<br />for these patients, and also for patients requiring concomitant use of medicinal products containing low dose<br />acetylsalicylic acid (ASA/aspirin), or other medicinal products likely to increase gastrointestinal risk (see below<br />and section 4.5).<br />Patients with a history of GI toxicity, particularly the elderly, should report any unusual abdominal symptoms<br />(especially GI bleeding).<br />Caution is recommended in patients receiving concomitant medications which could increase the risk of<br />ulceration or bleeding, such as systemic corticosteroids, anticoagulants such as warfarin, selective serotoninreuptake<br />inhibitors (SSRIs) or anti-platelet agents such as acetylsalicylic acid (see section 4.5).<br />Close medical surveillance and caution should also be exercised in patients with ulcerative colitis or Crohn&#39;s<br />disease, as their condition may be exacerbated (see section 4.8).<br />NSAIDs, including diclofenac, may be associated with increased risk of gastro-intestinal anastomotic leak.<br />Close medical surveillance and caution are recommended when using diclofenac after gastro-intestinal surgery.<br />Hepatic impairment<br />Close medical surveillance is required when prescribing diclofenac to patients with impairment of hepatic<br />function, as their condition may be exacerbated.<br />As with other NSAIDs, including diclofenac, values of one or more liver enzymes may increase. During<br />prolonged treatment with diclofenac, regular monitoring of hepatic function is indicated as a precautionary<br />measure.<br />If abnormal liver function tests persist or worsen, clinical signs or symptoms consistent with liver disease<br />develop, or if other manifestations occur (eosinophilia, rash), diclofenac should be discontinued.<br />Hepatitis may occur with diclofenac without prodromal symptoms.<br />Caution is called for when using diclofenac in patients with hepatic porphyria, since it may trigger an attack.<br />Renal impairment<br />As fluid retention and oedema have been reported in association with NSAID therapy, including diclofenac,<br />particular caution is called for in patients with impaired cardiac or renal function, history of hypertension, the<br />elderly, patients receiving concomitant treatment with diuretics or medicinal products that can significantly<br />impact renal function, and in those patients with substantial extracellular volume depletion from any cause, e.g.<br />before or after major surgery (see4.3). Monitoring of renal function is recommended as a precautionary measure<br />when using diclofenac in such cases. Discontinuation of therapy is usually followed by recovery to the pretreatment<br />state.<br />Skin effects<br />Serious skin reactions, some of them fatal, including exfoliative dermatitis, Stevens-Johnson syndrome and<br />toxic epidermal necrolysis, have been reported very rarely in association with the use of NSAIDs, including<br />diclofenac (see section 4.8). Patients appear to be at highest risk for these reactions early in the course of<br />therapy: the onset of the reaction occurring in the majority of cases within the first month of treatment.<br />Diclofenac sodium tablets should be discontinued at the first appearance of skin rash, mucosal lesions or any<br />other signs of hypersensitivity.<br />SLE and mixed connective tissue disease<br />In patients with systemic lupus erythematosus (SLE) and mixed connective tissue disorders there may be an<br />increased risk of aseptic meningitis (see section 4.8).<br />Cardiovascular and cerebrovascular effects<br />Patients with congestive heart failure (NYHA-1) or patients with significant risk factors for cardiovascular<br />events (e.g., Hypertension, hyperlipidaemia, diabetes mellitus, smoking) should only be treated with diclofenac<br />after careful consideration. As the cardiovascular risks of diclofenac may increase with dose and duration of<br />exposure, the shortest duration possible and the lowest effective daily dose should be used. The patient&#39;s need<br />for symptomatic relief and response to therapy should be re-evaluated periodically.<br />Appropriate monitoring and advice are required for patients with a history of hypertension and congestive heart<br />failure (NYHA-1) as fluid retention and oedema have been reported in association with NSAID therapy<br />including diclofenac.<br />Clinical trial and epidemiological data consistently point towards increased risk of arterial thrombotic events<br />(for example myocardial infarction or stroke) associated with the use of diclofenac, particularly at high dose<br />(150mg daily) and in long term treatment.<br />Patients should remain alert for the signs and symptoms of serious arteriothrombotic events (e.g. chest pain,<br />shortness of breath, weakness, slurring of speech), which can occur without warnings. Patients should be<br />instructed to see a physician immediately in case of such an event.<br />Haematological effects<br />During prolonged treatment with diclofenac, as with other NSAIDs, monitoring of the blood count is<br />recommended.<br />Diclofenac may reversibly inhibit platelet aggregation (see anticoagulants in section 4.5). Patients with defects<br />haemostasias, bleeding diathesis or haematological abnormalities should be carefully monitored.<br />Pre-existing asthma<br />In patients with asthma, seasonal allergic rhinitis, swelling of the nasal mucosa (i.e., nasal polyps), chronic<br />obstructive pulmonary diseases or chronic infections of the respiratory tract (especially if linked to allergic<br />rhinitis-like symptoms), reactions on NSAIDs like asthma exacerbations (so-called intolerance to analgesics /<br />analgesics-asthma), Quincke&rsquo;s oedema or urticaria are more frequent than in other patients. Therefore, special<br />precaution is recommended in such patients (readiness for emergency). This is applicable as well for patients<br />who are allergic to other substances, e.g., with skin reactions, pruritus or urticaria.<br />Like other drugs that inhibit prostaglandin synthetase activity, diclofenac sodium and other NSAIDs can<br />precipitate bronchospasm if administered to patients suffering from, or with a previous history of bronchial<br />asthma.<br />Female fertility:<br />The use of Diclofenac may impair female fertility and is not recommended in women attempting to conceive. In<br />women who may have difficulties conceiving or who are undergoing investigation of infertility, withdrawal of<br />Diclofenac should be considered (see section 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The following interactions include those observed with diclofenac gastro-resistant tablets and/or other<br />pharmaceutical forms of diclofenac.<br />Lithium: If used concomitantly, diclofenac may raise plasma concentrations of lithium. Monitoring of the serum<br />lithium level is recommended.<br />Digoxin: If used concomitantly, diclofenac may raise plasma concentrations of digoxin. Monitoring of the<br />serum digoxin level is recommended.<br />Diuretics and Anti-hypertensive agents: Like other NSAIDs, concomitant use of diclofenac with diuretics or<br />antihypertensive agents (e.g., beta-blockers, angiotensin converting enzyme (ACE) inhibitors) may cause a<br />decrease in their antihypertensive effect via inhibition of vasodilatory prostaglandin synthesis.<br />Therefore, the combination should be administered with caution and patients, especially the elderly, should<br />have their blood pressure periodically monitored. Patients should be adequately hydrated and consideration<br />should be given to monitoring of renal function after initiation of concomitant therapy and periodically<br />thereafter, particularly for diuretics and ACE inhibitors due to the increased risk of nephrotoxicity.<br />Drugs known to cause hyperkalemia: Concomitant treatment with potassium-sparing diuretics, ciclosporin,<br />tacrolimus or trimethoprim may be associated with increased serum potassium levels, which should therefore be<br />monitored frequently (see section 4.4).<br />Anticoagulants and anti-platelet agents: Caution is recommended since concomitant administration could<br />increase the risk of bleeding (see section 4.4). Although clinical investigations do not appear to indicate that<br />diclofenac affects the action of anticoagulants, there are reports of an increased risk of haemorrhage in patients<br />receiving diclofenac and anticoagulants concomitantly (see section 4.4). Therefore, to be certain that no change<br />in anticoagulant dosage is required, close monitoring of such patients is required. As with other nonsteroidal<br />anti-inflammatory agents, diclofenac in high dose can reversibly inhibit platelet aggregation.<br />Other NSAIDS including cyclo-oxygenase-2selective inhibitors and corticosteroids: Co-administration of<br />diclofenac and other systemic NSAIDs or corticosteroids may increase the risk of gastrointestinal bleeding or<br />ulceration. Avoid concomitant use of two or more NSAIDs (see section 4.4).<br />Selective serotonin reuptake inhibitors (SSRIs): Concomitant administration of SSRIs may increase the risk of<br />gastrointestinal bleeding (see section 4.4).<br />Antidiabetics: Clinical studies have shown that diclofenac can be given together with oral antidiabetic agents<br />without influencing their clinical effect. However, there have been isolated reports of hypoglycaemic and<br />hyperglycemic effects necessitating changes in the dosage of the antidiabetic agents during treatment with<br />diclofenac. For this reason, monitoring of the blood glucose level is recommended as a precautionary measure<br />during concomitant therapy.<br />Methotrexate: Diclofenac can inhibit the tubular renal clearance of methotrexate hereby increasing methotrexate<br />levels. Caution is recommended when NSAIDs, including diclofenac, are administered less than 24 hours<br />before treatment with methotrexate, since blood concentrations of methotrexate may rise, and the toxicity of this<br />substance be increased.<br />Cases of serious toxicity have been reported when methotrexate and NSAIDs including diclofenac are given<br />within 24hours of each other. This interaction is mediated through accumulation of methotrexate resulting from<br />impairment ofrenal excretion in the presence of the NSAID.<br />Ciclosporin: Diclofenac, like other NSAIDs, may increase the nephrotoxicity of ciclosporin due to the effect on<br />renal prostaglandins. Therefore, it should be given at doses lower than those that would be used in patients not<br />receiving ciclosporin.<br />Tacrolimus: Possible increased risk of nephrotoxicity when NSAIDs are given with tacrolimus. This might be<br />mediated through renal antiprostagladin effects of both NSAID and calcineurin inhibitor.<br />Quinolone antimicrobials: Convulsions may occur due to an interaction between quinolones and NSAIDs. This<br />may occur in patients with or without a previous history of epilepsy or convulsions. Therefore, caution should<br />be exercised when considering the use of a quinolone in patients who are already receiving an NSAID.<br />Phenytoin: When using phenytoin concomitantly with diclofenac, monitoring of phenytoin plasma<br />concentrations is recommended due to an expected increase in exposure to phenytoin.<br />Colestipol and cholestyramine: These agents can induce a delay or decrease in absorption of diclofenac.<br />Therefore, it is recommended to administer diclofenac at least one hour before or 4 to 6 hours after<br />administration of colestipol/cholestyramine.<br />Cardiac glycosides: Concomitant use of cardiac glycosides and NSAIDs in patients may exacerbate cardiac<br />failure, reduce GFR and increase plasma glycoside levels.<br />Mifepristone: NSAIDs should not be used for 8-12 days after mifepristone administration as NSAIDs can<br />reduce the effect of mifepristone.<br />Potent CYP2C9 inhibitors: &ldquo;Caution is recommended when co-prescribing diclofenac with potent CYP2C9<br />inhibitors (such as sulfinpyrazone and voriconazole), which could result in a significant increase in peak plasma<br />concentration and exposure to diclofenac due to inhibition of diclofenac metabolism.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy and Breastfeeding<br />From the 20th week of pregnancy on ward, Rumafen use may cause oligohydramnios resulting from<br />foetal renal dysfunction. This may occur shortly after treatment initiation and is usually reversible upon<br />discontinuation, in addition there have been reports of ductus arteriosus constriction following treatment<br />in the second trimester, most of which resolve after treatment cessation. Therefore, during the first and<br />second trimesters of pregnancy, Rumafen should not be given unless clearly necessary. If Rumafen is used by<br />a woman trying to conceive, or during the first and second trimesters of pregnancy, the dose should be kept low<br />and the duration of treatment as short as possible. Antenatal monitoring for oligohydramnios and ductus<br />arteriosus constriction should be considered after exposure to Rumafen for several days from gestational<br />week 20 onwards. Rumafen should be discontinued if hypoamniotic fluid or ductus arteriosus<br />constriction is found.<br />During the last trimester of pregnancy, all inhibitors of fetal prostaglandin synthesis may expose the foetus to:<br />&bull; cardiopulmonary toxicity (with premature constriction/closure of the ductus arteriosus and pulmonary<br />hypertension).<br />&bull; Renal impairment (see above)<br />Mother and neonate, at the end of pregnancy, to:<br />&bull; Possible prolongation of bleeding time, an anti-aggregating effect which may occur even at very low<br />doses<br />&bull; Inhibition of uterine contractions resulting in delayed or prolonged labour.<br />Consequently, Rumafen is contraindicated during the third trimester of pregnancy (see sections 4.3 and 5.3)<br />Female Fertility<br />As with other NSAIDs, the use of diclofenac may impair female fertility and is not recommended in women<br />attempting to conceive. In women who have difficulties conceiving or who are undergoing investigation of<br />infertility, withdrawal of diclofenac should be considered (see also section 4.4 regarding female fertility).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Patients who experience visual disturbances, dizziness, vertigo, somnolence, central nervous system<br />disturbances, drowsiness or fatigue while taking NSAIDs should refrain from driving or operating machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Adverse reactions are ranked under the heading of frequency, the most frequent first, using the following<br />convention: very common: (&gt;1/10); common (&ge; 1/100, &lt;1/10); uncommon (&ge; 1/1,000, &lt;1/100); rare<br />(&ge;1/10,000, &lt;1/1000); very rare (&lt;1/10,000); not known: cannot be estimated from available data.<br />The following undesirable effects include those reported with other short-term or long-term use.<br />Table 1</p><p><img alt="" width="435" height="804" src="data:image/jpeg;base64,/9j/4AAQSkZJRgABAQEAYABgAAD/4RD6RXhpZgAATU0AKgAAAAgABAE7AAIAAAAQAAAISodpAAQAAAABAAAIWpydAAEAAAAgAAAQ0uocAAcAAAgMAAAAPgAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAE1vaGFtbWVkIE9sYXlhbgAABZADAAIAAAAUAAAQqJAEAAIAAAAUAAAQvJKRAAIAAAADNTcAAJKSAAIAAAADNTcAAOocAAcAAAgMAAAInAAAAAAc6gAAAAgAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAADIwMjM6MDM6MjAgMTY6Mzg6NDQAMjAyMzowMzoyMCAxNjozODo0NAAAAE0AbwBoAGEAbQBtAGUAZAAgAE8AbABhAHkAYQBuAAAA/+ELImh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8APD94cGFja2V0IGJlZ2luPSfvu78nIGlkPSdXNU0wTXBDZWhpSHpyZVN6TlRjemtjOWQnPz4NCjx4OnhtcG1ldGEgeG1sbnM6eD0iYWRvYmU6bnM6bWV0YS8iPjxyZGY6UkRGIHhtbG5zOnJkZj0iaHR0cDovL3d3dy53My5vcmcvMTk5OS8wMi8yMi1yZGYtc3ludGF4LW5zIyI+PHJkZjpEZXNjcmlwdGlvbiByZGY6YWJvdXQ9InV1aWQ6ZmFmNWJkZDUtYmEzZC0xMWRhLWFkMzEtZDMzZDc1MTgyZjFiIiB4bWxuczpkYz0iaHR0cDovL3B1cmwub3JnL2RjL2VsZW1lbnRzLzEuMS8iLz48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOnhtcD0iaHR0cDovL25zLmFkb2JlLmNvbS94YXAvMS4wLyI+PHhtcDpDcmVhdGVEYXRlPjIwMjMtMDMtMjBUMTY6Mzg6NDQuNTY4PC94bXA6Q3JlYXRlRGF0ZT48L3JkZjpEZXNjcmlwdGlvbj48cmRmOkRlc2NyaXB0aW9uIHJkZjphYm91dD0idXVpZDpmYWY1YmRkNS1iYTNkLTExZGEtYWQzMS1kMzNkNzUxODJmMWIiIHhtbG5zOmRjPSJodHRwOi8vcHVybC5vcmcvZGMvZWxlbWVudHMvMS4xLyI+PGRjOmNyZWF0b3I+PHJkZjpTZXEgeG1sbnM6cmRmPSJodHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj48cmRmOmxpPk1vaGFtbWVkIE9sYXlhbjwvcmRmOmxpPjwvcmRmOlNlcT4NCgkJCTwvZGM6Y3JlYXRvcj48L3JkZjpEZXNjcmlwdGlvbj48L3JkZjpSREY+PC94OnhtcG1ldGE+DQogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgIAogICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgCiAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAgICAKICAgICAgICAgICAgICAgICAgICAgICAgICAgIDw/eHBhY2tldCBlbmQ9J3cnPz7/2wBDAAcFBQYFBAcGBQYIBwcIChELCgkJChUPEAwRGBUaGRgVGBcbHichGx0lHRcYIi4iJSgpKywrGiAvMy8qMicqKyr/2wBDAQcICAoJChQLCxQqHBgcKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKioqKir/wAARCAMkAbMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6Omk8qF5NjPsUttQZZsdgPWvPdH1jwlq11qtteeCBo9vZ3Jn1C51K0s1gS4VVfc7JI3z7ZAdxHrznIrpdS8UyWevy6RYeH9U1a4htYrqZrN7ZUjWRpFQEyzISSYX6A9vWuDGleJzbeJ4pPD+rE67epdowtdP/ANHK7Btw18d3yxryNpByR2xOt36fjdf8F/IH09fw/r8zorDWvANh4rjsdLsNJtr8ackthcW6WyC7hYtiO3YMC3Kn5Rgc5qx4XfwNrlnpl3pWkaTaXNyjahbWkltAlzHuO1pdi5IJxgsPzrzy18C67ayaeo0TXHt7SGGNkaCw3yGGZ5ozv+38fM4BGDkDqM8WvCHg3VfC2vafqcvhvX75rO0WDaTaRDcAyh1A1DYMq2CGV+nBFUtd/wClr/wP62l3T07L9L/qdtommeDdYv8AWtKh8G2Fo+mSra3Mc2n2+2UH96pXZuypyGwcEE9Aa6htF0p7tLp9Ms2uEKFZjbqXUoCEw2MjaGYD03HHWuF8Pv4k0fxLr+qXXhbWLqPWJ0mWGOOxiMOxAgBY3zbvlA7DnJ9h0f8AwlGr/wDQieIP+/8Ap/8A8lUdF8vv6/iU92PfwB4SYyPF4a0iCdyW+0Q2ESyK/PzhtuQwzkH1pvhzwNo/hrRrnTLaCO5t7v8A4+FltYEWUYxhkijRDxwTtye5NJ/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlUBu0yZfAvhFJN6eFtFV9wbcNOiByDkHO3qDzUi+DPC6qir4b0gKkiyqBYRYV16MPl4I7HrVX/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KoAnn8DeE7qNI7nwvosyRszIsmnxMFLcsQCvBOBn1xVh/C3h+T7R5mhaY/2pds+6zjPmjjhuPmHyr19B6VQ/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KoAuXHhHw3dTPLdeHtKmkcozPJZRszFBhCSV52jgenap77w9ouqXS3Op6RYXlwkbRLLcWySOqMCGUEgnBBII6HNZn/CUav8A9CJ4g/7/AOn/APyVR/wlGr/9CJ4g/wC/+n//ACVQBMvgXwisMkS+FtFEcqqsiDTosOFOVBG3kDt6VaHhjQRLJKNE00SSOru4tI8uy42knHJGBg9sVn/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVAGg3hjQX0saa+iac1gJPNFqbSMxB853bMY3ZOc4zVdfBHhRImjTwxoyxtt3INPiAO37uRt7ZOPSq/8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVAFtvB/hl1VX8O6SyrI0qg2MZAdiCzD5epKgk9TgelIfBnhcoUPhvSNrOJCv2CLBcEkN93qCzYPufWqv8AwlGr/wDQieIP+/8Ap/8A8lUf8JRq/wD0IniD/v8A6f8A/JVAGnf+HtF1W4SfVNIsL2ZNuyS4tkkZdpyMFgcYJJFQx+EvDkQAi8P6WgEH2cBbKMYizny+n3c87elUv+Eo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqlZbAacHh7RbW+jvLbSLCG6jhFuk8dsiusQ6IGAyF9ulVm8H+HhbQxW+i6dbfZS7Wrw2UQa1durx5UhWzznHXrVX/hKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KoavuC0H6R4G8P6RoVjpS6Za3cVkyyRyXNrEXMgGBKdqAb8fxAA1cTwvoEcHkx6HpqxZkPlraRhf3nEnGP4u/r3qh/wAJRq//AEIniD/v/p//AMlUf8JRq/8A0IniD/v/AKf/APJVN67gtC9D4U8O20ttLb6DpkUloALd0s41MIBJAQgfLgknj1NWn0fTJb37ZJp1o91uD+e0Cl9wUqDuxnIViM+hI71j/wDCUav/ANCJ4g/7/wCn/wDyVR/wlGr/APQieIP+/wDp/wD8lUAWR4L8LKsar4a0cLF/qwLCLCcsePl45dj/AMCPqatP4f0aSztLSTSLB7axYPawtbIUt2HQouMKR2xisz/hKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KoDctv4P8MyXsl5J4d0lrmVxJJO1jGXdwchi23JIPOfWn2PhPw7pd8L3TNA0uzuxuxcW9nHHJ833vmAB57+tUf+Eo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqhabA9dy7P4S8OXUksl14f0uZ5pDLI0llGxdyCCxJHJIJGfQ01vB/hlzl/DukscRrk2MZ4T7g+7/D29O1VP+Eo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqjYHrubJ0nTjaXNqbC1NvdszXEPkrsmLfeLrjDE989aoP4N8MSagL6Tw5pLXgZXFw1jEZNy8A7tucjse1Vf+Eo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqgCe08DeE7C4juLHwvottNG4kSSHT4kZGHRgQuQRk81ZvvC+gancS3GpaHpt5NMqpLJcWkcjOqnKgkjJAPIz0rP/4SjV/+hE8Qf9/9P/8Akqj/AISjV/8AoRPEH/f/AE//AOSqANW80HSNRm87UNKsrqXyWg3z26O3lN1TJH3T3HSs6/8AAfhfUbYxS6BpqOIRDFPHZRCSFQCF2MV+Xbk49Kj/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqlbSwLQm8O+DtK8NaJPpdrEk1vcMWnWS3hjWXICkGOJEjxgY4UZ75qSTwb4YmvFu5vDekSXKFCszWMRddnC4bbnjAx6VV/4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+Sqe7uKySsTQ+BfCVvcCe38LaLFMsglEiadErBwchshc5B5zVq/8ADGgarefa9U0PTb25wB51xaRyPgZwNzAnjJ/M1n/8JRq//QieIP8Av/p//wAlUf8ACUav/wBCJ4g/7/6f/wDJVHSwzQXwxoC3SXK6HponjiECSi0j3LGOiA4yFGBgdK1K5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+SqAOkorm/wDhKNX/AOhE8Qf9/wDT/wD5Ko/4SjV/+hE8Qf8Af/T/AP5KoA6Siub/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqgDpKK5v8A4SjV/wDoRPEH/f8A0/8A+SqP+Eo1f/oRPEH/AH/0/wD+SqAOkorm/wDhKNX/AOhE8Qf9/wDT/wD5KrW0TVYNe0DT9Xs0kS31C1juollADqrqGAYAkZwecE0AXqKKKAOWjEZ+JHiMTJ5kZ0LT96bC+4edfZG0dfp3rw3TPDV/B4Ru4k8LXQLaUiSLBoFxbOswuUZQ6spNxJjJ8xQAoB45r2G/8MaN4k+JmtJrWl2N88Wh2AgkurSOcwFpr3JXzFYA8Dtg4Ga4Wx0Xw/p2mLPqmgaTqFzocdwmrQDRLRftMvnCOEkJAWUEZYbBnA6MalWU7/11/wA/vt5hLWFn3Lt54j+JK3WoLHb6pFaLOQ0sOlq72q75AggBjJmVkERY4bbuPI6K7TZ/Fmp/Frw/deKdOv4fsiuirFpxa2hV7VCzGdUPJl3qQXwNo4HUsB0NrG5vj8I/DUFrYxwy3n2uJYJYo3YhnEbWucKFZvm2krg4ycDXvtH8LWljo9wPh14UVdRWSWQ3EMca28aIZNxP2ck/ICSMDB456001DV9P6/r/AD1I0ns9zN1/xJ8QINW8QDTl1lbSN4xZMmiiTbi5VXCARsXUxEnJJzjI29Bky6l4y17UvCp1+x1lre1vbafjRXHmMJpVeSUiLMRVBGQBsBDE4I6XEvvCv2Jbif4V+G4/LhuprlBDGxQQMg+QC3y+4SqQCFI5BGRz2fhnwj4P1/QIdQu/h5o2mzSM6tbz6QikbWIyN8SNtOMglVOCOBRCNoxb1tZ+v9WCVpcyT3uv+GOd1uLxFp3jPxPqXhZLmzZ7rTw+bMJHeqymN9sjxkMVLKcrnpg1j+JvEvxH0vX9QtdLufEN1DbTOsLJ4e8xJgsURX51t8ENJ5oyD0HUcGvUP+FceCP+hN8P/wDgrg/+Jo/4Vx4I/wChN8P/APgrg/8AiaIrl/r0/wAvxKaTdzyXxBq/izxDa+JNOH9raxYJLMhhOkZW3KSwtCIykQZ35fIJYgLkgYydnTfFHj+7vNEQw60kP2uSK8Mui+UHhMsio7Fo8hgnlngIB1OckD0H/hXHgj/oTfD/AP4K4P8A4mj/AIVx4I/6E3w//wCCuD/4mly6JdvxFZ2eu55N4duvG2mRoWi11nks7YXt0+hp9ot83L+cImMA8zAIYKfM+8xANena9Pra6poUGm32pRQ3KNFcCKwV3BZRtlkcxNGu3ByuUznjPCm3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNV0t5/wBILato4rS7/wAefZLCTU9T1Ce4mmuLWa3tdPjKgx5RZjIIdqqWjZtpI++ME4APO6fq/wAS9N8OQ2tsmqRpb6CJEMulu80lztbKgfZ2G9ZAFw7DK84Y/NXq/wDwrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0a6/13/zuO2t/wCt/wCkcb8PPEfjG/8AGs9r4gOsTaa0U5ie+0VrVVKuvlnf5ScspbgnsOAevH3E/iuTxzPqV7pmsSXk01pG+fD7SwRpHeOSqt5JUqsRVxJndno3avYv+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mhaSi/5fx/rYnlvGUW9zhLjxB8QY47JbNdVuSLqRGnOkhVuSHiwrI0StFFsaU7iAdy43sMbs7xJP401H4WGO5l1y9bUjeQ3Uf8AYy+ciqriFPKEIYK5CbnI+hWvTP8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JqXG8eU0WkuZf1/X9dLeaxa78RUjmghTULC0heyhtki0mSSQRFow7gNblcbDIWy5YMo4Xv6J4Zm1hfEusWWp3moX9rCI/s1xcWawR9wygiNN7fLklSy8jG3pU3/CuPBH/Qm+H/8AwVwf/E0f8K48Ef8AQm+H/wDwVwf/ABNXf+vu/wAvxM1CysvI6Siub/4Vx4I/6E3w/wD+CuD/AOJo/wCFceCP+hN8P/8Agrg/+JpFnSUVzf8AwrjwR/0Jvh//AMFcH/xNH/CuPBH/AEJvh/8A8FcH/wATQB0lFc3/AMK48Ef9Cb4f/wDBXB/8TR/wrjwR/wBCb4f/APBXB/8AE0AdJRXnfiPwD4Pg17wnHB4T0ONLjVpI5lTTYQJF+w3TbWAXkblU4PdQe1Zmv/DLRW8a6fbWFrpdjbXsczi3i0GwdE8tUwCXhLHJZs/MOMAYxkpuwHq9FeFaQ+hQaXZxaj8OfDV7MIDNLdG2hVpIgjvv8tLfG8iN/kGBnbzycSHU/Coicj4V+GGaGN5pgqwlfLEUUoKHyPmJSUcHGGGMkHdQmm2l0J5la57jRXiCp4bt9dnnu/h94faxj8uC4tI7K3drd/tMsHmRYgDS7iqkglcAHHobmit4T164trOy+GfhZby6CTxCRIfJNu0YkDbxATvwfubeoPzY5prVXQ5NRlyvc9jorxbGgs0YHwu8JxGHUPsV8rRI5iYGQsEAtxuPlxq4PH+sUe9VI9X8KSKZF+FnhYxLZm/Zv3HMGxHBX9xgvtY/LkDcMZIO6hO+39dQbtLl6/0j3SivEX1DwrJcSrY/CXRHhFxJDDPc2K26S7EmZsM1tgkeQchSwG5fmzkCxKfBtldhW+H2gXAn1NLcxm0gDQQssAEigQAEBp0yrNnLHDEYAI+87L+r/wDDg2la/U9morzLx14Y8HeGbPT9Tj8JaILeO4c3MEekWx8+NYJX28xkg5QHIIrEsrnwnM0f274V6FZBmhBEtiqOVkkkTcqSW6MR8gIyFyCemOVdDl7qu+1z2iivG9Tk8J6TpNjeXHwy8Lu95bS36xxRwsBaxhCSG8jDS4cfuxxwfn9axvvCiCCCX4XeFxfXhAtI1WExtzKG3v5AKH9y2BtO7I6c4b03Emmrr1PbaK8Pi1fwdfSK2lfCfSJrd/syrPPpywoHmaIBWf7OUB/fAgBmJ2tkLxl13c+ErGKS7f4ceHpD5FvIbP7PBhVYSmVlIt8kr5Z+8QpAXG0nBNldi5ke3UV574u8N+C/DPh19RtvAXhu9nyBFayWMURlOCSAwibnaCeRjjkgc1zYn8JH7Tn4ZeGEGx/sm6GL9+4aEKjAW5KFvtCAY3c5HTmlzJtrsV2XfY9morw621jwdfW089j8J9Ikjgso7h3fT0VEdkRzGZBAUHyycfNkkcqoINXBF4XuJ0gn+HHh2yAvkt2lhht3J23XkScNb/dzj0JDHlSAS3pJRfUlyUU5Poey0V5Hp1v4O1fwrrOoQ/D/AMN209jKsMB+wRSxyiRUaKXmNG2kSKSCAffvVL7H4b0nWp9KuPAHh/UvImZJbqW2tkYKn2dSyoluBk+eG2k9dwzjGD7XL1tf5f13G2lv/X9WPaaK8Y1TT/D8emadrtt4D8Mx2cs1wUtfssDG6iS2mkHmEwZibdEOFLdTn0EOsxeGJrd7fS/Anhq1uIrxVlm+z2xxCJYVyoaAhmbzgCvGOcNnGTdpdQlJRV2e20V4xpSeFpdT+xXHw48OvEJSJLhobcsm6W4RVCi3UEAwEZJBwQTkg56DwZ4b8M+JtLmvdS+Gfh/SkEoWAGwR/OXaDvw8EZAycdCDgkEjBIvevboDaTsz0eub+HH/ACSzwp/2BbP/ANEJR/wrjwR/0Jvh/wD8FcH/AMTR8OP+SWeFP+wLZ/8AohKBnSUUUUAc3Y/8lT13/sC6b/6Pvq2W0nTnF4H0+1YXwAu8wqftHG35+Pm445zxXKXOvWmifFPV/tsOoS+doun7fsWm3F3jE97nd5KNt68ZxnnHQ1pf8J5pH/Pn4g/8JzUP/jFAEp8E6DDYXNrpGm2mjrdqsdw+nWkMTTRjrGx2H5SMj1AJwQea0rvRdLv57ea/02zupbUMIJJoFdogwwwUkZXI4OOtZH/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MUAXYPCXhu2kElt4f0uF1jaINHZRqQjDDLkDoQMEdxV7T9NsdIsUs9KsrextY87ILaJY0XJycKoAHNYn/CeaR/z5+IP/AAnNQ/8AjFH/AAnmkf8APn4g/wDCc1D/AOMUCsjpKK5v/hPNI/58/EH/AITmof8Axij/AITzSP8Anz8Qf+E5qH/xigZ0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQB0lFc3/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAeKP8AkYvBn/Yak/8ATfeUy71TwrN4smg1qDT4dU0uHzIbm/EIfymUl2iYncFABDdMfTmsbXvFlle614ZnttP8QPFY6m89w3/CO342IbO5jB5h5+eRBgZPOegNYPiZU1zW7jULDU9X08yPGyZ8GalJJGFiljI3gL1EzHIAxgUnfoB18Nr8N9PlstRt4PC1rJ5DS2d0iWyHylB3NG4/hAJyQcDJqM2Xwxv7TY1t4Sube0WS42mO2dIV3ASP6KMgbj69a8+l8M6ayReVf6yHSCWHDeEdW8tdzysjLGjKuV85h8+/jpt5yPoKXDh7rV9SDrJ5ytb+BdSjw4EGzOd2VBtkJHfJGRwQ1vr/AF/X9eS10PQbS88CafrFvBbWWjWGES4sb1Ut44pmnLLiFwcl28s5wBnjrTbO++HepyjTNKi8PX6peNJJFbrbFIpghcy4JG444LKGIJ56Ejh57S0s9MuYLc+IbprmJEjNv4Uvomtrj7Q84nDMuAivIcIASAAMnmrepadpV7JcRW11rltYzys7Q/8ACIaizqGtPsxUPsA+6Awyp59aO/8AXVf8P/wRdben5a/r/TO8gn8Kw+Hzqd5q+m32nyXQnOo3c0DRNMCFU7wAgYbVUY54Hes2TSvAU+sR3cN7o0SaP51xPYwm18lXYrumlXblWDKPnyuD1rL1nVI9d8Ipo99eausu4CeWHwdqSRTR4IKGPaT3z97GQOCMg86mkosis2rapmNi8ZXwPqQ+bdbsu7OdwBtkyOMgkZHBpL4rbJbP5B0Wm+/9f1v8juIovh7q+kQ6/qej6Dbx6pMQJdRgtg08uWT7/IdjhsEE5BpHHw8t40bTdJ0G+Au4YHGnwW0hgeRxGjMB0GQoyOeOnHHMajFBqPgyDQZNR1pPLmmkkkTwdqQSQOXIHlhRypfI5I4HHQjM0kyXto9xqC65pdwmoPLBDJ4QvpCIhefaRuKAhixC45G0ZGCeaFul0/TQT5uW/X9dT0mN/Akul2VuJtBuLK0maOzV5YpUilUHcqEk4YAnIHIBrN026+GN7pcd5Yw+GBptnIggudtsscUjkMFHeN9wBwQpzjriuS0zTrXTrhJ/7U16SY3a3M848I6mssoCIrKTgg7/ACwW3KwzyACAQ7SbUaPNazW2qam8tkIUt/M8D6kVCxxNEQw7kqeoK4PqDimu/p/wSpX6f1ud9eWfgXSjHZX0Hh6wZWa/ihmSCMqyjLTqpHUd3xx61n6JpvgK00WPSvt+i6vHqly7b7o2rtfyqxY5CKqyMpPoSOK5zxitr4p1SG8iv9ctfJhMccUvhDUplRikqMwAVcZEvPf5F5xkVmyaXHcyRC61bV2giuVuBDF4K1NACvlDI6jdiLGSDjccd8yr3/rv/lb7glpa39af5neXZ+G2oXQuL4+Fbq4mxCJJvszu+xgoXJ5O1tox2OBVc2XwxhTzTpvhRLRbYTm68u0ESxliinPXBJYA429RnPFefReGLa1hSOz1TU1/dvFI8/gzV7hpVYw4JLucMBAg4wuOiitE2W9ZUbWNVEcqyK6J4J1Ndwe5M5U8/d+YrjuOvcFu6tb+tw1/L+vuPR9Ps/DmpxXumx6XbPDHci5kt54FeN2f5lmUHKkNyQw7g9CDWfLp3w0spL0z2fhS3exIF4XitkNvvxjzMj5c4HXGcCua8Oay2j6hC/2fVvIgtrbTpDJ4Z1HdPDCkn7xQsRCMXkHBLfKp6E8Ynios1zqWq6eviLUri9kRRDH4V1BZo4hIHADlos7cEDa8Zwc5zncS0laO3f7rf10Er8uu/wDV/u/H5nctcfCm6Us0vg6YeUsBJa1b92SCqf7pJGB0yRRFp3wpF4sMNn4OFzbybVRIrXfE4JOAMZBBVv8Avk+lcONPGo+HLqxvbrVLCO9WJWtbXwZqQSNEgMIjP3t2Mqw5wGX+IVNDYmK5WcatqW9JXmUjwNqQ+ZpVfn1A24/HPtQ7p6A2+W6O6ivPBkWn6pZ+Tp2k6ZKIkkuVeG3guxKuUZHRue4BODkcdjUE2lfDW31D7NrCeGbnVmMcc0l+lqbqd2+6XyASzYz057Vw6aNCLK2gfVtWZrWCK3iP/CEajtKLA8L71IO4lXJBGMEdxkVduXtbHwxeaLYjxFdWs8ySWZj8K3yXFnMCpEzSsgDKrLnATdjjkU9pO3y/rp/WwrtLb+v6/pnXQX3wykvZZIJfC3nwzq7yj7OCJpAQDu7swyODk8ipJ9P+H1vImn/2V4cfFwY3gWK1Hkv5ZJLKcc7EwQATgdMAkcVrelaRql5PJZ3WvWkM0P2fyX8I6hKFiaAQuPuAZ2qpVsfKQfvA4p1zZ2ctwfJvdYW0F0J1tJvB+qSJjypY2B6EFvNJJXauRkKCSSl/X4f1/Wtf8H+vv/pnd23gvwRqFp9s0rQdDKz5eO9srOHO7n50dV+8DnB9ateE/B+m+DtPltdL5Ezh5H8iGHcQMDKwoiZx325PcmsLw74nttG0uKyvpte1ARqcSHwtqSuWLsT8zIxIwVAyS3yklmJ41/8AhPNI/wCfPxB/4Tmof/GKrRN2DdK50lc38OP+SWeFP+wLZ/8AohKP+E80j/nz8Qf+E5qH/wAYo+HH/JLPCn/YFs//AEQlIZ0lFFFAHLRCM/EnxEJ08yM6Fp+9NhfcPOvsjaM5+nevI7S+8U+GfCelWnhGw1zSwY7h7mC38Nu2ZvtKbCwaAnmIv3xhQOtemX2g2+ufE7WvPnvoHh0Sw8s2moXFsMma9+8IZE39B1PHOMZNcZ4TnW80TU9T12XWLqCxijb/AEHW9RtXMrEgxBZ7wh+NhD7gG3YGajRSu/63/r1Bq6X9f1/kVLvxd8Q/7NsTDJ4jjnaIpMV8NsxJF3tDkfZzhjAS2OBkDjnBnt/FPxFN1oElyNeWG4igF2q6F/EJpFlLjyMp8gjbsOcjjNW5/E/gu2006hcJ4xhs8RbJ5fElxGrmSLzQo3XgIOzJwccqQMkqD3lv4L0S6tYriC98QNHMgdD/AMJHqHIIyP8AlvVculuz/pE6fev6aPMLHxb8UpfCs2IdUa/861DT3eiPC0Ksj+YQiwEuodY87UY4Y4xkEeia3P4jl1jR7ayv7y2F1aslz9isQ8cUpQkStJJEVChhjaSp5GQc4Gh/wgekf8/niD/wo9Q/+P1Fc/DrQb21ltryXXLi3mUpJFL4hv2R1PUEGbBHtRLW/wDXS39f5jX9ffucZb3/AI9k0mylvNQ1KW6u7a4SS2tLGNlikWNlSQy+RtwWj3bdwOZBjcMYxLbWfiPp2lPa2g1SGzs9It/su7SJJJ5JNsecKLcjcG3oyswO3BC5BY+oRfD7RIIUhguNejijUKiJ4ivwqgdAAJuBT/8AhA9I/wCfzxB/4Ueof/H6Nbv+u/8AmK239dv8jkPhv4i8Yaj4q1G28Rf2vLY+TI9q1/ozWiqVmKoA/lICWj2sQfXoMEVxenXHiw+NjqmqadrP226uLD7Sz+Hmkii2PMJFVhCRtQMhDg7jnhjXsf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9FtvL/ADuNq6ku5wsmveP400tIP7WnPnGOWY6UALoiVFcsDCpiQR73UkKSwxlhjdh+K5fHOqfCaygvTrt9JqtrcG9jGjKZklXAihMawhkRsElyM5AwwBAr1b/hA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+i2lgjpK551BrvxFmvp4Zm1DTrT+0re3gW30h5JEtyxBf5rcrtMeCSWYqw52g7a9A8J3WrvrGtWurXF9eQ28yi2ubizFujKd3yr+7QsRgZYblPBBGSol/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+qTt/Xp/l+IuX+vvOkorm/+ED0j/n88Qf8AhR6h/wDH6P8AhA9I/wCfzxB/4Ueof/H6RR0lFc3/AMIHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/QB0lFc3/AMIHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/QB0lFc3/AMIHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/QB0lFc3/AMIHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/QB0lFc3/AMIHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/QB0lFed+I/BWlw694TRLrXCJtWkRi+v3zED7DdN8pMxKnKjlcHGRnBIPNeL0bQNe1axtb7WCsFjb3Fn/AKXrNyAzuysJZI7oKq4Q4LbPvdTtOTqD0Tk+h7TRXk5utDiuGszpvja5vIbk2k6QeIrhSkny7SQ17wr7sryeOuMZqm/ijwMLs2tu/i65uRFHIbePxHdCQFinylGuwQR5i5JAXqASQRSTTV0K/RnslFeR6nrngvRrKe41SXxTa+Rc/Znik8UXAcOFLMMfbMZAUnGdzcbQ2Rly6r4UNrcTvD4xiSGTy1MviO5USnzWiJVjd7QAyH7xGcgDJOKa10QX0uetUV49JeaWjSxrbeK2CGctcDX7vEPl3IhwU+25brncGGeuOcCwbrQppraK2s/GUbSXb20pk8QXLCNkcoVYC9BUsVO04PqRip5lp5/8MDaV/I9Zoryfw3d6H4gmsrZ9M8Z2N1eQwzokvia5ZTHIrsJAVuySg8sg8A5K8c1peI7Xw54a1Cys7seLLh7wPsa28R3hClQSAwa6BGcYBxtzwSKqXufEM9GoryT+1vCYtbWeSDxkn2m6S2EbeIrrehdY2Ryv2vlSJY+RnG75gKo3OsaOTps1nZ+LkimcPPbT69eGaSBoJpFkiK3m3rCwIY54PHQk23Baq69T2mivI7yfSZ4L+LSI/FEN3ZMS7Xmv3jR7B5TbsLebsOso2n1zkcEVatZ/Dd9cT2tlbeMp7yG8NoLdPEd0TJhSxkV/tezZgHksDxjGeKCeZHqVFeQ2N9o91dXSTaf4whMTvDBAPEV07XbrcGEbGF5gcqchwoHXdgZOzrtn4e8Opph1EeKw2oyrCI4/El2zQMxVRvH2rkBmUEpuAJ9OaV7q47+849Uei0V47c6nok/hu6u9Ks/GS34h8y2t59du3LjY7+YQt4AUHltkbg3HAORnYvrfw/pU+jW17/wlMs2qxhke28R3hRG25wwa6DAE8A4IzgEijmQXX5/h/wAOelUV5GuseFG0m31F7bxpHFPNDGEbxDdbwsqBlk2i75XDc4yRzkY5qlfavpMV1p32ew8YRxyyv58E+vXhlliWOYloit5tyrQkEMenTqCXs7Ma12PaaK8jvJtJngv4tIj8UQ3dkxLtea/eNHsHlNuwt5uw6yjaeuc5HBFWop/DVzql1plnb+Mbm+t7r7OIIvEdyfN+8TIrfa9m0bGzuIYEYxnignmR6lRXkFprHhia8Nrc2vjC3kW6a2dv+Eku3WPMzwxMxF1kb3RlAAOCOcDBK6e+m6pfeHIbF/EckWosovJ5Nbv0WMvbvKqDF4xV8KCR84wfvZxQtVdFPRtPoevUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSVzfw4/wCSWeFP+wLZ/wDohKP+ED0j/n88Qf8AhR6h/wDH6Phx/wAks8Kf9gWz/wDRCUAdJRRRQBzNrGJfidr8bbgr6JpynaxU8zX3QjkfUU1Ph14ajt4IEtbsJAiomNSuckK+9dx8zLbWJKk525OMVJY/8lT13/sC6b/6Pvq6SlZActbfDfwzZWslvaWt5CjyJICmp3IaNkUqpjbzN0eFJX5SOOOldOiCONUXcQoABZix/Enk/U06imHmFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfij/AJGLwZ/2GpP/AE33lUNds/As+qaoNd1eCC8ubeOO+ifW5ICIkIKZQSjYMt1AGdx/vHN/xR/yMXgz/sNSf+m+8rN8ReALrxBe6lO2rxwLdPbvAiW8qtEYgww7xzIzBg7fdKEccnnMu/RB0KGr6Zod7DqHneK9It3hvbe41GZZSjxQRj90jyLOHRyMfvC3PYdqU2Hw41C5ksrS+jCRAJcRWWtyW8SCFFYO8aTKGwNnzgMeBk8Ulv8AC+8tNUj1C2123Fxb+WLbzLB3VAh+VGBmyygFgBkEZBySCWl1r4bX2syyeZr0EMclzJdMEsG3B2SMcHzcYDRg4IOQdp9aaulp/T0S/D/h9bka32/4bV/n/WhbktPAWp6kjjWbeXUNQKTQSQ67IJ5AA4XymWXcE5k+VCFPzcdaiPhvwTbaNd6paS3V1aThoZDaazcyidpJMmNQJcEtI/TuWx3qpD8MdQtrwXEGu2O95VmmWTS2Ks/2hp22gTDapLYxzgDqa1x4W1Cw8JCxiu0v7m2vUvIEKsikJIriEF3dhwuNzMeT2AwDpr/S0X5fl8htyvorr+v1+4yrPSfh5fj+zVuY7e4uJZkWzGvN5zlpdzgCOcnBeInaDwVYYHzCpbhvAcutJ+9jcXdz9rk1CDUysIuICkYR2WUfNmQfJjBJOeTzUj+GerPfXF1Jr1mqXNx5/knS23xqbhpym8T4zlyuQMcdK0JvAer3NjZWlxr1l5djZTWcRj0tkJVgmwn99jKmMZwAG5xtoW13934/nb569BP4mktO/wDX9WKl+3hTRjZBNVgW2nt30rTjY3irPbRswEjCVpdxCsijKj5McjHS/dJ4H8UXMMuo39sb+O0VniXV9k0cYAfLiKXB2h87skAMcHB5zP8AhWGrpveDxJZiaWbzpGl0oupYXEk67R5wK8yuDzyNvTBzWm+Gmu2WkTeRrFlfypa+UsKaXsaXFqbdQC85UcHPPGfSlryu/wAv69Wynfnstv6/RL7iS40r4cWmjw6tYzC9smuo7b7dDrMk8Nu4CBWkYz42r5UWRn+FTjjIbYaD8PtN0OC317xHptzdW7LHLeLqz22XeNwi488lAY3fCA4+ZiAMmtLR/Cerz+DLOwujbaZPb6it5ia3aZpArbz5gNzId5bOW81+Oe+Bl3PgPUbTw/qdta2817dRaENMh8vy4Y72XaVWVUaQ7SqttJZgTzjjFV3v/Stf89Pu7Cje66f8O1+Wv3mxFpvhCe3livNa0+aDV0jtLYwX7RPNFBnbGJRKXkYEnJDc9CKrafZfDN9PSXTtXtUiUfaUlTW5UeNYyybg3mhlUbipwQMcHjApp+GE17dx395qwSa5eOW/iFmArbJUlURASEREFACcvkE+xFV/g/KUuFXXIj51lJaq0ltMfKLI0YdUFwIydjYOVJJ6FRwFru9/6t66iiultP6/Qv3Wk/DsQ3GoC+glM0UswEWuuoYLIZHaPMwVCJATuBXBzyOava1D4Gv/ACLfXtUtVm06NAFm1ho5Yg7Ky72EgY5ZEILE5KgisqX4Z6tcR3qyeIrOI3kVxE5t9NkQMsqMoDKbgqwUuWBwG7BgCQYrn4S3U95Hcpr8AaG4F1EJNPL4kMkUkgY+aCyFoRtXI2gkZbjDXRdPyHrv11/Qvy+EPh7aaTbz3NxHHY3Yjitpp9bm2SjDBVRml53K7DAPzBjnIqa7g8B3UP21tRtbg6NAkReLWCDEqsQgdvNA3bgwBc5yWGeTTdT8AX+p+CLLQJNchja3L+bKlkwjmBDBf3fm8FSwIyxGR06Yp23w11a3uvP/AOEhsi6TPPGBpTAb2meU7wZzuH7xgBxj5TnjmJXd0l/X9XH9n+v67DbTwx4B/wCEb03VBDcW0N/bx/YobvV5g75jGyJQ02CcAfKDjKg9gRQ8NaJ4GvfCdlq2s6tbzS3MpP2ptRktCkkociHaLhtjBZmGwNjLEgZNdJJ4Iu/+EV0PSrfV4obnSFRFvVtXBdVwMbBKBghRkNuXIBwCBjAHwguzp6WsniC2+S1FnlNNIDRGAQyEqZiC5ABVv4SOjA4rSVnKT89PQEti9ew+FLK7utM1G6ju/tjwWFwLO7MUllDGjvELiTzvN6BsvnnjIxk1d0vwr4Q1C8uvsNteR3EMqS+YuoXCsQd7JJG6yfcbzHxtODkgjjFZ+p/DC/vtDGiW/iC3g06O/a9h36ezTozFmwZFmUEhnJB29gDnv0Wk6VqsfiC51K9liVmhgtGJjybhIhITIAG/dlnk4BLYC9MnhLd3/rb8b/56k2tolp/wf8v8tA/4QDw19vS9GnuJ1kaQMLqXBZnL5I3YOHJYAj5WJIwTmm2Xw+8N6dcWM9nZzxyWG37Oft0527QyqSC+GIVmXLZ+U46cV0tFC02LavuFFFFABXN/Dj/klnhT/sC2f/ohK6Sub+HH/JLPCn/YFs//AEQlAHSUUUUAcxbwx3HxM8QQzxrJFJoenI6OMhgZr4EEelcXaaDqOhaXdQ6Pofl3XhaK4h0ub7N/rlmlDBoztYsyxjBwrZY9CeK6K90C31z4nayJ7i+geHRLDy2tNQuLYZM17ywhkTf0HU8c4xk1wXhzUZGsbq+8R2/iG7som8pZ9P1TU7ZRL5zR7cz3e11woYuGAGdvJqN5W6v+v69e4Nq2vf8Ar+vI2rTVPGt1pGqX0+tatBPpdtFciE6UsMN0AWMiB57WNixRQMjbhmJxjAHRazd+IbODw/Gt3q7TypNLeixsY5dxEZdYy5hZE+bCAnbkHueRy1/deC7mW+0/U9M8XXEmn3UcT202vXEh84uggwDdkAuXBRjgfKxJXFZ91rdhpuseItP1SLxLA9kjSWbR65eyFNtsszrKPtoDMMn7rBSBjOcZbs43Xr/X3rT/ADFFe8l/X9f10NO11zx9JbIgn1iS5itbyVfM0gRLcMpjMKuxtwAdrSDgKSUHGeD6D4IutVvPCdrNr7mS9ZnDM0MkTFd527leKI7tuMny1BPIGK821jX/AA5p9nqMVrD4tl1G009byMS6/epHNuKKCB9qzgGReuARnBOKfeavoduwaax8aWNvBqK2N3dXGu3MkaPjcV+S+3dCDuAYD0zVcySt/W9r/jYhNPW/9Wuey0V5u9v4eg8GHxLeR+LrW1YIYYZPEV2ZZg5Aj2hboqNxYY3EYzziuP8AD3iGwuLR5tfh8TI8ccrtDa61ejAW7MAJdr4hdowWz8o5IY9KOvKXzLl5uh7xRXj91r/g61+2Zi8Zym1IAEfiG6PnHzVifZ/pfO13VTnHtkVUv9a0a18XW1g0fie0sLeO4OqyXWv3rNC8cAm8tTHdkFgpGeCDnhsg0rq1wvrY9rorxzS/EXhHWlRtItfG16rW0ty7W/iG5cRrG21wcXnzEHGAu7O4YzzjsNF8MaHrmjW+pW8/iSKK4XciyeJb1jjOOqXDL+RNVZ2v/X9aBdXsdnRXN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P0hnSUVzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9AHSUVzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9AHSUVzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9AHSUVzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9AHSUVzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9AHSUVzf8Awgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9AB4o/5GLwZ/2GpP8A033lct8QLjVrjxRp93pel3lzb+HJ4biUrBPmRpHCt5KrEwmKx7s4Ybd/cjA6SX4daDPJDJPLrkj27mSFn8Q35MbbSu5SZuDtZhkdmI71L/wgekf8/niD/wAKPUP/AI/R1T7ag7NNPqcDf+LfFUBvhBea8PtM8iWnm6E6eUBOuwKRascmMt1SQ4XO3qaQa54sS1kNhdateM4g8/VIdBxIzeQ/CoYF3J5wCtwWQMR8vUdpqXwu8MazZNZ6umrX9sxBMF1r19KhI6Ha0xFWIvh9okEKRQXGvRxRqFRE8RX4VQOgAE3AqVG0OVslq8uY4L/hJfH8dndjGryXb78o+kMiWwWZRmN1tn3HYz4+WTIUEA8kl34l8d2dp5dzJrT3DRMyy2OhPLGWaKBkwDb7h8/njDAED72DtNegf8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/TWisHLrucPqN948e51Cziu9aEEQOZo9PQMsSyReXJG4hG93Qyl0AO0rjavfU8I6jrb+JpLTU21e1sUuLgwEaN5SXjGeTmZvJG35PKYMNm4sxJbBx0n/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P046WG9U153OO1zXfiDBq+rrpltdvHEZAIxZ/u4ohJEI5IZBExkdkaUsuJMFfudA2Zcal4ymvbK/urS+udVs4JBaCLSZBbtvtj+8MjQB1cyAqUYKPlX5OmfRP+ED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH6lL3OX8f6/r8LN6v+vL+v6d/PLbxJ44NxBDfXuuIJFiG+28PyyKAzzByWe0Qh1UQnlVBbkLg4rofCXiDxVqfiyyGqW+pQ6fLpi+fFdaeYkW4EcTFw3lqVyWkXaWPKdBkZ6L/hA9I/5/PEH/AIUeof8Ax+j/AIQPSP8An88Qf+FHqH/x+rWjb/r+v1E1d3ODur/VLQxXWkf2h9vuUn+1XNnpX2to7j7XGrqX8p9v7tSNhONsa4AwDU41PWta8O69aa8uuzgafcQ2ttJobhL0YcCR/wBxkSZAwoKg8EKc8dhF8OtBgkleGbXI3mbfKyeIb8GRsAZY+dycADJ7AVL/AMIHpH/P54g/8KPUP/j9Qo2jy/1/SGrqfP8A10/y/M4mLXfFaK1lL/b3kCNkeUaLuaKPz12sg8nDOIXxtIbpypYMKw7DUPEmj2tlZ6ZDr9iEtIopJIfDRJASO4+XP2dhgSeVgZIG844Nepf8IHpH/P54g/8ACj1D/wCP0f8ACB6R/wA/niD/AMKPUP8A4/Te1iYxs7nPeF/EGs6r4+lW+1K9i07yCIrKXTXiR5diE/O0AwV+fK+aWJ6qu0g8zYT+JNJ1WSfw/a6xJc3OoXUl495owRbxTI6wqz+QrYUbGDFsAMQOAQvc2/wp8KWep3Go2kGqQX1zxPdRa5erLL/vOJst+Jq9/wAIHpH/AD+eIP8Awo9Q/wDj9DWi9BpNRcfP9LHMQa14rbWvD0VpcanNYTkG9m1HS3hYvu+eNlS2+UAH5WLRj1d6Zr2t+O7fxDrCaVb3bxQq/kw/YgYPJ2IUljlCMWkLGQFPn6D5P73Vf8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/Q1dff+P+X9a6i5dd+34f59f8tDzu7v8AxldS6ReXNrfXeo2O+S0CaVJ5LlradQ7u0COj7yilSEHRtuCCC38TeOPNtVvbzXV3+UD9n8PyyLtaZlcszWaHcsZz91RlVwDyD6J/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8KPUP/j9HW42rxt5HC6frniDWGdPFKanBpH9ksblrzT2tljuI0jcTK/loYzuL8FjymRtyK9O0O6nu9FtXvUkS7EMYuA8RT95sBbGRyMnqMjqO1Y0/w60G6i8u6m1yaPcrbJPEN+wypBBwZuoIBHuKl/4QPSP+fzxB/wCFHqH/AMfqr7/13/z/AAQNap/10/yOkorm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+kM6Sub+HH/JLPCn/YFs//AEQlH/CB6R/z+eIP/Cj1D/4/R8OP+SWeFP8AsC2f/ohKAOkooooA4PU7nWLb4ka62j6fZ3sf9hWJuPtF/LbMgE17jZ5cMjMTz0wRgYznjndFuW1Dwxp+h6ToFjJperiaa2RvEWqL5qg/vN0jWm5VJY/KxAOeAa7qx/5Knrv/AGBdN/8AR99WHceAdUk07XbKG9gSGUSLpWGOYklkEsqPlSACwCgYYbRyD0qX106f0v68w7W7ldvDPie+t9Rh1vwv4Xu1vnj3CDWrmDakX+qAIti29f74I56AdKo3/wANrjUr6a7vPB+lPPOMSsvjLUUDjYIzkLAByg2n1HWqX/CsW0/Q9SfVtG0+a8EMC6VcQA3s8VwjErnbbxBU3FAcAKFXBworqdZ8DS3MHh+3sbHSLhNMSYvJfL0leMgOIxGQ2ZCHOSvI9abVk3b+v67+RMemlv0/r/MyP+FfXJ+0E+CtDJuYTBKT4qvcsh2ZH/Htx/q0ORzkZ7mp5PBWpy2zQTeEtIlie9F+6yeLb5904GNxzb8jH8J+X2rJtfhLqyWyWzQaPAkVreR28sczO1tJMY2UoDCAAGVxxjAc4XtXoPgjQp/DfhO10y6wJImclVnWVV3OWwpWKIBRnhQigDgdKq11r/Wv/AuJeS/r/hjnl8N60nhdvDw8I6CdLbH7hvEt2SuCCuHNruXBAxgjbgYxisuy+HV5p7StZeFNPhaaJ4XK+NtSyUdtzjPkcZbk46kn1r1Silu7l9LHmD+ALp0uEHgjQI1udm8ReKLyMDawcbdtsNnzKrHbjcQCc1LeeCtQ1DW5NWu/BmhSXcoYSH/hKLwRybo/LYtGLbYSUwpJGSAPSvSqKAWmx51ZeFdc0+eOa18NaassVo1lG7eMdQcpCTkqC1ucc4weowMEYFaulQeK9F05LHTfDOgxQIzMA3iK5kYszFmYs1oWYkkkkkk5rsKKLisjm/t3jf8A6F7w/wD+D6f/AOQ6Pt3jf/oXvD//AIPp/wD5DrpKKBnN/bvG/wD0L3h//wAH0/8A8h0fbvG//QveH/8AwfT/APyHXSUUAc39u8b/APQveH//AAfT/wDyHR9u8b/9C94f/wDB9P8A/IddJRQBzf27xv8A9C94f/8AB9P/APIdH27xv/0L3h//AMH0/wD8h10lFAHN/bvG/wD0L3h//wAH0/8A8h0fbvG//QveH/8AwfT/APyHXSUUAc39u8b/APQveH//AAfT/wDyHR9u8b/9C94f/wDB9P8A/IddJRQBzf27xv8A9C94f/8AB9P/APIdH27xv/0L3h//AMH0/wD8h10lFAHE6p4i8b2Go6Nbf8I/4fH9o3rW2P7ZnfOLeaXr9lG3/VdcN6Y53LSv/iJrel6xJpl9oukxXEKo0rm/vjDGr52lphYeWoJBGS2MgjqK3/FH/IxeDP8AsNSf+m+8rO13w/4i1HXtZFnFpaadq1hFYvcTXUhmiVfM3MIhFtYnzSAN46Z9qOodC7FqnjWbfs8O6ENjFDu1u4XJ9s2fI9xxSzan41ggklfw7oRWNSxCa3cOxA9FFmST7AZNcpP8N9cmvLo2radpwkluxDdRTmSSOOZCAwQwgpJuOSVkAPfdgYzX+EOpz208dxpnh145LK7igtjK7RWcsqxBDHmHoGjZ84BBkOAcZKjqlft/SBbpPud+uoeN2UMPDugYIzzrs4P5fY6ZHqvjKWSRItC8OO8TbZFXxBMShwDgj7HwcEH6EVxMXws1wT3U19DpmotcXsNw6XN7+7ZFdmKlRa7iQGKBmZsrx8o+WoYfhNrq6XHBLb6D54uILl5lmfeJIoY41Ik8nd1jY9s+YeeCGa63/rb/AIP3E3f9f1/VzuYta8YTybINB8PycMd6a5cFOG2kbhZ7cg5GM54NT/bvG/8A0L3h/wD8H0//AMh1w8vws1ZHSO00/QFtU3efAZmVb8faHkEcoEPC7XHPzYZRwRU2ieAPEXhfVodUtbHSNTubaNQZmvXinuAtsI9hJhOMuAeW6KpPso3au9Ad72SOn1DxD4t0qCOa+0HQY45Jo4FZdauX+d2CqDtsjgFiBk8c9at/bvG//QveH/8AwfT/APyHWR448H6t4k1CzurBNPYwrEU+2SujWsiTLIWjKo3LAbSeOg68iuI/4VpqVm9jo81jb3l7cpdH7dLukhtiVhAlDx2yLHJuQuEPJbJLknNEddxvy/r+tv6R6d9u8b/9C94f/wDB9P8A/IdMm1PxrBBJK/h3QisaliE1u4diB6KLMkn2Aya47TfhbqVnqGi3Zh061+xyySXMVjdCMFjIWVw5tizEoQhAMfCgbiOAk/wz119NktooNFG+zurQCSUMAsiuE+7brhssCzrgEcFGIDATb38wXxJPy/4P3HaLqHjdlDDw7oGCM867OD+X2OkfUfG6Izt4d0AhRk7ddnJ/IWeTXEX3ws129u7q4mGkTtOQzGWd8zgyQuI5D5X3YvLcIcEnd0XnPVaPoesxeCNT8OahpOmQIIJYrMQ3jSQSLIXIRgYlKBQVXG1hjp6UpNqLa3CDbklIux6l42liWRfDuggMoYBtcnU8+oNnkH2NO+3eN/8AoXvD/wD4Pp//AJDriLX4aa6t3dSXOnaGou4mjmkgv3DlTBCm35rYqy74ixDAg7uQeQYJfhT4hlhuvOOizzyW+xZPMkj3jZGogbEZAjjKF1YDqfurkmqej0/ry/r/ACvN5WWmp3327xv/ANC94f8A/B9P/wDIdRrqnjV5pIh4d0LdHjJOt3AU59CbPB/Dp3rhE+F+vGeMy6H4ZaBrozTRG/lI2ee0ixgfZsEKjMg6DDHjBxSzfDHxRdaGbCa30FW22x8wXcjMZYYDGsm42+VIbYcjnAxnjBFdq7Kd+ZpHffbvG/8A0L3h/wD8H0//AMh1GuqeNXmkiHh3Qt0eMk63cBTn0Js8H8OneoPEui6n4p8PWlvdaRprTwaikr213dFo3iRyMhhG3LL/AAlf4iCfXzjXfAutW2k2thrWi2V9DObdJPsMk85dooDES5FnJszxhyvAH30IBpXevql9/UNf6+Z6HaeKPE97ayXEGjeHhFFcNbO0uuXEWJVfYV+azH8XA9cjGc1f+3eN/wDoXvD/AP4Pp/8A5DrhZvhhq16LmSTRtAVbqbz5LeW5dhIFuY5Y4n/cEYCK6Z5xuOAQTUWj/DHxLpVxay2+neG7WW3CKskV5K44imRm2/Z1B3eZHlc8iMDPTAm+W73BNtvtqd/9u8b/APQveH//AAfT/wDyHR9u8b/9C94f/wDB9P8A/IdefWfwi1eK3uLd7TQ4FFrKlpPFcGR4XeRX2hWt9qr/AKxcgEYc/Jgla9E8Gabf6HocOj31sscdpEojmW7WbeSWJXiKIALwBhAMEAAYprb+vMXM77DPt3jf/oXvD/8A4Pp//kOj7d43/wChe8P/APg+n/8AkOukooKOb+3eN/8AoXvD/wD4Pp//AJDo+HH/ACSzwp/2BbP/ANEJXSVzfw4/5JZ4U/7Atn/6ISgDpKKKKAObsf8Akqeu/wDYF03/ANH31dJXDX2g2+ufE7WvPnvoHh0Sw8s2moXFsMma9+8IZE39B1PHOMZNeb6H4it/tE0Xi2bVtPfTbSS8vY4ta1L/AEmElPJlhY3eFDb8ENuwR1HZX1t8/wCv6/UOlz6BorxlPE3hO5sbi803T/HGoW1rZC+nltvEc5WOIl1Jyb0biDG4IXPTIyOauDVfCP2mzhdPGCG6IAf/AISO6ZYwzmOMsVuzw7qQuM9OcCm9N/6/qwrq1/6/rVfej1qivHNK8ReEdYije2tPG6ebLDGol8Q3K/61WZGJ+2YA+Ujk5yQADmtjX4/D3h++u7WW28ZXb2lkb5zbeIbvDRgndtD3SliMZOBgZHOTih6b/wBdQTTdl/V9D0uivGb/AF/w3FoV/f2Nn4wk+z6fJfQPL4kuhHOikqGUi7JZcgHIBwCPUU0+KfBcdzNZOPF0l/bGFJ7aHxHdFleRlTGPtf8AC7qCenPG4AmjrbqLmVr/ANdP8z2iivLPC174R8VWeoXNu3i6ySwhW4l+2eIL0ExsG+YbLlsj5GHY8VzFl4j0+e8uZbqHxRFYf2hFBaxx6vfyTyRPamYbgL3AZsZBAbjgqCcgvrb+t7Dv/XornvVFeSjVvCBurOAL4wLXcSuCviK7ZYy+/wAtGYXZGX8p8YyOmSMisbWvEmkJ4f0+80Sy8WR3F+YZ41vtfvCq2zyxxmRgl5kZL4HU5GSuOaOtvO3z/r8NRcySv8z3OivHIfEvgq9kaLSR4w1KZb9bARW3iS53NIwcqfmuxhT5bD5sEY5AHNdP4f0bQvEK3hhHiq0NnO1vIl14jvQ24HnhbliPXnGQQehoWquv62/zQ20nb+uv+TO8orm/+ED0j/n88Qf+FHqH/wAfo/4QPSP+fzxB/wCFHqH/AMfoGdJRXN/8IHpH/P54g/8ACj1D/wCP0f8ACB6R/wA/niD/AMKPUP8A4/QB0lFc3/wgekf8/niD/wAKPUP/AI/R/wAIHpH/AD+eIP8Awo9Q/wDj9AHSUVzf/CB6R/z+eIP/AAo9Q/8Aj9H/AAgekf8AP54g/wDCj1D/AOP0AdJRXN/8IHpH/P54g/8ACj1D/wCP0f8ACB6R/wA/niD/AMKPUP8A4/QB0lFc3/wgekf8/niD/wAKPUP/AI/R/wAIHpH/AD+eIP8Awo9Q/wDj9AB4o/5GLwZ/2GpP/TfeVzev32tx/EtbTT5dXtLS4MCzXdnowlURiOclfOMDDAfy+CTje2O+JPEfgrS4de8Jol1rhE2rSIxfX75iB9hum+UmYlTlRyuDjIzgkHoP+ED0j/n88Qf+FHqH/wAfpNXDoef2154qnm0me5vvEryzx28lzIdEWJ4QLkK8e4WwIBADFWzxz92oY7nxpe3a6rLBqseoW5nisZpNLHmASJC6W8h8kDy96urSbRjb94ZBPo3/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9OPu/j+P9W/4ditq33t+B5011qC6hdyjSdT+2rdFJJh4dfbNENRVhz5Gx/wB2WYMOerZzk1t6PJ4stL+xW91vVpbS6kumuVuraFXtfJm3fKPJDOjp8o643DaemOq/4QPSP+fzxB/4Ueof/H6gHw28PC+a9D60LtoxEbj/AISC/wDMKA5C7vOzjJJx70ldJJdL/iDV3J9zM8a69qyS6TL4Xv75RfWc0sEFtZLN9okHlmLeGjLIh3EMcqADyQeRRvdQ8ZvLM9pfX8Xl6l9kKNaRpG6TAqjp5kCsfLcoxwWBGfmbtvS/DHw1PqEF/ONYkvLdWWG5fXr4yRBvvBWM2QD3x1qSX4b+H57iGed9akmtyTDI/iC/LRkjBKkzZGRxxTW/9d/8tPnoJ3a/rscXrk+uzrYzyTa++rWOo3Db10MulqognVDGywFXV/3eSS2SeNvQJeaz491JrwJ/bFlEyb2WDTdvkx74SjRM0e5nZGl3IdxUrjC9+7/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+klZ3Y2r28jm/COo62/iaS01NtXtbFLi4MBGjeUl4xnk5mbyRt+TymDDZuLMSWwcZHii41o+L7u8ks9WkeGGe2iSHRTcQiPzrdkCsIm3h1Vyck7TkDaevd/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9NaNPtf8Qet79WcVrHiHx0l9cRaXHqjxJPMYJk0wlJZPlMMJDQqyxEFgz8gED951qnqt14m1LR0XU2165ha/lkEP9iK3+qul8tSohDKvlAuHHJI4bI2n0H/AIQPSP8An88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8fpJWS8v6/r/h7jV1b+uv9f0rcZomueNbzxNbW2tXGqWdu94/mJb6U7KqKrHa0j2oQKSqgbWY/M3zk4x6pFIs0KSoGCuoYB0KsAfUHBB9jzXPf8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/Cj1D/4/TWisFtTpKK5v/hA9I/5/PEH/AIUeof8Ax+j/AIQPSP8An88Qf+FHqH/x+gZ0lFc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/QB0lFc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/QB0lFc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/QB0lFc3/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/QB0lc38OP8AklnhT/sC2f8A6ISj/hA9I/5/PEH/AIUeof8Ax+j4cf8AJLPCn/YFs/8A0QlAHSUUUUAcNeya0vxO1mPRNPsbxZNEsBMbvUZLQoPOvcbSkMhPfn5cYGM5456yX+21TR7fwrol0IrKSziefXL8+Zb7lLBJ3s/3ihtnzBjg9CK7O2jE3xN8QRkkB9E05SR1GZr6su78MeJr7wUfDkjaTHDaxQxwuskhF6sbIdkq7P3asqlWAMmd34FdXf8Arf8ALt1u7B1X9f1/wCK08Oa7ZXFzPH4X0eSW6tFsp2uPFd7MZIVzhTvtj/ebnryeahXwhqSS6ZIvgrw6DpUSQ2gHiO62qicoGH2XD7TkjdnBJI5NYS/CjWoryBm07QLyALGGE95IpiVZJ2MKjyDuTZMsYJIyqcjnAqxfCjxSbaVbjT/DjXDwlRcjUJS2/wCzxxKx/wBG7PEJOvU+ozTWrd/6/q7/AB7kvsl/Wn+S+5G5Z/D6809J0svB+kwx3DI0sS+MNQ2PsOVUr9nxtGfu4xjjGK1dU0zxlfXf2+DQPDy6jHG0cMlz4gu5oIwwwx8gW6qSVyM8Hnr1B527+Fet3Otvf3MOjXwe8M8y3Fw4N2rSiQCT90eY13RL1yrH7v3T6R4V0+80nwlpen6n5Ju7S1SGUwyNIhKjGQzKpPTuBSSUoe993y/pD+1p95xj+DdWuNMt7C88J6JcW1vZfYUibxReCMRFAhwgttoYgY3AZ96jn8DalcQ3EMnhPSxHcSRyypH4w1BA0keNr/LbjDjap3DkkAkmvTaKb1d3/XX8wsrWPN9A8G6n4ZF0NH8IaLGt3CIJlm8VXs6vGM4XElswA+ZunqapQfDi5tdpt/CGmRlJ0uFZfGeogrIiFEYHyMjCnaAOMcdq9Voo63CyPNF8EXyXFvOPBeg+dbqypIfE94WJYuSzH7N8z5kch2ywLHBGaju/AN5e6fYWVx4N0UwadEIbYJ4svkZYwwYKWW3BYBlBAYnBAxXp9FA9zziLwhq0PkCLwppCJbXv2+GMeLb7ZFPz8yr9nwB8zfKBtOTxWpp9n4q0u5u7i08N6L5144eeSbxNdSsxAwAC9qcAdgMAZPFdnRRt/X9dl9wrL+v682c39u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHXSUUDOb+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOukooA5v7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q66SigDm/t3jf8A6F7w/wD+D6f/AOQ6Pt3jf/oXvD//AIPp/wD5DrpKKAOb+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOukooA5v7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q66SigDzvxHeeMTr3hMz6FoaOurSGFU1qZg7fYbrhibUbRt3HIB5AGOchdS+IWuaRdX1vfaHpSyafCk9z5d9fSBEc4VgVsCGyc9M4wc9Djf8Uf8jF4M/wCw1J/6b7yue8X+BtZ1/XtWvrVbcLNY29vZ51i5tgWR2ZjLHGhVlw5wG3/d6DccLqD+Ftb/APBN+PUvG0sSyL4d0EK6hgG1ydTz6g2eR9DVf/hIPF39rDTDoOgi7MH2gIdaudpTdtJDfYtpOSOM55HHNcXqvwo8Q6i2t75tPl/tSdpS01yCBnzGTAFsGDRsy4cuxKpgbAcA1T4XeI7+a5R7Xw/cR33mJeXM1xJ586s4dM/uT8yEBQc52qMFc8F3o/62/wA/67D02/r+kdnqPiLxZpMEc1/oWgxRyzRwKw1q5b53YKoO2yOMsQMnjmrf27xv/wBC94f/APB9P/8AIdctdeANZuLWeGfT9DvJriazkkvp7qQTNHE0TPAf3LZTMZxyAd3Kg5qPRPAviTQtetdakitLp7Oz8iK0g1Daq4BURgtbbmUjBxvVQf4TjNP+vw/z0/rWOZ2vb+v6/rt0V/4g8XaYsDXmgaEguJlgjK6zcvl2+6DtsjjJ4ycDOB3qeDVPGtzbxzR+HNCCSKGUSa1cIwBGeVazBB9iARWR438Garr2vRahYWuk3yxxRLGmozPG0BR2ZwhWN+JFYBuP4B17cvP8LPEE4LyaH4Vnuf7NhsRPPeSsfkRQzEG3+Y5RMBsqApG35mJUW2nf+v6ZTvzWW1v1/r7jv11Txq80kQ8O6FujxknW7gKc+hNng/h071J9u8b/APQveH//AAfT/wDyHXnz/CnWjbpbRaH4ZjtY2UpAL6UjAtpIRkm35PzoS3cpnA4xab4X69NLqdxePZ3FxdpGU33qmIMCDtdDaEuFIIBZmOPuiM4If2rdBXdkzt/t3jf/AKF7w/8A+D6f/wCQ6Pt3jf8A6F7w/wD+D6f/AOQ6i8NaDqmi63qk88Vj9lvphJmOQmUHDFmP7tcgkgBWLFRn5yAFHU0DTuc39u8b/wDQveH/APwfT/8AyHR9u8b/APQveH//AAfT/wDyHXSUUDOb+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOukooA5v7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q66SigDm/t3jf8A6F7w/wD+D6f/AOQ6Pt3jf/oXvD//AIPp/wD5DrpKKAOb+3eN/wDoXvD/AP4Pp/8A5Do+3eN/+he8P/8Ag+n/APkOukooA5v7d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q66SigDm/t3jf8A6F7w/wD+D6f/AOQ6Pt3jf/oXvD//AIPp/wD5DrpKKAOb+3eN/wDoXvD/AP4Pp/8A5Do+HH/JLPCn/YFs/wD0QldJXN/Dj/klnhT/ALAtn/6ISgDpKKKKAOWiMY+JPiIzv5cY0LT977ym0edfZO4Yx9e1ec+EPGMmkeHL28k8QI9zc28I0+K/1CS/jnbzWRp90kikAEhXRWATbk5yM+kW4lPxM8QC3ZFlOh6dsZ1LKG86+wSARke2RWHY+PdSt9Jtb/xBLp6JaRXR1lILdk8uSOURIqM8uFBYnlsggZyoqHu9en+f9f1oPZev9f1/T5lfjDrc2hyalayaFNse3hkhTA+zPJDvbzJJLhFUb1ZOSuCe5G1vY7OZrmxgndVRpY1dlVgwBIzgEcH6iuKt/ivp15aG8sdE1e6skERmu4jbGOISMVBJ87JAYMCVBAwTnGCdi48ZRQ2+lSppOoTjVC5hCNANiqN29i0oAUqCwwTx6HitG0k/X7iU02rM6OiuFj+LGkvZx3TaXqkcRiuJZmkEAECwsquWPm4I+dCCu4EMD610nhnxHY+K9Bh1bSy32eVnXDMjFWVirDKMynkHlSQexNLdXHdGtRRRQMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vxR/yMXgz/sNSf+m+8rB8V6rJovjOO6W7ub2R4gtvpVvevFIXVWY4h+5Mjcbm+8nHODit7xR/yMXgz/sNSf8ApvvKwfEfjrUtB8e/2WLjS5bcravFp5hZbudZXdJCjmXb8mzecpjB5IxkzJNtWdg+y2zmLj4x6rbWYnlvvDqIFldJpEdEuSscT+WmZeHBkaM/e+Zc4GCtWrf4vXb6v5B1Tw7cxwTCGWK3JEk7G4eIBCZiFJUI2CG79iCOntPinY30BlttD1ZgkMs0gY2yeWI22kEtMAckrggkHcOeuIV+MfhpnijCXazSWn2ryX8pHTjdsZWkBU4Byx/djBy4pvpZ/wBa/wCTI3Tinr/X+aOUm+KGozWdhqkstq80M7mOGzkeJJ91nK7W7xs/zPHIEByRzjhM4qdfi9qsMdrPdz6AVaBJGto5UaS4LTSRjy3S4dFJCq23L4ORk9Rv6h8Tp4NSgFrol01ksyLOT5TySq9q8/7vbLgFQoznIIJxVqX4t+HEv7yziE881ps3BHhGdzBf4pBswSPv7d2QF3E0bysvuDaOr36/MzIfiPqB1jw/aRXei6lBqWGmurd0hjGWwY08y4yXQEEgByf7qdaufEDxZd6ZY2t3o2q6cmnXGnXlwZJAWW4KRBkCSpIhGckgqc8cVoWvxAtHvrGyurS78y/vrizR1jjCwtHIyASASs2CVwHAIJ67c4q54h8V2Pg1bW3k0u7lgaGSRfsUceyGOPbuyC6ngNnAB6HvgE3j83/w3yKi+WevT/P9ThZvirqqxC40u60LUbNtQNpE8boqqAisA80lyF3MGIBGTlCQrZwKT/Ey/g8TXEi67o1rLeCBBZ3pkK2gBud4KGYDzF2R7iuAcjgZBPZP8WdBi1GHT5be9jvphKPsr+SsisjOu3Bk+YkxNgrlRxuK5FKnxW0jy2kuNO1S2QKMNLHFhmZEdEGJD8zrIuO3YkUtWtH/AFp+dvx080vd92T1/wCD/SOWtfi/q1/b3tzDHo8Nvbwxyh3niZlB25Ij+0K7ggnGQmMceYcA9v4b8XDVtZ1SwvbmzV7e4WO3SLALBgzBSd7ZfahJQhGXByuMMc9/ipYrFNJHoGtSLaxmS82rbj7KFkaNw+6YfdZDkruGOQSM41dQ8XpaaHaapHY3RhuLowqoSJ2dRuww/egANt+U5P3gSOuK5kld7f8ABX9feJJ7X1X+X9fgdLRXDr8VNNNtPOdH1dUghaZ90cPQRJLj/WdTG4b8CDg4Bnn+JFhBc21tLpepR3FxLJAYysJaGRV3AOBJ0YEYYZXkAkUpPl3KUk1c7GiuDtPihDLYxSHQtXuiXihaaCO3RHleATAKrTkgFSDyTjOCe9JJ8YPDsAtftMN7bvdSrHFHMIkZlZI2VxmTkESpwMtyfl4OH1sF1+vyO9orirD4lQandaZBa6FqaNqFykI88wrsRo5HEnEhyP3TDHXg+2d/U/EEWmajBZm0ubl5I2mleEIFt4lwDI5Zl4yei7m9qTaW/wDXUL/187fma1FcK3xY0oW/nf2Rq5G0ylfLiyIvK80S/wCs+6UDMMc/KQQDgG1/wse0+0xw/wBi6sN161m74gxEwkSMM373O1mlTGATg5IAp9bdQ5la/Q7CiuIsPiHHNJ59zbv9lu5LdLKMLHHKnmKxKyFpdrEFD905OcAHGabD8T7Bf3c9nfTSLI6SNDBGqwvvkWOJsyn5m8pgCCVzgkpuAqXJLdgpJnc0VjeGvEtt4nsZbm1tbq18p1VorpVDfNGsin5WYYKup659QK2atprcE01dBRRRSGFc38OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJQB0lFFFAHN2P/JU9d/7Aum/+j76rj+FNFdtUY2Q3asVN4wkcGQqMKQQfkI65XHPPXmqdj/yVPXf+wLpv/o++rpKVkBy8/gWwXTtRttOlnR9UhW3u5b+6uL3fEMggCSU4bazAN2JyQelaWo+F9J1Y2n263kdbON44Y0uJI0CumxgVVgrArx8wOO1a1FPdWYbHMw/Dzw1BIXSzuGJikhIkv7hwyyBQ+QzkEnYpyecgHOa3dO0+HS7GO0tnuHijztNzcyTvyc8vIzMfxNWaKBWSCiiigYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfij/kYvBn/Yak/wDTfeVoSeG9Ll1HUL2WGWSbUbcWt0HuZGR4gCAuwttX7zcgA/MfU1n+KP8AkYvBn/Yak/8ATfeVy/jb4e6x4i8S3epWcGkSrJa/ZYzcTNE5QgHD7Ym3YcbgST7BcZMv0C7Sujoo/ht4XgaZ1tLwmWPy33andNkZVsgGQ4bKKdw+bIBzmn2nhPw5Z2q3tot9YQyQ4P8AxMLq3yrcjepcfN82AWG4dOMYri5/hprqxwT2OleGRcwTTKIJ5pWhe3eZ5FQkQgjYG+UAYByeRgVWPwj1q5YtqZ066zY28Aie53RAxCIGMg225kJiLAlwAXPyZySL3lqv61JektF/Wn9fI72T4deGZVjX7FOixqAoiv7iPpG0eflcZOxmGTyc8mnQ+C/DphvLO2N55TqIbmCPVrnb90cMokwGK4JPVgcnOayPCPhxfD99qV1oukxraPfeRaQND9lNtAxDTMoZQSvmFiBgAqi44xnP1X4aXN/4wvNQSw0Vre6upLn7VIxFxEWtliXC+UQSsi7wd4554ND2vbp+Omn3P0urDW9u35f10Oki+HPhm3mEtvZ3MUqyNKrpf3GVYsXyPnxwxJA6DccdTmfV/BGja9a2cGsi+uvskBgSQahPEzqwAbeY3XfnaM5zXm8Xwl1+3jtlSy0W4dCpeW41AhlxPHIdgjtEABCMMY48xjk5OZr34U+Ib2zSNotEBS1MEKG5lItVBlHlIfK5jdZFDDAxsHDcYHdRul1/piXxNtHewfD7w9bSPJbxX8byeYJWXVboGUOSWDnzPmGWYgHOCSRgmq0fwt8JxIU+xXkiHOUm1S6kU/II+Q0hBwoAHpgYxgVKui6ivgq68PWml6bZbbBYoCrh7eSRlPmAqY+AD3KnO7OOorkI/hjrsWkrZW7aba7bOa2Eiz+aVQys8ca7oMquG2kksuP+WZ605aNpa/0/6+f3ibaTa/rT+vkdhJ4F0iwtLt9IH2Kae1a2lmuppriMxMxZyyNIAzHcx3tk5OTkcG3eeHdE8QaPBpNxFctZ2Jj8nyJ5rYcJ8pV4yu4bT2JGfcV5lp/w2ubjUbzSRplrbG3tVWW/nSRi5aKVPKjcW8UcifOmcAbQijacAjc074eapY6gsr6R4fmsUuYphpxnfyci3ji8zHkYDq0ZK8HIY8qRQkm2n5fPX+mvv63C+ztrr+n5r+uhrX/wo0J9Gu7XR2u7K5nheJJ57+6uVTdH5RJjaYBsIAoBPGB6Vop8PPDuyBprSVriNRumS8uFaRs53MfMJY5JwWJIBIziuf8AFvgLU9b8aPqlvpeiXVpJHbo5vLp45CI/NDrtELAhllC/e6Lz1rnk+EniRpEm1A6ZfzCO0VlmviI2ETQlkI+y72B8psEuQPMYBRkki95+9/X9f10HLR2W39f1/TO5g+HPhSK3k0qC11OONJI7okalerhwhjUrL5nZBt2huBtyOlPT4e+GNKjFxb2+pRNDt2vBqV40gAVUCjbIWK7VUFRwdoyDgVxjfDLX50giu9I8NzQRi3DRPeyMp8pZlA5t+hWVR9FxWTN4G1XUvE80dx4dsrrVILeCGO8uXlWCEpHFmRZWtDvyYyBtkyN3+rXLMSN3Jr+noS20tun67fqei23gXwmjpBp634kVSI54dRun8gx7o8CTeQjjzXGMgnLcHBxs6hoOlTtZ3mpNKJLFPLS4N3JEWU4BWQqwDgkDKtkE9q4CX4ZatG062dhogSb7WWYXJjLtLcrNHuU27qwXbtIIPtXWa1oN/wCI/BNzo2oWFh5yPEsayvugnEZRt2NpKAkMMYOPejeN+v8AS/L+uzfxWtp0EPwx8JmzFqNPnSFQ4Cx6hcJ8rJsK5EgO0KSoXooJAAq4nhHw5dQ3ckNqJBqHlGeeO5kLSGHAjYOGyGXaPmBByOTmuKs/hrrNvaXaNb6KJLjUI73y0k/cBgGV2MRgxypB2jac/wAf8Rm8N/DLUdD8UaLfk2kdrp8LRmO0nWMKf3mTtNuWYPvBZRIg3AE7sA0R1ev9aX/MV7bL+r/0zYTwj4O0m4k0iODU1M0cc7Wy3l9Kjxq+1RjeVKhm5QcAHJGKtr8PvCMN8o+yOLqRZGCtfzlpAWJZsF+drSkg/wABf5cZrltS+HWvza1d3dtaaHOZroTG7muZI5pQLqOdN4ELcqqGMYPAx9Ax/hVfTiOS4s9Ekkt0uhaiU72iZzE0bmQQruYNGwLbQwD5y5yWI2cU5ef/AAPv/qxT0bt8vP8ApnXw6B4f8FGO/t5dRtITIkLIbu5uI5GcJCm5WLdNqANwB3NdTXkdr8LtXlmvpNT0zw8GZGNs8c7yHJu2n2HMI2KVcxkgnA5wc4qtefCTW3ZzbwaG4+zyQRI07xiKN3LiLIhJZY2xsJ7AYC45d21r/X9f15p6NqK/rT+v609lory62+HWtIt0klrosQktrm3spI7h2bSvMklZWgzCAMrKFIG3/VryRwH6B4G1/wAMSWF7aWljcz2UE4aB75G3ltxWOIraxiIFm5IwAOCrYDAWrKl5anp1c38OP+SWeFP+wLZ/+iEro0JKKWXaxHIznBrnPhx/ySzwp/2BbP8A9EJQB0lFFFAHN2P/ACVPXf8AsC6b/wCj76ukrmLbf/ws7X/KZVf+xNO2llyAfOvsZGRn8xWRB401a08P6NrOq/ZbmCewlu7yGxsysjYZAvl75sADzOc7iccYzij+v6+4Oh31FcLa/EYT+Ko9PNnL5dzbs0FoY0W4SWKWRJgzGXYQPL/h59M9kHxa0c6Wl62m6qpePzxbmOLzPIEQlabAkxtVWGRnd6KaV1a/9dv0Yfa5ep3dFcDa/F3Sby9azg0jVTdBXZYT9nDOEZ1YgedxjYTzjIIIzXS+GvEtt4nsZbm1tbq18p1VorpVDfNGsin5WYYKup659QKa12FdXsbNFFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/FH/IxeDP+w1J/6b7ysjxLqviO11LWF0w6j5kFsrafbw2O+3nBA3u0oiciRfmwuew+R84rX8Uf8jF4M/7DUn/pvvKfd6hrl5rt5Z6G2nwxWEaGU3kTuZndSQoKsNgAwdxDZyRgYzUy16hex54Ne8fvpd1NFd6q9xCsClf7JkjjAbdvdS1l5jsMR5AjP3m+UDG1TP4t0aO8/s9tTt/PkFxcLZaMXjR5GhzJEDCWYtmYspBK4yQh69UfitpTsFtdK1W6aRl8gRJD/pEbeZtlQtIBtJicc4PTIwc1Wk+JNxD4glMulXQ0VbYSQukMTSTv9nNxwxuBt+RWwpj6jlh0oTSbl/S6/p/XSHHVRvr/AFr+P3fjkSal8QhdakEm1QpYs0jr/Z0f7yOOZNiwt5WJGlg3lsZKuAAF+7U91q3jaLWBFFPqiQtYsX83TQ6LIw8xCrxwNhlGYyCH5GSnTdvXHxK02O7VPLnggiuBHcTypGyqPIkl5Al3pxGeSpzxgEMGqIfFbTCwX+xtYDjcZUMcOYUCo+9v3vIKSKw25OMjGeKdnbl6/wCfX+tvUd0nzN76/wBf11Mu11zxPPpt1c3EniC3vYPs0iWZ0lSjwBozI24QndIQZMoCGHZAa559a8VpFqt3pNlrsWsTQwxm6bRXTzGja6I3K0G18r5KEqB94fMMGvTfF/iC78Owadc2dr9rSa8EM0CIGldCjt+7JdVDZUfeOMZrHv8A4jwyTtaaPC63CC1nElzGrxSxSyRKwGyTcrhZVOGAxkHBFCfM+Vd/8v0/X0D4d/61t+ZBpesa9P4J1zUpptckuzcSJawyaYIJYE3fK0cbQbnADZ5VyQuACc5oWeueLzpoN8+rDUI9NJgjj0f91dTAuHaQ+WdjjapVNyA5/izxqad8S4I45YtdtZkngupIZbi3jUQ7BJcKsmDIWAxbNkcnPbHNWb3x/wDYGgmu9F1OGKS2M4tmigMrgyxxqwYT4H+sB2kZIPYgqU9XZen4P/h/+Guk1bd/1f8ApHO3eo6udRmS1bXruzuLG2SW/n0AC4VTJKJBtNuoY8xgoVOAxYDqawtE1bx5ZaHHZKmpafbWlhawwxR6TK8oIMKswU2xXvKGBkY4AIVQMnttT+Kun6da7/7J1B5msprpYi0I2tFv3RPiQlW/dvzgqdpwT0p8fxNs4k/4mOnahFN5ziaARRFrONWRC8hWVgw3OOUJPP3Rgmmmru3X/g/l93Ucmrczfb8v10IPAmp6zcaxfya7ca3LGyRQ263mmvAhIeUb8CJcMQFJPA5HAGMd/XGQ/E3TJIWeXTdRt2EkcapP5K797yICG83bjdE4wSCTgAHIzteKNeOg6T5kFvLc3twWitYIo1cvJsZ8kM6AgBWY/MOBgc4ocko8zHGOvKbNFcLp/wASI2giF/aTPczSwwLFCkUY3vbxynDPN8w+fgcNjPykKWpll8VrSbRre+vNA1W1eeISLDugfIMDzggiXoVjbGcHPUCqkuW9+gRfMk11O9orgrP4ktHfXqazpd1b2+/No+2FMD7OJvLkYzFd5UOQeFwBkg1NafFXSLpoi2napbwtEJZJ5o4wsAPmjDgSFs5gccA8gduaT03BO6ujt6K428+Juk6bdada6tZX1hc6gN0MExhMm3OFbashLbj2UMR/EFqzL4+0+Pw1Yawlndz/ANoSGK1tIGhkllYBmOCJPLICozZ39B64FHS41q7I6miuN0rxncavqGpX0NuyeH7KyjuY5DAGkut8fmBlYS5A2/wtHz/e7VTv/jF4c05oY5o7l5prRrtYoZLd22BXbjEvzZWNiGXK8AFgSATy/rr/AJCTT2/rb/M76iuTi+IWnPPFBJY3lvM6Ts0c7wRmPys7s5lwemcrkDI3FcisqH4rW+oXFmllpGoQQTtGJbq4SEi3JuDCUdBMD1Ujcu4DIOCKV1p5/wBfoDaSueg0VwY+LekSRo0GlatMZMPEiRwgyxNHJIkozIPlZYpMZw3y4IFdxBMlzbxzxZ2SIHXI7EZFML62JK5v4cf8ks8Kf9gWz/8ARCV0lc38OP8AklnhT/sC2f8A6ISgZ0lFFFAHN2P/ACVPXf8AsC6b/wCj76lbwD4daC7hNnN5d2rI6i9nARWYMyx/P+6UsASE2g45rMudetNE+Ker/bYdQl87RdP2/YtNuLvGJ73O7yUbb14zjPOOhrS/4TzSP+fPxB/4Tmof/GKOtwK8Xwy8LQ34vVtb1rgSGVXk1W6faxZmJAMhAOXY8f3j6mkj+GHhOO2FuLC4aJQoVZNRuX2qqbAoJkJClTtK9GHBBqz/AMJ5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/Cc1D/4xRsHW47/hAfDI1KXUE0tY7uXzd0sc0ikeaio+MN8uVRRxjHUYJJq7oXhnS/Dcc0ekRTxrOULia7lnzsQIuPMZsYVVHHoKof8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MULTYVkdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUDOkorm/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigDpKK5v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAOkorm/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigDpKK5v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAOkorm/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigDpKK5v/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YoA6Siub/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKADxR/yMXgz/sNSf8ApvvKh1s+C31xp9a1Sxtr+3jCzo2p+QWjALBZUDgOoBJw4IAJPesnXvFlle614ZnttP8AEDxWOpvPcN/wjt+NiGzuYweYefnkQYGTznoDWD4iWPWvEsmp299qNvCzRusE3gjUpmBSKSMZcbQR++Y42joPfMu62DR6M3L3R/AFvM628ZuZxfQJNHp+qP5lq8rFYyVWUGNMysdq8ZcsF70keg/DqaH7PBeJeW8ocO39vySLEIIyjfenyAEba23s2G4rlbfS1hnW4l1nV5rgG3BlbwTqWSkMqSIo9ACmB6A9zkl1hpVvZXDSPqer3QlaR5/O8GapumZ4FiLFxgg/IGJHOScY4w7e67f1tb9fyJV27v8ArudzB4c8D6pqlsILmO/vIYkmhj/teWZhEAyKdvmHKEOw5G05Oc1M3wy8Km3EIsblECuuU1G5VirBVILCTJG1FUAngAAYFcVoFrZ6H4gbWGv9dvbpoSu648K6udkhRULKudm3aij5lZzjlzXe/wDCeaR/z5+IP/Cc1D/4xT0BLuizJ4S0250qz0++kv7uKylMsMk1/N5oY7h80gYM2AxA3E8fnWcnwy8LRqFS0vFChQMapdZAUoRz5nrEh/4DVj/hPNI/58/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/ABihaO6HZEY+HHhcSpIbCd2SQygvfTtlizsSwL/NzJJwcj52HQmib4deHLiOBJodQdbdPLiB1a7+VNytt/1vTcinHbaKk/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8Yo2G1fcgX4aeFhu3WNzJuDhhLqNy4beHDZDSHORI4/H6VIvw58MLIkjWM8rpM0waa+nkLM23cGLOdykopKHK5UHGaf/AMJ5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/Cc1D/4xQJpPRkafDnw1HFPEtvfeXcII5kOqXRWRNzPtIMnK7nckdDuOav3XhXTNQ0iLTdSFzdwwymaN5LqQSoxJ6SKQ2MMVxn7vByKqf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/Cc1D/4xSsmrD63Etvh74ctIHhhtrswvJFI8cmpXLq5jAVNwaQggBVGDxwKhuvhn4VvIYIprK6VLeIRRCLUrmPagDKB8sgz8rsvP8Jx04qf/AITzSP8Anz8Qf+E5qH/xij/hPNI/58/EH/hOah/8YpvXcFpsSS+BvD04ImspH3W4tzm7m5ULsDff+/t+XzPv443VVX4a+F0nWYWd1uUgkHUrkq2GdvmXzMMMyOcEEfMam/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8Yoeu4rJKyJYPBWjWzWzW41CNrVSkTLqlzu2f3CfMyyjsrZA7AU6fwZoVzo66ZNaStbpOblW+1S+aJSSS/m7vM3HJGd3QkdOKg/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8Axiiw9i5YeFtJ0uS7fT4ri3+1xJFIqXk21VVdqhF3YjwOMoAaoSfDvw3JbNbm1u0ikieGZY9SuU89WLFvM2yDzCS7Hc2Tyeaf/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQC02Gn4e+HHtmt5ra7uIGeSRorjUrmVSzqVZsNIRnBPPbPGKT/hXfhrMZFncqY5PNBXULgFm8zzMsRJ83z/ADc55J9TT/8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigTSasyBvhn4UMPlLp88Shy6+Tf3EZTKsu1SrgqoV3AQYUbjgDNbuk6TDo1q1tazXUkO4FFubh5jGAoUKrMSccZ5J5JrJ/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKNh7nSVzfw4/5JZ4U/7Atn/wCiEo/4TzSP+fPxB/4Tmof/ABij4cf8ks8Kf9gWz/8ARCUAdJRRRQBy0QjPxJ8RCdPMjOhafvTYX3Dzr7I2jOfp3rzPwFo1/pvhLV/7EsJdE18W0r2twNAez2oshfy5Xmj2SlvlAIyVGcBcEnu7/QINc+JmtCW4vYJYtDsPJa11C4tl3Ga95cQyJvHA4J45xjJrihY6fdaBbTeMJrm4trWO4fWrf+19RKxyxTKkYTzLvavzc5bI+XOVqHu9baf5/wBfh1B20v3/AK/r/I6LR9U8fP460W3vix0i4slublpbYlSz72aLfHDgMmYwNzJkA5DE8cT4tm8Vz+OtRvrjTNXmmhhuLS1SLQTcwLGLiFogG8llcOisxLE4PTaeK6S31vwvd2ZvLHT/ABtc2SCIy3UPiScxxCRioJP23JAYMCVBAwTnGCdi4tdDht9KlS18YTjVC5hCeJbkbFUbt7FrsAKVBYYJ49DxVtpSU+1/x/yWhCtKPLfe34f5sx9V8QeP4biRNLGrXSC7kMUw0nakhO0xQlWiDLHhmDScj5R84yRVTxBd+Nr3wnqqyza3PBdand2UkA0ZHeK1CSeUUQQbnV22KXwwwexy1W49c8JPZx3TW/jSOIxXEszSeIrkCBYWVXLH7Zgj50IK7gQwPrXS+GdG8NeK9Bh1bS7zxF9nlZ0w3iW9YqysVYZS4ZTyDypIPYmp5OaNvL/LX8Gv6d6Ts/n/AJ/18vu4Vdb+Itjpz2unQX9jZWejWwtETSZZZXk2R5wpgYbg+9WVmB24IUY3H0XQbjW4vGVxYX99qWo2As1kjmnsFgRH+XIZhEgZjkkbCQBkFVIy1v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfrTmvK78yVG0Ul5fp/l+J0lFc3/wgekf8/niD/wAKPUP/AI/R/wAIHpH/AD+eIP8Awo9Q/wDj9SWdJRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0AdJRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0AdJRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0AdJRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0AdJRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0AdJRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0AdJRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0AdJRXN/wDCB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wo9Q/+P0AdJRXn+veE7Ky1rwzBbah4gSK+1N4Lhf8AhIr870FncyAczcfPGhyMHjHQmsXXdHn0rxDqlgl/eqj6etxo4k1vUy0s28RsjkXY3Dc0fQL/AKwenJ1sHS/9b2PWqK8le60Cwe5t9QHiqe5t/tJdYPEF1HlYFy20Pe5bOCRjoCu4LkZnmuPDEd3bWn/FWRy3V41kjt4iu2Eb/JtdlF3uKEyJyAcZwdtK6smuom7b6b/huep0V5BqItbD4b2mrq2vXOsXWnvdLFBr2oGNdibncq12CEHHRieRjNW1bQYnaGf/AISmS4M1xHHGniK7jP7kAn71582c5BHODyq0Sai3fp+g3pa/U9Uorx+31rw2+lLd3OneNYJfLZ5IB4kuXK7UicgEXeDlZlI9gcgHii2utMtPt6a9aeK4poJJTAsfiG6TzVUp+6yb0jzR5ig8hWP3Tnim9HZ9rkqSaTXXQ9goryS01jwjdr5ixeNI7YwiVbh9fvNr5hEoQAXRbcVJ424yDz0zcjl8KjxTYeHb5vFNjqt9HvW2n8T3JaLhiAwS7YnIRjldyjgEgkCjrbqHMj0+ivONdtNC0LVhp0lt4wu5ntvtERt/Ed1iX96kexd92p3ZkXqAMHrWRDfeH5tHSVJPFDXH2GG8d/7euwFWRlXPlG93cbsnBK8EBmIIoWqv/XX/ACZT0V/6/rU9eoryI614TdgtrbeNbppGXyBF4huv9IjbzNsqFrsDaTE45wemRg5qzrkWk6PLpV+r+I7nSLyxlu5hFr1/50Sr5beZk3QG0K5LAAt0xnpQtdg626nqlFeRafcaQs1zaamniea4ivTAstp4gvVjdGmkjjOHu85/d4PuQRxnEJ8Q+FI7Fr27sfGtpbC2gulmufE0yIyTEiLk3uAWKsPmxjHOBilfS4PRtdj2OivKNPbRNd8QaRBocniSTTbxSZrqXXr/AGhjAJkRSLrIYKQSChGG4bIIq14k0/TtK1mx03Tj4kuZXng+1v8A2/fMkUUjsijJulIZipwQGHy84yDTl7rsxcys32PTaK8VTVtIuvDss1rH4qhu/srPDdXWt3n2d5hb/aFQol6zjKA9+x56ZvS6t4Vt5zAYvGFzIG8tZLfxBd7JpA6JIqFroHKNIoO7HXjODTs07DelrnrlFePzav4ZtbTUL+6TxetvZCNZLX+3rsTI5aVZOTeYfaYmyqjPykjeDx3UfgfRpYkkS88QFXUMD/wkeodD/wBt6QrnTUVzf/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/QM6Siub/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+gDpK5v4cf8ks8Kf9gWz/8ARCUf8IHpH/P54g/8KPUP/j9Hw4/5JZ4U/wCwLZ/+iEoA6SiiigDmbWQRfE7X5G3FU0TTmO1Sx4mvugHJ+gqpY/8ACH6w8jWdrcufFEZndza3UfnLFgbtxUeVjII+6STkZJzUN1rtpovxS1f7bDqEnnaLp+37Fptxd4xPe53eSjbevGcZ5x0NcVeSXN54XbRZ7C5lis7N7SzL6Hqn+kbpI2V5P9E/dlRH0Xfk85FLrr/X9af1sdDuJPDOiNcavoOmXN0l/fWcYvjqEt1eB7Yll+Uyybd2N4BBODyQeh3tR8L6TqxtPt1vI62cbxwxpcSRoFdNjAqrBWBXj5gcdq8Ws7fUIfENrdPpDJp9q0qpZDSNUkjaN5ZXUbDYgKUEgCkdNp9eKUWg3X9hR6c2nSQxxxKnlR6NqjRtL5Ai+0/8eQIlRlDL65IyvBo1cdf63/T8/UW07Lbv/X9WsezQ/Dzw1BIXSzuGJikhIkv7hwyyBQ+QzkEnYpyecgHOa3dO0+HS7GO0tnuHijztNzcyTvyc8vIzMfxNeCWvhe1s/EE9wtpc3GnMtwBayeF9QBl3AtEXP2U8iSSTJ5woXHcV2Pw91eHwvpt3aahpeo26SSRPEljoepSLkQxo5O61TBLIW753c81UdVr2/Xb9Sdnoj1Oiub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxikWdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAdJRXN/8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAHij/AJGLwZ/2GpP/AE33lR+ItQ8KRa7p/wDb7ZvrBhPC6xysttv+UNKyDaikjjzCFJXI5HGH4j8aaXNr3hN0tdcAh1aR2D6BfKSPsN0vygwgscsOFycZOMAkZXiDU2vb3WotLttRNjr9stvdvc+H9TElthShZFFsRJlT0JTBGcnOKWt1YNLa/wBf5+h2s3gzw2kslxdxSstxcNKyXGoTvE8soKEiNnKZIbAAHfiqtr8O/CrKk8FnfqRJ5gMmoXatuUryQ0mesann0z358sg0Wy/tLz18O3EVvbX7yxxTeHtQLXifaVkUyYtSF2qG2/eJ8w52853vCF0mh6nZ3GpaDNKIbbyI5Y9D1NpLIB3OIc2YG1gwz9zp/EMURSsmv6VtCJOV2mv+Hv8A0z0K48CeHrrQbXR7izmeys0ZIUN5NuVWBDKX37mUg4wSR09BSQ+BNAgAVYbyRBcG5KTajcSK0hGNxVpCG6cZyAeRzXjmq6PNeXd81npU9rDd3M8sxi0bUQ9yrTb0Rw2nunAz1V8E8DvS6xozXMyLaaRLd2+9ZG+3aLqfmZKW4cEiyIb5rcnOBuL5wMYKjeSu1v8A1/XoU9+Xoj0y98B+CpEZbi0v1aCJlEcV9eLJIiIittVXDSDaIwSA2cKOcCtm58E6BeXE1xcWcjyz7SzfapQVKsrBlw3yNlEJZcE7RknFeQXmj27/AGwWPh4QJtvorKJdA1JVhWYxGNhiy+Qgo2QBxu4PWux8KeIV0W51BrvS9RjivbozEQ6HqDuuVJYlvsab/mOADyByWPQUtUm97f0idU7W62Ohi+GPhSFdqWNz5eMeW2o3LJjy/LxtMmMbOOnFW28EaTtzBNqtvN9nNv8AaItWuRIVIIBYmQ7yu47S2SvbFM/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8Axigvrc077QdO1K5sri+gM09gWNvL5jKyFlwTwRn8e4B6gGslvh14bbT4rFra8NvBB9niQ6lcny03BsKfMyvKjkc4GOnFP/4TzSP+fPxB/wCE5qH/AMYo/wCE80j/AJ8/EH/hOah/8YoFYj/4Vx4XGSljPGTL5oaO+uEKn5uFIcFV/eOdowuWJxnmr03hHRbjT7CxntZJINPTy7cNcylgmANjNuy6kAZViQcDIOKq/wDCeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MUBZEVx8N/DNy7PJa3gkaVpi8ep3KNvL785WQHhiSPTLYxk5fB8PPDdtbtDDa3SobeK2H/ExuCUSJi0YU+ZlSpJwy4Iyead/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8JzUP/jFKySshvV3Yy7+H2hXVyt0P7Rt7xQu26t9UuEk3KuwMTvwzbeCWBLAAHOKuav4P0XXL+K91G3mNzEqqssF3NAcK25c+Wy5wckZzjJx1NVv+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKe4GXpnwr0ayuL9bnfcWM6CK1thPcKbaPyvLYbzMdzFcgPhWAYqDjiptX+GulXdnONJAsLycxhriV5p8KrIzYXzV2swjUFwQxwCSSKvf8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xR/X9f1qKxA/wANPCsqssmnzEOgR/8ATrgbuHBJ+fkkSyZPVt7ZJzXS2lpFZW4hg8zYOnmStIR7ZYk49qwf+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoCyOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoGdJRXN/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xQB0lc38OP+SWeFP+wLZ/8AohKP+E80j/nz8Qf+E5qH/wAYo+HH/JLPCn/YFs//AEQlAHSUUUUActEYx8SfERnfy4xoWn733lNo86+ydwxj69q8y8C+MhY+E9T1P/hIYbvUYoyIUutan1BWUz7RJLEWJjIyoAG0EHluSV7690Sy1f4n6y+oT6hCtvolgQbLUri04M17nd5Lru6cZzjnHU1l2thYjTxq+sQa5YaNLEJobkeLNRllIYqEVoQ+Q7buFQv6dSBUW1evT+v+AD1sv6/r/gB4I+IGt+LPEOn2U0+kW6NpS313Atu5mL+a8bKv735R8oPIbGcc5zWJ4j+Mer6Rr+q2cEmiLb2tzFDDLcRyAKDOIpA5LrkgHcSAAMH7w+atn7d8P8oF1vxM5dFdQmq6u3Db8Dh+GzG429dy7cZ4oN98PgzA674lO0Alhq2rlcbUfOd+MbZFb2BJ6AkVq5K3S9/v/TYltJNX7fl+u5y9x8U9T1y98Gia8tNKiuprK4m8mV4zeF5JEdEO/BjXYNysG5YcjAzf8WfEO98IeJ/Fh0u/t7maJ7Xy7O9lkmVD9nkd1RAwCE7BnlR1OGOFO7c3HgG0vZbSXW/EjTxSeUUi1fVpNzZ24UrIQ+G+U7c4bCnBIFb9j4Q0DUtPgvbLUNfltriNZYpB4j1AblYZB5mz0NG6vHu399tPwHZKWvZael/8zgvDnjbxNPqWvadoNxZanNm7u4IbnzZ3tCvlsiO3mfcfcwQALjHGRxVqb4g+JLu0QNfaFYLc6DNrHl3FrKs0cYb5VO24UglT94EYIOM9u5PgLSCMG78QEf8AYx6h/wDH6SP4f6LFGscVzryIgCqq+ItQAUDoAPPpNe7y+Vvwa/y+7zCN1v3v+K/4P3nlGl/GvWtRiv7C0n0aRodLuJbZrcySSq8dtHIC26Vi3LOvqSh9DV/wF8QL0fEcaJd67aanDqJi4admZGFmj7ogZG2qWzkc5OTmvSv+ED0j/n88Qf8AhR6h/wDH6P8AhA9I/wCfzxB/4Ueof/H6tP3r+Vvx3J5dEr7X/T/L8TyDxb8TtRt/HWombVbSwjs4bi2j0x7maIsUuIQrOFmXLupdlKhflz94ZrpNV+LOsafcSQw/2RdMl3IimBGkjkUbTHArrIQZnVu4GCrfIQQa7v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfqYq0Yp9Px1uVJXk2uv8AlY858QfEnXz4T1WcX+jwQPqd3pSXUUUsf2QRpIQ7uJuHbaqrjbgkHnIWqq/F/XbDTngtl01obHRra4F5qE4Zp3ZIzv8A9arurFmTKqdrAEsc7R6h/wAIHpH/AD+eIP8Awo9Q/wDj9H/CB6R/z+eIP/Cj1D/4/RFW/D8F/TB6u/r+Lv8AkrFTQfEmpXPjK40PVL3Srox2a3CHT4mBOduS/wC8by/vcKRyMEMeQOvrm/8AhA9I/wCfzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/x+q6AlY6Siub/4QPSP+fzxB/4Ueof/AB+j/hA9I/5/PEH/AIUeof8Ax+kM6Siub/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8foA6Siub/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8foA6Siub/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8foA6Siub/4QPSP+fzxB/wCFHqH/AMfo/wCED0j/AJ/PEH/hR6h/8foA6SivP9e8J2VlrXhmC21DxAkV9qbwXC/8JFfnegs7mQDmbj540ORg8Y6E1narZQ6ZrOsWP2LWZBZaet7Zu3jHUVN6S20x43HYQwx1b7y+vCvrYOl/67HqNFeaTTeCLWU291qnib7UkgheG21bWJ8yfNlUKOd4BRlyoxkYODxVSy1LwTeWU999t8Vw2kSx4D6prPnsXL4xFuyy4QkMpbo2cY5LoPI9Worz3TLfwVrGox2On6z4ie5liEqI+t6pHuG0NjLSgbgrKSmdwBBIGa3v+ED0j/n88Qf+FHqH/wAfpiTT2Okorm/+ED0j/n88Qf8AhR6h/wDH6P8AhA9I/wCfzxB/4Ueof/H6BnSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSUVzf/AAgekf8AP54g/wDCj1D/AOP0f8IHpH/P54g/8KPUP/j9AHSVzfw4/wCSWeFP+wLZ/wDohKP+ED0j/n88Qf8AhR6h/wDH6Phx/wAks8Kf9gWz/wDRCUAdJRRRQBy0Lxx/ErxC8ylo10PTy4VC5I86+z8oyT9BWFYWHhnX9GsNOtde1y6sNSjMmko8LotsIXVgyMYRgqyrt84t6DIJBv3PiPQ/D/xT1f8At7WdP0zz9F0/yvtt0kPmbZ73O3cRnGRnHqK5K4ufDcmna7ZQ+P8AwwkMokXSsatDmJJZBLKj5yACwCgYYbRyD0qXdO/9afr27ah2t/X9dTq1+FdjDeR3Frr2sW7KUd1T7MRK6vJJvbdCTkvNITjA+boAAKqQ/B2xhtHtR4m15oHiaIo32T7phWE8iDP+rRR+GeuTXnnkeCtP0PUn1bWfB814IYF0q4g1SK9niuEYlc7YYgqbigOAFCrg4UV1Os33g25g8P29j4j8EXCaYkxeS+1KDiV4yA4jAIbMhDnJXketN3im1/X9f5ErVq/9f1/mdMfhXpgvlu4dW1WCWOc3EOxoCIWZxJJtDRHh3UMQc4I+XaOK6nQ9Jj0HQbPSoLia4is4lhSWfbvZRwM7VUdOOAK8JtdL8OpbJbN4r8DwJFa3kdvLHrUTtbSTGNlKAxgABlccYwHOF7V6D4I8VeD/AA34TtdMuvGXh4SRM5KrrdvKq7nLYUqkQCjPChFAHA6VS0jb+uv9fMXW9j0Siub/AOFj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8AiqRZ0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQB0lFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQAeKP+Ri8Gf9hqT/033lZfijUfCkni/TE1i41GPUNPkLILewneJwdjlZJFjZNoIic/MNpCkkDrT8R+PvB8+veE5IPFmhyJb6tJJMyalCRGv2G6XcxDcDcyjJ7sB3pdU8aeGrnxho9/a+LPCj2NrDOlwZdbjWTMgXG1QCGHy85YdaV2mmgezLdp8NdHXXTrmnXl9ZvJfG9eJbW3j3yZbIZmg80qSzcF+/GBisjxF8OltrAW2m6lPMsxi3w6k0K26xRFyo3m1kTIaXgSK27HHI3DgBY6YsMgTXPhysrIYQw8RqMxmGaMqf3HT96hx0PlgemLE1hoFyqW8mu/D1LOMSbYv7dR1O5rdsbTEBgtAxP/AF0J55yorW21v6/yFLe73e56xpPgGHT75dRk1O8N8ybmEfliJJ2jWN5kTZwxVQMfd7hQTXSX2p2um/Z/tkjILmdbeIiNmBdvug4Bxn1OB714bJbeHUW9t7XxP4FW1aMpaKutQoFAuJJkDoYmUqol2he20EFTgr1XiDxd4d8S+GbWzu9f8H+ZHfo09tca7F5UsMbnkEBvvKAdhHGcE8ctt2ul1/C/+X3CUeW6X9O3+f8AWp6lTJZlh2bw53uEGyNm5PrgHA9zwK+e4rHTCzPfeOPB1y0lhBaSRya/A8ZRVjV4yGgLMCI2YMWwrPkJnLF+lWeg2MMUt1rnw8udQt57XZdPryF2ijh8twXMWQWwvHIPQnjkldbf1qV3t/Wh9CUzzl+0eTh9+zfny224zj72MZ9s5r5m1Wfw5pnhiy0bUtU8I3VtJLDvTTtX84O6QeWzMRbSeWWOPm2cf30IBPZeLdS8O67f29zpuueBvJFrao0V5r0cbAxTrL5fyo427QVBz/EeMU/tWW17fhuTd/16ntVRzzpboHkEhDOqDy42c5YgDhQSBzyegHJwBXzjPceHNLGnwXuoeB71Li4hjEEOrefCGVLhS0rCH5E2SRpuI/gUdOl62ttLsLn7SnjDwLf3Aa13Sy64kP2jyHUqzAI2GKhlLEseeuDgK+vz/wCHCTaWm9j6EqrY6lbaj9oFo7MbadreUPGyFXXBIwwGRgg5HBB4NeAxaRoMaacbXxv4Q02SGxeB/sGuQKIpj5g8xSYdz7g6hgGi+4MlsDHceB/FPhrw5a3Npc+IPBNjazXDTpHp2uRssWUQbQrKvGQxzn0454a1ev8AWv8Aw45Npq39af5nqFFc3/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VQM6Siub/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KoA6Siub/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KoA6Siub/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KoA6Siub/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KoA6Siub/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KoA6Sub+HH/ACSzwp/2BbP/ANEJR/wsfwR/0OXh/wD8GkH/AMVR8OP+SWeFP+wLZ/8AohKAOkooooA5eBpE+JXiFoF3yDQ9PKKT1PnX2BXE+HfFUdr4Nm1nUNduH8UW8Ms+pWN3cyvDayDKhZIBkRKMjaAF3cHJxkdLfaZfah8TtaOna3faU8WiWB22i25ExM17gMZYZMYx/CB1Oc8YwbfU9dTSNJ1XWPFWsWVjeWkl1cyRNZztbhWUKAq6fl87xk/Lt564zU23/rv/AF8kD6FfSvip4g1OONo/7IaaHSru+uLJIHM0rwTNHsQCU7dwAPIbGD97tyumfFO/spZtQute02+83Vpmw1zceTEv2ESKEVZWOwPlSpDjceACBXoseo20gQp8R/EmDFJK5Om2oECIWVjKTZfusFHHz7clSBnFVf8AhItM2xk/EvxMvmbuG0q3BTayqd4NllMGRPvY4YHoc1S0b81+t/0t8hNW3/rS3/B+ZH4R+Jmq+IdS0mzv206xNw9yskv2aQi6aKXYI4h5mEbbhzkvx2xzXN/EX4jahYeObu1bU7XTINNhu4orOS4lha6P2VXV32ypkMx2ptAYMDhs8V1B8Q6cGVf+FkeKdzKGCjSLcnkuAMfYeGzG429crjGeKkuNc021ZhN8TvEGFt/tJZNPtHXZsEn3hZkbthDbPvbecYpPX8f6+SCOj/rb+rGZd/FPVbLT52juNGIU23lzhHmito3jY5mcS/eLJsCnaQWH3u6Q/E/xDcaDreqONJt47G4tbXyXgk3WnnLEzSTN5v3Y97gjC529VwavHV7qbXdIsNO8VeMb2HU3ljN2mn2SJbtH1Dh7QEc+o6YPOa6z/hF9X/6HvxB/340//wCRaN7t9f8Agfn+t0SuiT2/r+vxPIdB+Lmv6foFraQPY36QaXc3kmoX1zvMrK02NpeYM4UogKjc2HySuBu9H8O+LdWu/EOlWGq3+i3CajpwvEWwiYSZI3EEGViqgFcMQQ3PKkgVr/8ACL6v/wBD34g/78af/wDItH/CL6v/AND34g/78af/APItVfX+vP8AzX3DcX0f9af5P7zpKK5v/hF9X/6HvxB/340//wCRaP8AhF9X/wCh78Qf9+NP/wDkWkUdJRXN/wDCL6v/AND34g/78af/APItH/CL6v8A9D34g/78af8A/ItAHSUVzf8Awi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLQB0lFc3/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i0AdJRXN/wDCL6v/AND34g/78af/APItH/CL6v8A9D34g/78af8A/ItAHSUVzf8Awi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLQB0lFc3/AMIvq/8A0PfiD/vxp/8A8i0f8Ivq/wD0PfiD/vxp/wD8i0AdJRXN/wDCL6v/AND34g/78af/APItH/CL6v8A9D34g/78af8A/ItAHSUVwms6Zr2nat4ftYPHGuMmpag9rMXt7AlVFrPNlcW3B3RKOc8E/UZOpanqOjeLLvR9W8X+IIYksftlrcotg32kjO6Lb9jG1+OACcg9ulJtLcD1GivJ9B8Sf2lpEFzqvjrxFpl08Mc0sH2S1kSFJEeRCZfsKqRsjYkj5VKkZrUs9Qt9Qa3Sy+IniieW4kaNYU0q2MiFcZMifYt0YG5fmcAfMOeRVNWdmK9tz0SivMo/EGnSkBPiT4oB/e7g2k26+X5WPM35sfkxuX72PvD1FU7DxHNcW89zfeNfElrBALh322MDyBIpVj3eX/Z4b+L5lOGXjgj5hN0Pb8j1mivN/P1AWesXp8b639i0+1ju4rhY7JxNE8ZcMyrYll6HoG459qq6h4gis7HUZIfHvii5urCJ5Htk0y2+YqVBCt9h5ALpkgHAYN0oegk00mtmepUV5db66q4ttV8e+JbbU0eOOezh0yGUo7qzIBnT1ZgQrfNtAyCOtJfeIYLW2WWLx54slSSKeWKY6RAIWWJdzNvFicpgj51DA9s0xrXY9SorzO512wsrpra7+JfiJZ1KqUj061kDMxVdqkWWHIZ1BA5BYZxmtqGwnn0MawnxE15dPMJnM8ltYIFQDJJDWgIx3BAIo6X6CTu7I7KivOX1KCFrRbj4g+LIGvY5JLdZ9HgjMgQFmADWI+bCkhepHIBrJ1XxV9iWzksvHPiS4iuEkkeSawghESLDJIrEf2eSQRGeOu07gGFH9f19zHueuUV5zJqdvBdXNpP8RfEq3dqsbSW66ZbM7eZ93y1FlmXPP3Aeh6UzxDPq2i3mmW1v4s8TXT34eQk2NuBFEg3OT5dg534PCEDPTIpXQrpnpNFeV3GuTNHZz6R451+/t7kwMWNvaxOEknEO4KbHBIY8rkNx06VZGt2LCDb8R/FDfaPL8oLpFuS29C68fYuPlVj7bTnGDT6X+QXV7HpdFcTo9tLr9rLcaV8QvEU0cL+XJus7KNlOAw+VrQHBBBBxgggjINY//CQ6cLV7h/iT4oSKNkVzJpFuu3cSoYg2OQu5WBb7oIIJBo62C6tc9Oory+01p/PNrq/jrxHY3f2mSBVSytZoiFmMSsZRYhVywHBxgsB3GYl8T2sUMsl94/8AFUMcNulzLOmlW7xIju6LlvsIK8oc7gMc88Gjcb0bT6HqtFeYR65FLeSxf8LA8SwxQfaBLJcafapu8korGP8A0La4y4HDZzjAPZ9rr+m3lysEHxM8R+YRk79MtUEf3+HLWQCH924w2DlSOtHS4HplFcjp2kX+q2Ed5Z+O/EvkyZ2+dY2UTcHByr2gYcjuKtf8Ivq//Q9+IP8Avxp//wAi02mtGB0lc38OP+SWeFP+wLZ/+iEo/wCEX1f/AKHvxB/340//AORaPhx/ySzwp/2BbP8A9EJSA6SiiigDm7H/AJKnrv8A2BdN/wDR99VR/h1ZPp89l/a+qC3eF4LdA8WLONnVmWPMfIJUDL7yAMAioLnxHofh/wCKer/29rOn6Z5+i6f5X226SHzNs97nbuIzjIzj1FaX/Cx/BH/Q5eH/APwaQf8AxVHW4FGL4bWKLepLq+qXEWoRyxXsUhh23KSO7lW2xDGGlkwV2n5uScDFWX4T2EmHXX9ajmYOJ5lNsWuN3lffzCRwIIh8oHC+pJOx/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVC0dweu5jxfCq3h1BrtPE+uh2mExXFpt3CSSQf8sM43TSHr/F7DDf+FP6J9ia1/tLVfKa38kjfD9/yfI87/V/f8r5P7vfbnmtr/hY/gj/AKHLw/8A+DSD/wCKo/4WP4I/6HLw/wD+DSD/AOKoWmwdebqaGgaGNBtJ4BqF3fmadp2kuhGGBbGQPLRRjj0z71qVzf8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQJJLY6Siub/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiqBnSUVzf/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVAHSUVzf/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVAHSUVzf/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVAHSUVzf/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVAHSUVzf/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVAHSUVzf/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVAHSUVzf/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVAHSUVzf/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVAB4o/5GLwZ/2GpP/TfeVX8ReE9HvdQ/trX9UmhSCaGaDznhSK1kQMiMpZM5JkPDFgTjjtWP4j8feD59e8JyQeLNDkS31aSSZk1KEiNfsN0u5iG4G5lGT3YDvXPeMPGOiX9xrkcPiCz1Bbi0WOwa18R2scEYIAdWiadAXzkhyp4wARjmZaiezOus/hvYxhLK/wB95YwaW+mRyzTAzTROed4REUFRkKRk4Y9O9mx+HlppswuLTWdWS6ct9pud8Je7VlRdsn7vbwI0AKhW468mvLo/Fszavbg+NobXToRcRxga7aTy7TJLsLsbxQco0QDMJGBT+DknW8M+KdDgh1qfWvFFhBcXempFG48TJIcqZeBi4dkfBU8FsZwHJyaJP3XJ+f6v8f1Br3+XfXf7l+n4I66x+E+l2MjldY1aSJ7Z7fyWMCqA6xqWGyIEN+5jI5xlenJyz/hWWnaiUuf+En1i7UyO+/faursZFds/uefnjBx26DHGPOYvGDyWWmyWvimKGNbmK4aOfxVA04wIRIr5uMFH/fEKSxBxwmcCfR/HCWmt2F1d66zxQiFHR/FdnIhAacSFlN2Q2VaLk5ORnqKprVX9P6+8laxul5/M9Tt/AVrb6LqOljVtSe3v7COwbeYd0UaRlAUIjHzEE53ZGegFUJfhfbymcnxLrYM6So5AtekgjDf8sP8Apin61pp8SPBLRqzeL9BQkZKtqkGR7cPinf8ACx/BH/Q5eH//AAaQf/FU/tX6lWVkuiMyH4X2EGtx6omt6sZlnE8ik2+2Ztzt837nOMyydCDhsdhieX4c2c2jxaY+tat9ngt5rSD5oC0UEqbDGCYuQABgnLcDk85uf8LH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUulh/a5upkzfCjSpbhZl1XVYnjmFxFsaHEcu+N3cAxEZdokLA5HXAGTWxY+EVtvD93od7ql3qOnXFubcJcLGsiBt287o1XOdw7cYpv/AAsfwR/0OXh//wAGkH/xVH/Cx/BH/Q5eH/8AwaQf/FUdLCSs7oo3nw4t7+8t7y81/WJbu3iESXDfZ92Asig/6nGcSv2weM5wKr3/AMKtPv7GO1Ou6zBGsKRP5TwfvCsLQb2BiI3GNipwAOhwCM1rf8LH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUDWjv8AIzk+GNhFem9i1nVkvA4kjuA0G6N8g7h+6wf4hhgRhiMYAA0vEPg6PxItut3rGowLDBJA4gEH74OAGL7ojzx2wPbFJ/wsfwR/0OXh/wD8GkH/AMVR/wALH8Ef9Dl4f/8ABpB/8VR0sLlSdzMHwvtFktWi1/WI0tnDiNfs21yLj7QM5hz9/HQjgAetFr8LrC11S2u01vV2itmBS0doDEQEdFUnyt+AkrL97PcknmtP/hY/gj/ocvD/AP4NIP8A4qj/AIWP4I/6HLw//wCDSD/4qlZWt0Cwzwv4Jg8HItvot6y2GHL2htLeMOx2hWLRRoSVCkZOSd3JOBXP2vwqGpaWP+Em1G7S+3SgLZ3EcsUMbGT5E3wj/noTkqWzxuxxXR/8LH8Ef9Dl4f8A/BpB/wDFUf8ACx/BH/Q5eH//AAaQf/FU93d/1/X5aBZWsYy/Dy5HiRGfVLqXSCJJpt1xGss0rzCXYyrAB5YZc5DBuxyOKWf4SaVc2iwXGr6tIPK8pmLQZdf3uM/usZAnkAIA6g9QDWx/wsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVSSskhrRtrqZ1z8L9KvDi41LUmi/fYi3RABpSjFgfLzkPGrjng+3FMt/hbY2moG9t9d1dZpJFmnz9mYTuGkbcwMJ6mV8gYHPAGK1P+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qn0sKytboWfD3hv/hG4xa2eoTy2CoQttJFEoRy5YsuxVCjB27QAoAGBnOduub/4WP4I/wChy8P/APg0g/8AiqP+Fj+CP+hy8P8A/g0g/wDiqBnSVzfw4/5JZ4U/7Atn/wCiEo/4WP4I/wChy8P/APg0g/8AiqPhx/ySzwp/2BbP/wBEJQB0lFFFAHMWyCX4neIEJYBtE04EqxU/66+6Ecj6iuFi8TJpfhixu7PWZJdT0XTpjfpf388qRTeZGu24UyD5jlwu85HUcCunv9M1DUPiZrR0vWr7TJYtDsCEtRb4mJmvcBjLDJgDHVR3Oc8VzWg69rup6dHf6l4n1fTreH7V/aOJrKVrMwuExtFgN5YnpxwOM0uv9eYPbUgsPic0vjqOH+2tNdp43tbh452kt43immVGEPm/IZFVfmycZXOcimxfGTVZNCjnjn0Ka5aJZmeJWMSsYBItsQJSRK7blU56jG0ng70Ot6dPAs0fxO8Q+Ubd7lnbT7RRHGpYMXJs/kOY3GGwcqRioZvEFnHdQWQ+IfilL26RGt4LjSIId28sqbi1j8gYqRk/4Uvhjr/Wr/r5eotHJy6f8Bf8D79zPtfib4qfxBPpN5HpltJGtwWmexlEcJhBdg2ZucxtEc8YLd+3ZfD3xdL4t027kurnTrie2kiBbTydgWSGOQAgsxyC7LnPO3oOlcnoniuHUtJ0+fUPH3iKxvbyzN2bRLS0n2KFZiN62WC21GIX7xAOBWq9/GPCo8QR/ELxKbByFgd9NtUadm+6EQ2W9t2Rgqpz2zVXUL83T87/ANL5CWrTuei0V454c8Zf2xYwT6j441+wlnggkW2jtraeTdKHIXA08BhiMncpPRshcc6sviHTIfO3fEzxIxhuFtmWPTLZyXYsq7QtkSwLIyhhkFhjOeKbTTsxqSZ6dRXkb+K0Hi59IXx34h+ywWUt1c3r2tonktGyKY9rWI3N84yFJII2kZq7/wAJJphZ1X4leKG8u3Fy5TSIGCRkkAkix4OVK4PO4bcZ4pdE+/8Awf8AJhdXt/XT/NHp9FcraaDqV9ZxXVv478R+VMgdN9pYo2D0yrWgI+hFTf8ACL6v/wBD34g/78af/wDItGwzpKK5v/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRaAOkorm/+EX1f/oe/EH/AH40/wD+RaP+EX1f/oe/EH/fjT//AJFoA6Siub/4RfV/+h78Qf8AfjT/AP5Fo/4RfV/+h78Qf9+NP/8AkWgDpKK5v/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRaAOkorm/+EX1f/oe/EH/AH40/wD+RaP+EX1f/oe/EH/fjT//AJFoA6Siub/4RfV/+h78Qf8AfjT/AP5Fo/4RfV/+h78Qf9+NP/8AkWgDpKK5v/hF9X/6HvxB/wB+NP8A/kWj/hF9X/6HvxB/340//wCRaADxR/yMXgz/ALDUn/pvvK4jxbrNlZfErUo9T1+6s9HitLJr4W+ryxPbM0rAMqK4Cq2Iw5UZwwP8RNdddeB729ubKe58beIHlsZjPbt5VgNjmN4yeLbn5JHGDkc56gVZ/wCEX1f/AKHvxB/340//AORaOqfYN4td/wDM4v8A4Wnqba5NEj6VDpsM7JK8kbs1rGJBHG0j+YAfNDLIjYAIBHP3qyv+FxXl1otzPNqvh1VewLLEhdJFm+x+cRuE4Iw4KYGGBI5BHPpP/CL6v/0PfiD/AL8af/8AItH/AAi+r/8AQ9+IP+/Gn/8AyLSWkbAvi5vwM7QPGc+rWevGObT5ZNNiEkBjkBi2lWKl5RIw52gnOwrzkYwxx4PHfiG5jtpoJdM+yXljLcxXT2T7IjAWE28icqV/1e0qxB3EgkDJ6n/hF9X/AOh78Qf9+NP/APkWqo8DXw1RtQ/4TnxGblovJ3MtkVVc5wqm22rk4yQATgZzgUS12/rR/rZ/IUVZWf8AW39I8/vfind6ppIhm1rRrRopYJ5bm2kkjEiEW8nlqVl+VgJJNxYkERnKgbiulD8UtbYadIlxol3FeSHymggcC5H2jyWjjYTN86r+9PX5TjHBau4/4RfV/wDoe/EH/fjT/wD5Fo/4RfV/+h78Qf8AfjT/AP5Fp9UJJ23/AK/q/wB/oec2vxp1BoUkN74d1F/LVvs1mWWR3aKZhGP3rfMGhXIx0kA4IyfRvAfiG68UeFYtSvha+a0jputJY3RwDwf3ckiqfVd7Yo/4RfV/+h78Qf8AfjT/AP5Fo/4RfV/+h78Qf9+NP/8AkWmuo2trHSUVzf8Awi+r/wDQ9+IP+/Gn/wDyLR/wi+r/APQ9+IP+/Gn/APyLSGdJRXN/8Ivq/wD0PfiD/vxp/wD8i0f8Ivq//Q9+IP8Avxp//wAi0AdJRXN/8Ivq/wD0PfiD/vxp/wD8i0f8Ivq//Q9+IP8Avxp//wAi0AdJRXN/8Ivq/wD0PfiD/vxp/wD8i0f8Ivq//Q9+IP8Avxp//wAi0AdJRXN/8Ivq/wD0PfiD/vxp/wD8i0f8Ivq//Q9+IP8Avxp//wAi0AdJRXN/8Ivq/wD0PfiD/vxp/wD8i0f8Ivq//Q9+IP8Avxp//wAi0AdJRXN/8Ivq/wD0PfiD/vxp/wD8i0f8Ivq//Q9+IP8Avxp//wAi0AdJRXN/8Ivq/wD0PfiD/vxp/wD8i0f8Ivq//Q9+IP8Avxp//wAi0AdJXN/Dj/klnhT/ALAtn/6ISj/hF9X/AOh78Qf9+NP/APkWj4cf8ks8Kf8AYFs//RCUAdJRRRQBw19rM+i/E3WpodFvtSi/sSwaV7WW3jWALNenLmaWPg5PTPQ5xxnm7O+0i6XVl0fRdeEvi12mEtnqulF32AK/kYuTkA5Lfe5Y5ruLIZ+KWug8g6Lp3/o6+rmh4W8R2elarZaZEIP7OSWLRJEkUGSOWQSMoAZSpVQIxllPXkdal7vTp/S++wPZev8ATMtPBsY0yLTZPCPjGWxhjuI0gNzpS8Tli43rMHwN/C7tuQpIJANLqHhO41LUNPv59B8ci7sY4k84Xekkz+UxZC4aUjILH7oUHvUP9j+ILTQ9SvNevdesbq0hgbT5rrWDDHcThj+58uK6lzv+SPDFi2c5LHJ6nWdG1tYPD8NpHql69ukz3kkOqvAjSGMlRIfNV2UyYwAGwBjgcFy2vvb/AIP+f9aEx10a3/4H/A/q5ylv4F+zCx8vw746Lafbtb2zPeaS3lqyOhwDLjJEhPTqqn1zu3dld3nhLT9Bfwl4tRNOMLW14lzpfno0X3W5n2E9uVx7Vj2vh3x39mSA/wBuRyw2t4YJrjVgyiVjG0KuFuCXx+9UZJxkZbuPQfBFrqll4TtYNdkupLxWfd9rx5iqXJVSRNLnAwATIxIAyc07KSd+tn+L/Hr8xJ67d1/Xkebaf4DbTrOa1i0Lx1JFNBDbsJLjRiVjiZmQKQ4KkFydw+YdiMVbh8Ii3uRPb+FfGcbpcwzx4u9LYRrE7yLEMzH5N7sect23Y4r12infW5TimrM8cvfA0F9qN/cz+E/Gfk3yXCPaC60ryk89leQrmbdneqtyxGRjGOKv6VoE2jfavsHhPxVGLqyjsmRRoqxqiMzZEayBMku+eMHceK9UoqbLl5em35/5sfW/z/L/ACRx+k6tqWj6Paadb+CfEssVrEsSPNdaezsAMZJ+1dauf8JRq/8A0IniD/v/AKf/APJVdJRVN3d2JKysjm/+Eo1f/oRPEH/f/T//AJKo/wCEo1f/AKETxB/3/wBP/wDkqukopDOb/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KrpKKAOb/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KrpKKAOb/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KrpKKAOb/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KrpKKAOb/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KrpKKAOb/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KrpKKAOSuvHF7ZXNlBc+CfECS30xgt182wO9xG8hHFzx8kbnJwOMdSKpXnxSttOuLiDUNBvbWa1VXuI59T0tGhViApYG7+UEkYJ65Fa3ij/kYvBn/Yak/wDTfeVyvjXQPEep+INcuNLtdWFvLp1tBElrJZCO9dZHZlbzTvUASdQU6NyeMrqD+Fv+tzqI/FmqTRLJF4H1543UMrLcaeQwPQg/auRTv+Eo1f8A6ETxB/3/ANP/APkquB1gy2txdXL6xqU9n/bEUFpb2+uyRSu8uPOtyxmCFkIIA3YXJwQRmo7rQPiOtwwuZNYu4zBboq2N8icDyy4aQ3MeHBV8lYstu5cjgEXzK/8AWyf6k31t/W9v8z0L/hKNX/6ETxB/3/0//wCSqP8AhKNX/wChE8Qf9/8AT/8A5KrhZvCXi/T7+OPSH1iOwGozTSbdQNxJIhZChLSXSfKUDId28g5IXOGp+kaT43h02zju7LXzLDLbvMtxqyOJj5arMfMW53AAgkAhlOT8mTkJO8eb0HfW3r/XzOzg8YajdW6T2vgrXJoZBuSSO505lYeoIusGnt4q1VFLN4F19VAySbjT8Af+BVcANC+I0lhbCVdXWdNPEZ26qoxiB1eNsTfNK0ux1lzwOrLjB7PwZLrFhFNpmsaVrKlneWC4vbmO4G0JHlTIJXIJcuVB4wD0AAqnu0un4g3Zrz/AntPGd9f2kV1Y+DNbubeZQ0c0N1pzo49QwusEVN/wlGr/APQieIP+/wDp/wD8lV55baN4j0rSbO2eTU9Ju2mt1tILjVgY5pHLpMipHKxIVCsm0AAbCePmp8Vlr97da1b+Dr/VLqDT7p7ad5ddabzkDREwxl5S0cuPNG87Mbhz02i1dv60t/mK+39d/wDL+tT0D/hKNX/6ETxB/wB/9P8A/kqj/hKNX/6ETxB/3/0//wCSq87l8J+PYrO4lt31VbqcwhpBfiWUQKZ9sePtMYMiboSx3gNhuXyVa7BpPjWJL9WtPETPOsrB31KN1YiZWjCr9rBjyu8HawwCBkgAUr62/r+v6QXdk7f1/X/BsdlF4w1Cd5Uh8Fa5I8L7JVS504mNsA7W/wBK4OCDg9iKl/4SjV/+hE8Qf9/9P/8AkquJ1PSPiBdSTLZxanbp9okaAJqq/u5Gii8uQnzcvCrrLmM9d4Ow9tfwUviXRtSkj1zS9dkt7oJGJLm9julik82Ylv8AXMyr5ZiHA6jnnJql0BS0vb+r/wBP+lff/wCEo1f/AKETxB/3/wBP/wDkqj/hKNX/AOhE8Qf9/wDT/wD5KrB1jQfEq6xrjWB1G6s5l+0Wu3VZIyHdVjeFB5q7QoDyDlRuKgEdsiLRfHMNtapPHrV2i2qRXY/tRYpXVJRkRus+C7JzuIRhz+85AEJ7f1/Vht2v/XY6+78aX1havc33gzW7aCP78s11pyKvOOSbrA5pp8bXiwyzN4O1oRQttlc3enbYz6E/auDyOvrXJeJ9F8WS/b4NK0jWruzu4ZFjifVY3CCS1EexxJPglZF3E8jnIJJaodV8P+LbrUP7Rh0vX/Mt5br7MiayiMoeSB06XAUphZBtJx0G3GKpaysJt2/rsd3/AMJRq/8A0IniD/v/AKf/APJVH/CUav8A9CJ4g/7/AOn/APyVTfDCaxa32pJqlpemCa7LQTXE6sQhBP3fOcKoOFG3Gf7igZPTUdBp3Ob/AOEo1f8A6ETxB/3/ANP/APkqj/hKNX/6ETxB/wB/9P8A/kqukooGc3/wlGr/APQieIP+/wDp/wD8lUf8JRq//QieIP8Av/p//wAlV0lFAHN/8JRq/wD0IniD/v8A6f8A/JVH/CUav/0IniD/AL/6f/8AJVdJRQBzf/CUav8A9CJ4g/7/AOn/APyVR8OP+SWeFP8AsC2f/ohK6Sub+HH/ACSzwp/2BbP/ANEJQB0lFFFAHDX3hrRfEXxO1pdc0mx1BodEsBC93aRzGHdNe5K71IHQducDNeTeE20S0s9S1LX/AA7peoQWFhJPJbXmh2UbTt55jR4DDCMx4BD7gSDjA9fV9Rt9auPiVrg0S70+Ff7DsBPFe6e115w869wq4miA7g5yDkdMc8h4eeLUrCUzW3hHQLaxtvtA/tHwtHHGkMxZCwZL5lUNsIIJBOORio15m0+n+YNXS9f1X57EV3feG7XSWvZfhH4ftT9kFxHDf2yWzzMJFR1UNbZwNwOTgkEfKAc1Rk1bwvHcXUo+GXh5ntYSj2nl2/lGVbwW7FW+zbjywIOQCMgqDzWzrfh7TtT0W70pPGfgHSleGOOWWx0WOORIiyMqfNdEBG+TgjBBGOorov8AhXV48ESOngeVI4hEm7wiSAgbcFH+lYA3fNgcZ5q0vev0uTra19dP6+ZxXibUfDOjTazpn/CtfCseoWOmTXSSxRQTIsqKhKkeSOB5gxnDHHKqCCX3OreErBbuGX4YeG557S3dxthhHmyReUJV/wBR8o/fDacfNg5C8V3k3grWbi5muLibwdLPOrJLK/hZ2aRSoUhibrJBAAOewApkngTVJkmWZvBcizxpFMG8KMRIiY2K3+lchcDAPAwMUlfS/b8df68xu72/rb/J/eYmm6Roc/jUeHNU+Fnha0m8hbozwRJMnkHcCwJtlG4OFXbkfeznisf4k6Ro2iXepWui+EPDVtHa6BPqAuP7Mt2cSiRQuEaEggYIxnoxPYV2F54J8WX6X8d54m0OaK8t/syxN4dO23iwMog+09CQD827n24qe88Ha7qKoNSu/CV6UhMCtdeGZJSIzjKZa7PBwMjvijXT5/k7fdp87grp/d+l/v1/A4K11rwSyWiT/DPw/wCZ9pa2uz9mg+TFwsAZP3Pz5ZgSPlwM9eMvudT8LWGgWWrX3wr8LJHd3TQLGnkM4VJPLZ8eQCeTkDpjqVJAPaWvgHUrEQCy/wCEKtxbyGWHyvCbJ5TkAFlxdcEgAZHPFOHgXVRaRWobwWLeEsYoR4UbZGW+8VX7VgZ7460ybSXX+tf+AcXez+Dwtpfr8P8Aw9Fpp1eax/cwWzTyCJZd3mRNbkKCYyQFcHpyORW21h4Qi+Hi+Jpfh94SLyiNobaNIGUrIV2bpDCMNhgSqqx7LuJFbjeCtZa7+1NN4NNx5wuPOPhZ9/mgYD5+1Z3Y4z1p48I68ul/2at34RFhv8z7KPDEnlbt27ds+14znnOOvNTZ8rV9dP8Agl/aT6f8FnnUHifwNJf6ekvwt0FLS8tYLgzLbQM8fmxyuF2eUM4MLDOe4PtU/haDQL7RvGOt6h4F8NyR6akd3Z2P2K32pE1ssuzzVgByc55U4JxkgZrtF+Ht8l3DdInghbi3AEMw8JMHjA6bW+1ZGPan2vgTVLG1u7ayPgu3t71dt1FD4UZEnHPDgXWGHJ6561T+1bre3lqJbxvsrX8+557F4o8GRy3w1P4U+H4EtbeWVGhhhmLsgiJUjyAQMTpyM9+Djmvql9od9qOjw6X8OtF0rFwi38V1psMbuXimZYwslvuC/ut3mYB6fKcmvQ7b4a3NnI0lnbeBIHZGjZovCBUlWGGUkXXQjgjvS3Hw3urtIUu4PAs628flwrL4RLCNM52rm64HJ4FKSbSt/W//AAP63ST1u+/9fn/W3F6NqXhO9Om2Nt8MdCvrm70j7ZGTFamWSUQrJsYLAFXO7rgHPITBGaWp3mhrrX+jeAPC/wDZ6Jp5cQQQq6vPO6EfPanI+XawIQjBwc9PRk8A6lEoEf8AwhSALsAXwmwwuMY/4+umOMelMuPh5fXcccd3H4HnSKNYo1l8JMwRFztUA3XAGTgdBmnLWV13/wA/+AgSfLZvp/l/wfvOEtfEng248JXmsP8ACvw3FNbrC627LBiRZEd/veTnICH5QrdjwMkXtMg8JQ2fi/WL/wAHaJd2enm2ls7U6VaqY1lgR9m5Y+m5+pyRXWW/w5vLSN47WHwNAjsGdY/CJUMRnBIF1yRk4+pq1b+DdbtILqG1uPB8EV4oW5jj8LuqzgDADgXfzDHHPal1l57eWw9br8Ty7w82nfbJodR8AaHqlyhv2WCCztdgENyibfltQzbFbIYcsAfkJxWlqHiDwRayXAtPhn4ZvEjh3xukcAErrHFI4H7n7u2YbX/iIwQuQa7GL4YywbvJs/AUe9drbPB5G4eh/wBK5FWrjwNq12ZDdP4MnMsSwSeZ4Vdt8akFUObrlQQMDoMU1sl5f1/X4hZ3b8/6/U4LxP8A2DpvifSrD/hAvDdnHbXMR1UQWdvN5ivDLIIkDQAkYjzvBUg8YI5q3od34d8QXOnQ2Hwh0FDfW81yv2m1SHMcZj5QPbDfuEi4PAyCM4+au0uvBWs319Be3svg25u7YKsE83hZ3kiA6BWN1kY7Yplt4E1SzdWtD4LgZUdFMXhRlIV/vqMXXRu4796ST1v5/l/wwrO6foL4Y8JeDNf0KO+ufAnhu0nLvHLbx2MUnlOrFSpJiU5BHIwK1/8AhXHgj/oTfD//AIK4P/iar2WheLNNtFtdO1fwzaW6ElYYPDsqIuTk4Au8deasfYfG/wD0MPh//wAEM/8A8mVT1Y1fqH/CuPBH/Qm+H/8AwVwf/E0f8K48Ef8AQm+H/wDwVwf/ABNZuqXPjfTdR0a1/tvw/L/al61pu/sSceVi3mm3Y+18/wCp244+9ntgw6xrHinQ9U0rT7zxBohm1WcwwmPw/MQhA+85N6MDJVc88sBS62H0ubH/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E1z+s+KtX0RZluPGnhea7j3gWUGkOZndELlApvQA20HhiO3rUsHiXU57a2mHxA8GotyMxB9NYFjkKR/x+8kMQpA78Urpgbf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNZtrqmu311BbWXjnwhcT3ERmhih0t3aWPON6gXuSuQeRxVSXxF4gt9QmtrnxX4bt0hLh7i40doo/kAL43XwLBcqCQCATjPXDFc3f+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4msl9a1wW8MsHjbwjcG5LraxxaWxa5dM7kjzfAMwIxjPHfFQ6Z4j1jVdNt72Dxt4UjWeA3Hly6S4eNQqs24fbeCoZd3pkZo7+Qzc/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4muZ03xlq+o2ouW8Y+F7OH5/nudM2jiVogeL85DMp2kcHHXPFaMWtaxNqFtYw+PvBsl3dRiW3t00xzJMhGQyr9tywIBORQK5q/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNc/P4p1i08RSaNdeM/CsM8Uas8kmlMqI5YKIz/p24OcggEDIPGeasPr+qRbvN+IPgtNv3t2nMMckc/6b6gj8DSurXHfWxsf8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNZcGsa1c3S21t488HTXDp5ixR6Y7Oy7d24AXucbec+nNFvrGtXa2zWvjzwdMLsstsY9MdvOK/eCYvfmx3x0phfqan/CuPBH/Qm+H/8AwVwf/E0f8K48Ef8AQm+H/wDwVwf/ABNZFprPiHULy3h0/wAW+GruO6DiG6ttFllhd0+9HvW9I3gc4PYH0ONf7D43/wChh8P/APghn/8AkygA/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mj7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMoAP8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+Jo+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTKAD/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaPsPjf/oYfD/8A4IZ//kyj7D43/wChh8P/APghn/8AkygA/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mj7D43/6GHw//AOCGf/5Mo+w+N/8AoYfD/wD4IZ//AJMoAP8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+Jo+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTKAD/AIVx4I/6E3w//wCCuD/4mj4cf8ks8Kf9gWz/APRCUfYfG/8A0MPh/wD8EM//AMmUfDj/AJJZ4U/7Atn/AOiEoA6SiiigDmLYO3xO18RMqudE04KzLuAPnX2CRkZ/MVhab8M9S0jRJNNsNftII7ra175WmMgndXzuAE2V3L8rjJ3dRtJOd23hjuPiZ4ghnjWSKTQ9OR0cZDAzXwII9K4u00HUdC0u6h0fQ/LuvC0VxDpc32b/AFyzShg0Z2sWZYxg4VssehPFQ7Xd+39fp/SB3srd/wCv6/zLcfwfuhoJ02fX4JBHLC0DR2U0ICxwtDsfy7hWYFG/hZOc9QcV6VaW4tLKC3XGIY1Qbc44GO5J/Mn615Taap41utI1S+n1rVoJ9LtorkQnSlhhugCxkQPPaxsWKKBkbcMxOMYA6LWbvxDZweH41u9XaeVJpb0WNjHLuIjLrGXMLInzYQE7cg9zyLlJpNsle80d1RXj9rrnj6S2RBPrElzFa3kq+ZpAiW4ZTGYVdjbgA7WkHAUkoOM8H0HwRdareeE7WbX3Ml6zOGZoZImK7zt3K8UR3bcZPlqCeQMU0rq/9df8g5kzfooopFBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+KP+Ri8Gf9hqT/033lZ3ijwFd+JdUlvn1oW0sPkHTQkUwW2aOQSMZFWZVm3EDqBtwMc5J0fFH/IxeDP+w1J/6b7yuJ8W+HbzU/iNqd7o2mrZz21naz/20tnJ9oR42kZltz5LJKzKUVl3dMDDYwJbSafb+rjteLRu33w71G7ubydNet4TcGUrELGRoo/MikRyFaYkEmTdwQvH3ckk5918LNZnuGZPEemJE0bR+WdGc4DeTu5+0D/n3XHHduvGMmLxJ4/lFhBA2pbWuE8+7u9HliYbooW2FVtWyoZpxnC4KrucfxMuPFPjWKOGKSXxJHKqos8kXh8y/OIJQ5G23II85YuRx82R8pFNpQfP12Isp2+/7/10Op0f4d6jp/iSz1S816C6S0uJpo4EsHjCiUyllUmZgOZuuMnYv4Q6p4C1XVorvTor+3sLXzL1knktfPMy3e4twJEKFCzDkEEbeeoGFH4m8eTXEcUMesFRKGjlk0YoJnZYW8qTdENkQ3TgOMHKDLf3oxrviu5Rbe5fX52M8TRySeHiPLPmTocH7PgYUQvu6gnOcZFKTstgjK92umv52/r/ACOu0rwTrOlalPfRa5p7S3AkSVf7LcJsZtyhR5+VIYnJyQRjgYzWVb/Ce+ggghHiOHZDEF404jc4ihjDf637v+joSvfLDPIxR0zVfElnarhtcnmBsPNebSGSaYGLDpv+zYbDdS2Mc5da9WhmW4hWVA4VugkRkb8QwBFVblul6fdr+pMWn0t1/r7jzpvhlrDPn/hI9Px53nYOkN977X9q7T9N3y49PeovDPhHxDonjuKS7jgu7SGPYL0QGKMrsxlEFy2Hzx80THGfnAwo9NooWlvn+JbSd2+p51q3gDUEXUntrwX0d0s6W1ulqiTQSTTCZZTM0gBEcg3fdzgAAEjlPEXgjVbZFm8PS+f89mgtRHkAxSxMZ5PMmVWIWLGECFsgEnAI9GooXu2t0/r+uv4Derb7/wBfp/Wp5rc/Ca5ug8MmvQrazDEqpp5WQ5imR9riXCg/aHIG04wBzzktfhLLBrcWrTa2kt20oluQtvLFEzKFCMkaThQw2g/P5gyScCvSqKVluJpNKL2R5/o/gXVdHuLWBb6G4EN0+om9eAqPONv5AUoZGZ8kl2O5fTPOR6AM4GeT3xRRVXdgt/X9eYUUUUhhRRRQAUUUUAFFFFABRRRQAVzfw4/5JZ4U/wCwLZ/+iErpK5v4cf8AJLPCn/YFs/8A0QlAHSUUUUAYmqeC/DWuaqdS1vQdP1K7MKQCS9t1m2orMwChwQvMjZIAJ4znAxW/4Vx4I/6E3w//AOCuD/4mukooA5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/ia6SigDm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JrpKKAOb/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mukooA5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/ia6SigDm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JrpKKAOb/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mukooA5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/ia6SigDm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JrpKKAOb/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mukooA5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/ia6SigDm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JrpKKAOb/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mukooA5aX4Y+BZpIXfwfoYMLl1CafEoJ2lfmAADDDHhsjODjIBEv/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNdJRQBzf/CuPBH/Qm+H/APwVwf8AxNbem6fa6RpVppunxeTaWcKQQR7i2xEUKoySScADknNWaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4z/hY9p/z4Tf8AfYo/4WPaf8+E3/fYo/4Vxaf8/wDN/wB8Cj/hXFp/z/zf98CgA/4WPaf8+E3/AH2KP+Fj2n/PhN/32KP+FcWn/P8Azf8AfAo/4Vxaf8/83/fAoAP+Fj2n/PhN/wB9ij/hY9p/z4Tf99ij/hXFp/z/AM3/AHwKP+FcWn/P/N/3wKAD/hY9p/z4Tf8AfYo/4WPaf8+E3/fYo/4Vxaf8/wDN/wB8Cj/hXFp/z/zf98CgA/4WPaf8+E3/AH2KP+Fj2n/PhN/32KP+FcWn/P8Azf8AfAo/4Vxaf8/83/fAoAP+Fj2n/PhN/wB9ij/hY9p/z4Tf99ij/hXFp/z/AM3/AHwKP+FcWn/P/N/3wKAD/hY9p/z4Tf8AfYo/4WPaf8+E3/fYo/4Vxaf8/wDN/wB8Cj/hXFp/z/zf98CgA/4WPaf8+E3/AH2KP+Fj2n/PhN/32KP+FcWn/P8Azf8AfAo/4Vxaf8/83/fAoAP+Fj2n/PhN/wB9ij/hY9p/z4Tf99ij/hXFp/z/AM3/AHwKP+FcWn/P/N/3wKAD/hY9p/z4Tf8AfYo/4WPaf8+E3/fYo/4Vxaf8/wDN/wB8Cj/hXFp/z/zf98CgA/4WPaf8+E3/AH2KP+Fj2n/PhN/32KP+FcWn/P8Azf8AfAo/4Vxaf8/83/fAoAP+Fj2n/PhN/wB9ij/hY9p/z4Tf99ij/hXFp/z/AM3/AHwKP+FcWn/P/N/3wKAD/hY9p/z4Tf8AfYo/4WPaf8+E3/fYo/4Vxaf8/wDN/wB8Cj/hXFp/z/zf98CgA/4WPaf8+E3/AH2KP+Fj2n/PhN/32KP+FcWn/P8Azf8AfAo/4Vxaf8/83/fAoAP+Fj2n/PhN/wB9ij/hY9p/z4Tf99ij/hXFp/z/AM3/AHwKP+FcWn/P/N/3wKAD/hY9p/z4Tf8AfYo/4WPaf8+E3/fYo/4Vxaf8/wDN/wB8Cj/hXFp/z/zf98CgA/4WPaf8+E3/AH2KP+Fj2n/PhN/32KP+FcWn/P8Azf8AfAo/4Vxaf8/83/fAoAP+Fj2n/PhN/wB9ij/hY9p/z4Tf99ij/hXFp/z/AM3/AHwKP+FcWn/P/N/3wKAD/hY9p/z4Tf8AfYo/4WPaf8+E3/fYo/4Vxaf8/wDN/wB8Cj/hXFp/z/zf98CgA/4WPaf8+E3/AH2KP+Fj2n/PhN/32KP+FcWn/P8Azf8AfAo/4Vxaf8/83/fAoAP+Fj2n/PhN/wB9ij/hY9p/z4Tf99ij/hXFp/z/AM3/AHwKP+FcWn/P/N/3wKAD/hY9p/z4Tf8AfYo/4WPaf8+E3/fYo/4Vxaf8/wDN/wB8Cj/hXFp/z/zf98CgA/4WPaf8+E3/AH2KP+Fj2n/PhN/32KP+FcWn/P8Azf8AfAo/4Vxaf8/83/fAoAP+Fj2n/PhN/wB9ij/hY9p/z4Tf99ij/hXFp/z/AM3/AHwKP+FcWn/P/N/3wKAD/hY9p/z4Tf8AfYo/4WPaf8+E3/fYo/4Vxaf8/wDN/wB8Cj/hXFp/z/zf98CgA/4WPaf8+E3/AH2KP+Fj2n/PhN/32KP+FcWn/P8Azf8AfAo/4Vxaf8/83/fAoAP+Fj2n/PhN/wB9ij/hY9p/z4Tf99ij/hXFp/z/AM3/AHwKP+FcWn/P/N/3wKAD/hY9p/z4Tf8AfYoo/wCFcWn/AD/zf98CigDs6KKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACisTVPF2laRqp025GoTXawpO0dlpdzdbEdmVSxijYLkxvgE5+U1W/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKAOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKAOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKAOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKAOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKAOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKAOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKAOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGKP+E80j/nz8Qf8AhOah/wDGKAOkorm/+E80j/nz8Qf+E5qH/wAYo/4TzSP+fPxB/wCE5qH/AMYoA6Siub/4TzSP+fPxB/4Tmof/ABij/hPNI/58/EH/AITmof8AxigDpKK5v/hPNI/58/EH/hOah/8AGK29N1C11fSrTUtPl860vIUngk2ld6OoZTggEZBHBGaALNFFFAHLwiU/ErxCLchZToen7Cegbzr7H61wvhtNR0mxtVj8H3DeILe3nl1bVpIZVl+0BGAdfk2Xe7cQqiTjOPlrqb7RbLVfibrUt/LqEa22iWDD7FqVxaZzNe5z5Lru6cZzjnGMmsOHSlstDh8Q65eam2m3cUbQWdpr2pC4V5Sgii3tdbHJLYJ+QA47ZNTa7du3+dvv/GyDS6/rt/Xlco2uteP7jQYhdza0t2ZbqHy10kJJIpUNDIz+TsAGCMfITnuRgrpFz41tdKkgsLnW9mn+H7WS3t7jSkQPcEMsq5aEFmQbSEBySBnPIqWPWPC08ix21l43mchQVXxBdZV2aVPLObsfNvhdfTODnHNN/tzwmY3lS18bPAibzMviC627fKjmJ/4+88RyBunYjrgFrW6X9br9b/kZtWer/ptP9LGHLr3xCiu7m7S31hJmS3jjvF8PBppYBduCWAgznySHKdieAuSKli1f4jfZbrWFg1f+0pNHskEcmmlFDee4nYL5LYkC4baFP3s7GAAG5Pq3hOLUjZQQeM7uRp2ggaHxBd7bhlk8p9ha7HCyEKd2OoIyOa6vSvCug6xo9pqVpd+IxBdwpNGH8RagGCsMjI8/rzTWsbrv/np/X4FP4mv60t/l1OG1a68bX0Vrb6he6w6i5sJriXTNIYRwgEb9qyW+9yGXf0YDOGVcAGhoviTx3YaholsltrSWGIxPAPDhjQ5uJQ5bbAuz5NjcFeTn1r1P/hA9I/5/PEH/AIUeof8Ax+j/AIQPSP8An88Qf+FHqH/x+lb87/hYOXR69LHmui3XivXPFfhu48TabqkrWesu8VzcaS0Jige0OdxVAqjzGAwScYwWbG6s/wCIL+KbnxpqFydN1a4e1tr22sY4dCN1b7GWIxfN5LK+8hwwYkDH8PU+tf8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P0+qfa/4q1/X/Nj63/rRt/dr+BwureIPHcNje/2Z/a8u25GyeLRsGNDFIyRpE8QYjzBGjt8wAOQy5O2C/1Hx1c+G9Te7l1n95qX2Oa3j0dHMFsY8s0S+SWlG/5N3zDbz1+avQf+ED0j/n88Qf8AhR6h/wDH6P8AhA9I/wCfzxB/4Ueof/H6mUeZNPr/AMD/AC/H7xaWt0/4P9f8A8p0/VfiLpPhe0sNLtL+xt7Lw5H5Mf8AZkjytcCMjAUwMN4kAG1mX5TkKeo9G0GfXovF0Frf6jqmo2UmniRmn09YEil+U/OwiUEndgBW424Zcgk6H/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/Wjk5Scn1v+N/8/wACVGySXT/gf5fidJRXN/8ACB6R/wA/niD/AMKPUP8A4/R/wgekf8/niD/wo9Q/+P1JZ0lFc3/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP0AdJRXN/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9AHSUVzf/CB6R/z+eIP/Cj1D/4/R/wgekf8/niD/wAKPUP/AI/QB0lFc3/wgekf8/niD/wo9Q/+P0f8IHpH/P54g/8ACj1D/wCP0AdJRXN/8IHpH/P54g/8KPUP/j9H/CB6R/z+eIP/AAo9Q/8Aj9AHSUV5/r3hOysta8MwW2oeIEivtTeC4X/hIr870FncyAczcfPGhyMHjHQmsDxJaf2Dq2rWjXWqCEWiy6fdNrepsscxDkQzAXQ3bvLbawKjPy4zjJ1sDaSuz1+ivJ2vvDMGr3Okyx+L57u0fypJIfEN15cjbJGyp+2HAJhdcHkHAOOtQXfiHwPY6ZNfXU/imKGN4oxv8T3KFmeMyAYa7G3CqThtu7jbuyuTT+vMNb2e56/RXnXh+28L+I9Wv9PsZ/FCSWSo5kk8R3pSVHyAyFbk91IIbBBHIqnfXHhfTrrUILyPxfGbCfyJGPiK7w5KKylR9qzht6KCQPmYA45oem4ro9RoryNNW8MSTLClj44aTcI5F/4SC6zFIZWh8tv9L6+Yu3IyOQc4yRWudW0VIo57Gy8YXcdwYxGi+ILpHjDW7zbjuvAGwEI2/L0PJ4yrq1+g/tcvU9loryeC+8NEXKzQ+Mc2kDSyTDX7tUkKxRykKPtZIJWRT82AOcnitfQtO8Oa54VPiBZPE9lZASN/pPiW8JKISC4MdyylTtJBBORz0IpvS9+gotStbqeg0V47YXFhJfXg1KLxNawQzTGNH168R/KS3jmAdje7VY+YcHpgYOw05Nb8NTQxyWul+Op1YQ7tviG4UxtLK0KKwa9HPmIVOMjvnHNHZen47Be+v9f1qewUV43pWo6ObKVNZt/FX9oi6kt4ILbX7wfaiJpI1VN12RuAjO7cwHBwSKdH4n8BXEzw2d34ouZVtFuliXxLdI75CtsCvdqQ2HXqApPAJIxSurXH1t1/pHsVFcJBpHhqfwhH4jS78TCyktRdKp8Qah5m0jIXb5/3u2PWuY0S9064vJLDWdP8XwXpuJVgRdfuk3osuwjH21ssgIZsHGOR1ApvSXK9xXXLzHsVFeURX/hiUW8gtfGX2aZA5uk8SXEkcSmQR7m2XhPDEZwCRn2OKFr4p8FX6SSacnjG8hhWSSWW38SXLrHGgUs7YvM/dcNtxuGCCoPFC12C6PZqK8rebw4bx0ifxR5MBuRK7eJLnDGFdxG43o8snr84Hvt61taJonh/XfDces203iaGF1cmK48R3ySIVJDK3+kFQQVI6496XMrXBNN2R3VFeN2eq6HdX0Nx5fitNKkTZJu169820lEwj3SMLwq0Z3rjYGPOeR0SHVdEW5u5LiDxbJausUmnww67eieeIxu7S83e0ptjLD7rYONpOMl1y83QOZXsey0V5Jbav4Uup41jtvGoill2JOdfu9jDzViL8XedoaRO2cN04OFtbvw+biK3uofF7NI7ZnXX7qOOIefJEqtm9JzuTaSMg5B4GQpdJJ9xcy112PWqK8r8PR6R4l1y0jsn8R29lPa3LPFc6/fiaOWGSNfvLdMhUiTIxnsc812H/CB6R/z+eIP/AAo9Q/8Aj9VbRPv/AMMNNO50lc38OP8AklnhT/sC2f8A6ISj/hA9I/5/PEH/AIUeof8Ax+j4cf8AJLPCn/YFs/8A0QlIZ0lFFFAHN2P/ACVPXf8AsC6b/wCj76n/APCCeHTaXFq1g7W867TC11KUiGQ37oFsQ8qD+728gHtTLH/kqeu/9gXTf/R99XSUAcq3w18LtcRTraXkckQUKYtUukB2lmBYLIAzZdzuOSSxJPNVo/hN4QhiaJLPUBGyGModYvCpUoIyMGXH3AF+gA7V2dFAHLv8OfDEly1x9hnSZpRNvjv7hCrgg7hhxtJIDNjG4gFskZrd0rS7XRdKt9N05HjtbZBHEjytIVUdBuYkn8TVuijZWQrK9wooooGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34o/5GLwZ/2GpP8A033lXrrwvpN9dX095byXDX8aRXCS3EjRsqHK4QttUg85UA55zVHxR/yMXgz/ALDUn/pvvK4/xF4SvvEHjrWW0fTbG2lSKJjqF5bSL5zGF0aJSYikisGUMctjaAVbAwnvoHTU6ubwH4XnvpxJp9x51yTM7rc3CqDvZjtYNhctI/ygjIduME0SeA/DNrZbpYrxEt402XDanc+ZAkYbGyTzN6ABm+6RkE5zXEf8Ku1tE0y3Ol+H7q1tAqOk97J/q1uHkVB/o5yAjbecdSMY69fYaLrT/Dmfw3q2nafJPFp62cRa7aSC5Pl7SWJj3KAf9k0tVTbW62X32Even733/mN8M6V4V1G8m1Lw02p288FwPtHmPdwlycybWSbG5D5pbpgls1q3+geHdR/tDU7u1S6+1WptrmSNnffGhJKhVP3gR1UbsgDsK4K5+G3iG8tUtzY+H7WCK4guIY4blz5LxQxopVvIBXlDwMZDcnjDSWXwy1bSNShuNLsdBRUuhcOBK8RYq1xhvlhPzFJ1BPby8cjkOporR/rb/g6f5ii29Wun49v+CdLaeAPB+q2ljqVlDetC8SSwSx6ndx+YNxlV2AkBZtzFtzZbJ5qWD4YeFbe2aCK0vdjFT82q3TMu1GQbWMuV+V2Xgjg4rhG+EniGQRm6/sy8YWdrb+XJelY18oRBlx9lLsv7osPnABY/LnLHXg+HmtrY3Nu9nokMktlLa2lzFcuz6aC8hCw7ocbSrqCBtxt6MMCnOyuo7ahd3N29+F2hvYzppZu7S6kjKJNLqF1Mq5RUyUMw3fIirnIIwMEEA1qaF4W/suyaLUNSu9SaWEwzJPcTSQkEknCyySMOpGS7HHGcAAZ3hXQ9Y0PwnNoD21vEY7Zzb3D3S3EfmuznZsWGIBF+XACAYOAOOeNsfhVr2nzWrW1joSG2kWSGQXsgaA/aI5WCYt8AYWQDGB854AJFJ/Hy9P8Ahw2in5/0ztx8MfCozizvMEMCP7UusHKCMnHmddqqM9tox0FLF8NPC8LStHa3oM0kcj/8TS6OWSQyKf8AWcYdi3Hcn1rjNG+E+rWWuWVxqEOjXEEORLJ5rs7yBHUXW0xY81iyMw3cGNTuJ6RWnwl1qysLZo4tHudQtrgy+ZezmSObmLIKx28e1TsLleTvAJc7mzS+L9f67A+1v6/r+tmdvD4A8LXSSyrZXw3yPkyXt2jK/nFy6hnBU79zB1xweDg1YPw/8OY2x2U0Ee2NfJt72eKP93t2NsVwu8bFw+N3A5rk9C8A+IdN8V2GrT2+ioli06xi3uXDGKRpm2E+QCRukj4JwNpwPX09CxjUyAK+PmCnIB+vGalbDu23cxrPwnpVlpNzpUaTyabcRCI2k1w8iRoF27U3ElRj0PXmqmneCdP0vVobizG22gEkkccjyyyiaQASP5ryMcEAcADnLEkmulop9bj6WOP/AOFdad/wksF+zmSxiRmNpLJPI8s5kV/MkkaU+YBtXCOpAwCMYGGXPw10yXUrAxSyrpVssok0+W4uJA+/bhVYy4SMbceWFKEHGK7OihaJJdP6/r/gCstfM5q8+H3hy/vZLu7truWeXdvc6jcjIZdpGBJgADoOi9Rg1asPCWl6db3Vrb/amsruIxSWk11JLHhmdnIDEkFjIcnPPHpW3RSsrWHsc7b+A/DtsYDHZSkwS+avmXcz7m+U/Puc7xlFOGyNwz15qt/wrLwntZRp0wBZSoF/cDy9u4AJ8/yDDsuFwNp24xxXV0UxWRyX/Cr/AAqJ2lW0vULMW2pqt2qKS6v8qiXao3IpwAB8ops/wt8KXMcsc1pfOk2fMX+1rvDfOXx/rem5mOPU119FFtvIZhaX4L0PRdQjvtOguEuI0dFZ76eQYfbuyrOQSdi8kZ4FbtFFHkJJLYK5v4cf8ks8Kf8AYFs//RCV0lc38OP+SWeFP+wLZ/8AohKBnSUUUUActEIz8SfEQnTzIzoWn702F9w86+yNozn6d6858IWt94Y8OXp0/SdT06+1C3hS2bT9FkiWMLKwZ5UaJx5q7iSWX50C7R1x6XY/8lT13/sC6b/6Pvq6Sp5dX5geLL4j+Ic+hyXUUmrpdo9vFNFPo7RJFmHMjoBau7jzVwdocYY/dBDL7HZvK9jA9xjzmjUybVIG7HOAQCOfUZqairvuK2qCiiikMKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8Uf8jF4M/wCw1J/6b7yuV8a2lyPEGqTz6G+qXcltEuhzSafLeQQtyJEPlkGFiT/rCV4I5O3FdV4o/wCRi8Gf9hqT/wBN95WX4y8fTeHtQSCxtJJoofM+2z+QsixkW0kyqv71DvwgODwQcbgSKXVD5XJNL+v8zAn8QeOItQ1YMNUMEc0fkRx6Wdxw8iOsTCBlwwWNxv3ABsGQcsKDXnisW17Ddah4mnW3jMzW82hrMkz/AGtlMeTbHevllThT05BwK7Of4lWVvqk2mrpOp3d1E0KAW4g2zGXgbSZQBhsAhiCMjjHNUj8TXGp6fLNo17a6VcwzmTzkiM0bRyxRl8pMR5YMhB43fLkZFC1tr3/L9N/zM3yyul93l/X9bGAb/wAT2NxM5k1qa5AvvLml0hpGjX7UpREkW2cgNEOAQw4HAwMdnrniKb/hA7680uS6h1C3EcLA22ZY5m2fLt2MCfnH3VfrwrfdOVcfGfwzZ6ebu7jvLdCY2iWbykM0ThmSZMyYKkIxC5DnGNucCrl74r07xL4d8UWsGnxztpcDs8WpQxz29xgMVbarkMuUIIJUggggGpl7sGn0/wCH/X+rMtK9S/d/1/X+aOX0bxB4xuLtEGpardwiymjmmn0hhGLgAsrKVtUYFSDGQykkjOwZG5LTU/GkusW5+2eJIheTx/uptMQxLGLdzkv9nxHmUKDnaQDyFPTo7D4haPpmmaTbPpFzpyTS/ZfIijhRLVgEIJRZMhD5i4KhsbgDg1DZ/GXQNQTfYWWo3UY3F3g8iRUCmMEkrKe0yHAyRkggMCKpq7aT/rf9fu8jOL0vf+tvwt95yl7r/jgaJHdzQ6zLdxs7QMdAEksM5tX3KFWE4RZSEV8YZXYFmGTV251rxoVmutOn16d4YZoo1n0toFkHnx/OV+zn5hEzbSEOdvCsdwPUT/FXR7dYy+n6kWxidFSLNq5leJEf95jLSRso2lhnqQDmqmo/E24+zwnS/D+oRysbKZ/tSwFWguJvLXG2fIdgGxngYG7FG8rr0+/Qq1kk35/1+H3mNc6n41u9PEM13q6P5VnK9xpunOnljzohL8stsrM5Uu2ADwCCi4w1fTPEnimzmtR5fiF7aOKMNar4eMQmctOHJP2cBDxC2eFy2ehIrsH+JulRyojWGo/vNPa/UhYjgKMtGf3mVcDP3sKcHDcVV0r4pW2rSO9vpGpgSJH9ktSluZLtmeVd0cizlCv7puTtGF3BiCKPi0Xf/gW/AFblv5f5amb4OuNYvPE1lP4jttQnuFsb2F7u40p4d8ZkheJXIjVc43gDAzg8AnFc/Y6v4t0XwjDp2jw67G8KRSwL/YjBYVCyFoMGA5UlUHZgW+90Fet61riaFoZ1O5s7qVVaNWgh2GQF2CjqwXgsM4P0zXNTfFnRLTTri7v7O/s1g2jZc+THvJeRCAxk2AhonBywHAwTkZLpWXb/ADb/AF/q4lHd3/rb+vl2OSvPE3j9L26Nw+q2sH2uREjstGluGjTy5thybXbtLCHo0hBLZbBwJpvE3j17QLZx6uzLK5jlfRirSyGKF44XVohthLtMpcAEbVy46npbL4l239oLDewvLDd3629nPbIqhI3ihkRpFaTd1mCllBGcZAzUVp8ZNA1AbtOstQvIwz75IDAyxqoUl2/e8Da+cfeGCCoPBcdH8l+n4/13BtNXv/Wv9f8ABOT1m48Vaxo+pWl7c+IriC4stSBtG0MBGZJNtsoP2cN8yEn72TgYx31F8S+K4b+wjR9Z+yWtxKt1NcaOUSeHJCk5iXaUBU7gygjscMR3vh7xTaeJJ9Rhtbe4gk0648iQT7CH4yGRkZgVPPfPBBArD1D4l6Zb6hrOnSaPqF1/Zaf6Tta22vlgoQK0wbLbuAwG4A4zxmHslfp/wf1Lfvff+eljjtN8S+PZE08pqF5dedd5uftGlyobdMR7EZVsgxVh5p3BVUEKPN+U7um8eXcup2Hh3VvDwvzJHczTRXNrprzSRD7NMOUMZK5bauGHen2PjPQtI09Lbwl4afyGmtgLaxS2tx/pABDbN4wcHuBk9Djmp7b4qaZcPaq2lapB9oEZzIsJEQlYpEX2ynG91KjGcEc4BBNyaasv62IhJLV66fg76nKt4q8fXNrqlxZ22qxRSGFoFudLeN7Yb5Fk24tmZgcRtjy5GAbGeCQw+KfGsV24luNefy97usPhyUxEqYSqoxtwSrEzD+9hR0PJ6GL4tW39hy3baNqU0kNn9p3+XDFHK3kedsA81yp2565xtPJ4zaf4t6DHeXVm8FyLu02CWDzIMqxIUqSZcKQSB820N/BuyKErTt17f1/XcJLS7f8AX9P+tTmF1nx3dTy3MJ1wCOeaW0tptN8sHNvJshlPkruUSKBu4+8PmPysYLfxN44821W9vNdXf5QP2fw/LIu1pmVyzNZodyxnP3VGVXAPIPVt8TRFqF2lxoeoxwWjSxhVWB2uSs0cW5G84bcF+VZeQQQeCC7VPiXBHZtFYWdxBfzWE9zAbpI3jikiEhMcqpLuB/dPyPlODhjioVrKV9P6/r/glW5m4X1v+q/r/gHPW3iLx9dy2+77VaRNpiszS6XOrSS7PmO0WrhH3g/eOMHIibjNi11zxL/bEcgg1hPMlsjcI+k7HkUxgOPNFvsIBJJBKEZPzLjYfT7aUzWkMrYDOiscdMkVLVtNS/rv/SJXvRuv60K9hf2+p2EV5ZszQTDcheNkPpyrAEfQisP4cf8AJLPCn/YFs/8A0QldJXN/Dj/klnhT/sC2f/ohKCzpKKKKAObsf+Sp67/2BdN/9H31dJXN2P8AyVPXf+wLpv8A6Pvq6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/FH/IxeDP8AsNSf+m+8rI8Z6b4GvDf3mt/6XewRt51pZ6o8M0hSJiV2LKgL+UzdcEqT2rX8Uf8AIxeDP+w1J/6b7ysvxd4A1DxHqcl1Ya3b2CSLho5rAz/N5MsJORKnG2Y8eoB5HFJlRtfUgfw/8O4Lo3E98lpcWXl3Mqvrs0bQZIZWkXzeMtg/NwSSeSTlz6D8O5LKWN9ThMOlI6Tt/b83+jLJIHbzG83K5dAfmPUYovPh1f3miz6a+uQCFroXkRS0ljZZSPn3PHOrFDlsAFSAQNxA50tG8FNYeGdX0S9u7e4ttR3qogtmjESNEse35pHLYCjkmjVJ+W3rp/wUZRWquvX+v63MmPTvhzBaxx6Vd2rmW5TyjY62UlQ7imI3EysqLvb5EOOWAUk4KaBceAdS1HUtI0acuNUtQHk/tJyt5GzTZWL94WBUiXIULjPHFN0v4XXWlWtwE8RG5uLm9tLx5bi0LDdCQz4AkGN7gnrxnGDipbD4cX+n6rZ3Sa3aPHa/Z1VG01txSJpSBu87gkTEZxjjOO1Oy2f9Ky/r5ege9Zu2u69bj7nw98OrC+nN/fwQ3Fo0cs6XOuSgxHKbC6tLwCUTGRg496ivfDnw58yztr7VwjtEDaRP4kuFLRSMu0IvncoWRcAfLkDApuqfC6e91S6u7XW44RJO88CTWRlMbSSRSSBm8xS65iG0cbcnrxjR8c+AD4za3dNWl06SGCSItFFuDksjxsRuH3JI1bHfkd6SbtF/f5aFWV2kc/qEXwwt7eRzIt6yLI0QttZaSS6Yhp2UHzslgcuu8jDNlSCc1qwaT8PrqxsbldQjEV4sFtbFtcl/eGBt0ca/veXRuwyc5zTb74b31xdTPaa3bQRNbi3ijfT2cov2ZoDkiUbj827oMYxz1qu/wquZrgyXGuwbJP3c0cenlQ0X7k4XMp2vugUhuRyRtPBAr8zXT/hyJc1k0tdf0Ib3Qfh6baOy0jW7W3v9QAgtJTqk1zuZ1bB2iYE7lVgDkE4ADAhcV4LLwrYWutHXZ9R1DWdJAF2o1OZZzHHiVZIVe5Z1QeZkMX3csM87a2bH4c3tn4pt9WbXIZI7aZXig+wkHYDcfKW8zk4uW5wOVBx2qbXfh7Lq91q0sOqx26agkhRXtC7RSyQrCzEh13LsXhcDDHJJ4FEbXv8A10t+pcl0Xl/wf0/rQtXsfhO50TUbDVdeWWyW6T7SJtYZWtpPlKRmQOHQ5UEKWyST61z7ad4A03X5NFhN093sj3SLr8m6JmmyBua4DpJmRn4wxDNjdkio5vg2ZobkNrKmaW4EySlLsfL+93RsFuh8n758CMx9ed2TmwfhfqkFzbnTvENlDb203mxxzaW8jAees+0v54J+dcAnnacdeSLdfL8v6/rdSvye7/WpP/Z3wz3S68+tWjotxG0t5J4gkaPzRsKbiZtucRoQD1xVi68J+AxFZQ3d60cd4jrYxNr1wiyI4BZYV84DbgDhOAOlc7q/w516z0m3tba4g1hC8UckdvY+SVVElBLZu4yQ3mkEK4OOCGBIPS6z4DuPEE+n3k9/FZTJbQRXcCQGVCYpFlXyiWGzDrjPOV464IOlul/wsH9fj/kN0q28B6FYW+o6P4gt7SwjnC+eNbaSGZljYCNmeRgwCsTtz2U9hWcdF8NW+r6hceIPF9nJZ3LfbUtF1KW2EYkkDJIf9IK/ewAyJHuyc7s1fvvDmt6b4H0XRtNaPUL20vYS10lqqxxorljI0TzAkAdQr5Pashvg5LBOZNO1yJMrF/x9Wk0uxkEYYqi3CRqGES8bCR03YwAbtt97fgv1/IfS3z/F/p+ZLptx8OdSu5LW0u1a2tTBZ298ddzEXXDxxQHzy4bgHgANjq2KvW+n/DOK4sYYNU05p7LdBbqdaZ3+Vi+1syEuUYlgGyUPIxUWsfDK91u+vLi716BVu5J1ZI7BhiCVY1ZcmU/vB5SESDGDn5TkYcfhrfulikuvwslpfy3uwWDBWZ7gTcDzuGHzLuOeG4A5ytWl36+v9f11atv/AFprb9P60VLTNF+F76ZJcWt2v9lJCjNcz6/KYcSo0QRg0+V+T5cMAOQByDjfg0fwbf3l7plnqRmnuE/0qyt9bmyQANxMay8EgrubGTnknNYw+Fd8sdoE8QW++xgt4bctpxK/uklj+dfN+YMkzcDGCAc9qveGvh5deGtbguYNYgnsoOBC9i3nEC3jhAMvm46RKfudzV6OTvt08wd9LGlc/Djwzd3DTSWd0rMSSsOo3MScsrHCrIFHzIp4HUVGfhl4WKsGtLw7w4YnVLok7g4bnzO4kcZ/2q6yilbSw7JO6I7e3jtbWK3h3eXEgRd7lzgDAyxJJ+pOakooo3BJJWQVzfw4/wCSWeFP+wLZ/wDohK6Sub+HH/JLPCn/AGBbP/0QlAzpKKKKAObsf+Sp67/2BdN/9H31dJXMW6NJ8TPECRytC7aHpwWRACUPnX3IyCMj3BFctY+LdY07TFn1TUrrULnQ47hNWgEES/aZfOEcJISMsoIyw2DOB0Y0uZJ2f9f1+qB6K56hRXnY+I+uNY3N8fCsUFrYxwy3n2u/kglijdiGcRtb5woVm+baSuDjJwNi+8X39pY6PcDTLRV1FZJZDcXzRrbxohk3E+USfkBJGBg8c9aG0ldiTUrW6nWUV5snxVvvsS3E/h2OPy4bqa5QXzsUEDIPkAhy+4SqQCFI5BGRz2fhnWZ9f0CHULvTp9NmkZ1a3nR1I2sRkb0RtpxkEqpwRwKq11cOZGtRRRSGFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34o/wCRi8Gf9hqT/wBN95WH4oudQg1nV7nTZJhqVrDbi1SCEyym3YsX8tRHIAWdcFimDsAJXhhueKP+Ri8Gf9hqT/033lVNQee/8WX4TWY9IOk2qGNhBC7MsgJZnaRSfLyqjClclDknpSe6C9kcfeeI/HaaxJ5/9tWlp9rKzrbaN5/kR+aBH5RWFvMDRFmY/NtZQOM7TB/wlPxAk8Pxm2Gp/bGMDzS3WjTReQWibcoVbZy671G7CkjcfmXgjoLb4h3eu3VvHY27WA+0QSxESrILqB5JItsgZMxNujJIGSOOeoqtonxD1rUP7PMumgwSywRqYrxWnlZ7R5irjyQpGVA+XZz7ZBI25fRr+v61JavN+l/z/r7jFGqeLdNu7ozXHiKW4NwQZRoRn8mI32GWNxbksphO7GTjAxjGKe/ijx8dHcWf9rSTN5DNcXWjSQmEHzlbCrbMW5SEsAjH52xtHK9uPFN3qehaS9skdjeanfGzfaWf7MVV3biREIbbGRhkGCwyDjByLT4mXcPli90gPAsCzzzreh5F3GfCqgiUNgwEduCD1o+Fcr7j+05fP9CxBqOvXeheKYtSfUllitybae1sXGCyt8sKNCHZhxniQcghuSq8jYv4kstPudL0Jdd0/TUtImi8vRVgkWQPCZHXFuo3OHlypDHKHociutvPGOtWGs6JNdWtstvqVud9nFeCRE3XEEccok8oEtiblfu+hOOc24+JGqaj/ZVxpdrFbRMGN1F9sU+Y5tZZVQZiJ2jYp8wY542nmh6Xm/T7r/193USXMlFPz/J/p/SIdFv9e1HxZpcmuWurSpDqrvbS3WlMjW8L20qsjukSrgPs5PHI5IANSX+u+Kk1bWrfTbzWbuOGeSHMemxlbQF4vLeNxCfMKh3yuHO1eQDybw+Jl7DHch9ESVbdAschviXmk8qGQAqsPGRMPuhjkYVTkCln1PU9M8NaTq2laDaaLf6lqRku9OjIjW53JIcyu0IcMdqsTsDDoe9KXu/E9LW++1n+fn1CL5ldev3Jv9V5GFpep+M9XW1uNS1HxJZGC7tEubePRxEpBh/ekbrcs6+auDgkAN6YIl0HWPFX/COq9wdcsrmzitDHYw6EEilhHlmZiPIyJP8AWjYpU4A2ryCdW7+LRt5pVi0Rp0a3iktmilkcySOYwY2VIWYFfNXlBJn0zxTD8VdRWGeaTwv5CQKzSJPetHKm2COdgyGLIISQjH95ccA5Fx6tf10/r/hmLmj08v8AP9f61MOTVfEhF5eWFrrkOs3FlFbm/wD7FYNlLifaXBh2t8pQYA6NnKjLCzbS+IPEF7p11c3GuW95/aMsdvLNohjFijWbjeN0A+XzHAy5IO1fQmtlfihd3V35GnaFBKZrgRWrS6gUDr57QMZMRMY2DgfL83ynOcjbVT/hNtYvNRtm1jR7M6RfQm3uLEXYmRQblbcyZaFS2WcgoTgqM8Hg5xaeie90vz/rtcJNOW+1v0iXmvdem+FU2o6k13PqExjYW8VnHdMoVkVgESI7w21m+6SA3BGBhnhDWPEepQ6tBqE+sM5sjJay3mlG1aOTzJlwpMSKTtETYIJyx7cCvb/FC9lsUh0XwtHczrdfZoLeG6k2PF5aOki7YCyqVkX7yKq925Gdnwx4w1DWtbuNMFhFutJZjdyy3oJjUTyxoIlWIbxmI/e24BHLGqlFzuu6/T/hv+HKS5Fd/wBa/wDAaOCtL7xXoq3N1o8WuT3V3HAs63OjyDzZBarulZ/IJ3hl25wQe6sa6bWNY8bQ/D7RrjTyzanNKVu5xZzEouG2FovspkwSFDYhTPOCmQRtap43ubB79odMt5YLe9i06F5b4xtJcSFAA4EbCOP5x82ST/d5GcODx9qU8yXcUcjRXU6KlpJNGogYW8zMm4REuhaHrkNzkHHy0nJW5+mn+dvuf3W8iIpJ8ieuv4f8N99/Mw7kaobeG0i0vVIbOLWjeJFBo8hWVxfh2J3R7kURncrLjdluTgilsdX8Zatmy8UnVFt5Ybo3NrDoskiNiMERM7WgBBO8KELEg43scGum03x9qjNbNqelwr55tBNJHcs0EAmjDbsiHKkk4w528ffBIBs+JviHPoGvT6fbaTFfJDbGUyi8MZWQAMY2HlkA7G3AgntkDINEo+64Pz++3+X+RUaif7z5/j/n/mYCtrJ02+ttTv7xNNtdIi1C38y3SGSCQx7Y4sbA4ZZI2YZw33Rzzn07T7h7izQzo6TqqrKGjKfPtBOMjkc9Rkdu1ecyeJ2vtVtLaz0axsJ21SF9VYSRv5jC4eBcBosy8wk7/kZcJjPIr0+rve8vP+vzt52TJUeSSh2X9flfyvYKKKKRoFFFFABXN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJQB0lFFFAHN2P/ACVPXf8AsC6b/wCj76tltJ05xeB9PtWF8ALvMKn7Rxt+fj5uOOc8VjWP/JU9d/7Aum/+j76ukoAwD4J0GGwubXSNNtNHW7VY7h9OtIYmmjHWNjsPykZHqATgg81pXei6Xfz281/ptndS2oYQSTQK7RBhhgpIyuRwcdau0UAZEHhLw3bSCS28P6XC6xtEGjso1IRhhlyB0IGCO4q9p+m2OkWKWelWVvY2sedkFtEsaLk5OFUADmrNFArIKKKKBhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+KP8AkYvBn/Yak/8ATfeVNrdx4Ri1KGbxHNoiXtknnxPftEJLdcgb1L8qMkDIxzUPij/kYvBn/Yak/wDTfeVnaz8PBq3im71f7dGEurcxNBPFLIEYxmMsqiVY+VODujY+jCk73Vg6FzyfAN5dfZ/L8Nzz3UzXXl7YGaWWPIaXHVmX5gW6jmq8afDRLW2liXwosAVpbZ1FsF2x53Mh6YXLZI6ZNYd18Jb/AFGKGDVPFLXVvbiRIUNjtMSMsqYU+ZgnbLyzAsxQEnqKsa58M9S127ivbrXbP7YtmLVyLGdYuA4V1iW5Vdw8xvv7x6Ac5Htp/X9aB11/r+t7/gXrbWfBWrWl1o9jeWOmQ6bJ58LW1xBEuFAdp4trEbBvIYkY+8CMHmKJfhhHqFtFpmneGJ73MMtuttDahtruQjoxwDzuPykn0BJALrr4dXVyxddbWGTylKyRWhVkuBb/AGfeCJMhNhJ2Zzk531Si+Fd1DZtbw65boshh3409gAI7mScBcTcf60r1PQH2oej08v6/L+tp15fO39L8X/W+qI/hlFArBfCaRFpLdSBbBScjfGPfJXI9cZq5f6F4GtprS01PSvD0Ms4MVrDcW8CtJ1JVFI5+8Tgep9a5dvhHejT/ACI/ENr5hga2aSTSycx/ZzAnAlHzhWJLdCcYCgYrd17wG+u6lZXkmprEY4YYrpPs5YSiKVZVMeX/AHZ3ryfmypx1ANHVev8AX9eYK9r21/4b+vkYsWmfDjxTotw9ppmj6TatcG0ttSihsR57J94R/fBGEwVdRlR90rWjpH/CDw6Gul3UenHT9OukS2n1FbbyZ5ZUEivDt+QbhJwFVepAGKvx+E9SHhWPTJdXtTeQ3pu47pLFljGZC+0xmUk/eYZ3Dt6c5Hh/4cavoElrNH4hspp7XakZbS2CmIQpEQV8/wC8RGp3AjB3cEHAcdnfy/T+v89A1/P9f0/pamibb4aW7PamHwpEZWNm8Oy2Xew2gxFe5+58v+7x0rNuW+EcEkBFn4QnmvFZLcRxWn7/AGkIUVzhSRkDaT7DpRo3wxu9E1qG8tdbhMcUsjDfazSTFWR1Ub3uGVdu842oo/2aqp8J9RhtnEPiO2+0SCQPLJpruG3+RuJBnyWLW4OSx+8frSjdv3u39IHe1kb7L8OHhluWHhZohIJ5JSLcqHjOwOT6qTtz2ziprnQPAdj9iiu9J8OW/wBoPlWaS20CeaS2/bGCOfm+bA781laj8Mft1tfxpqxi8+8F1bKIpFW3JJaRf3cqOQ7MxOHXsOcc683hOdZNNOn30FslrYnT542tmkEkJ258smQNG3y8El/fOM0k5W8/+B/nZfiDvey2/wCD/wAO/wADlfFGmfD68hsZY1sRZLPOjvpqWJg81Iy7LK0gIRtsZAcFWXn5lzW7YXPw/j1YLp1voKXtnJK0skYt1ktWCq8jE5Dd13Mueep4rDm+El+dHFnb+I7ZJdvlNM+lkhohbPbqNqzL84SRiWzgkD5QBg6p+H+oG5DtrNm8ReaSSN9Pk+YyQpGcMs4IAKbhjnnGcjNPa/L/AExatRuvX0/r+u2xqEPgySE6rqsegtHqarbm8uVhK3an7se9vvg44GTVRoPAAW91KCy0C5k0wqbh7W3hllgaMFVB2gsGABUDr2FVdY+HtxrHh3TrCfW83NpBNbTXElsXWaOZdrjYXyGAxtYsxGOd2Tm9p3g2S18L6lo13qIlF5cSTRTwW/ltDuIZeGZgxUgHPAPpQ+tvl/X9f5vWy89/6/r/ACo2aeCrW8hbVPDOmeHLxmj+zf2jbWsLykHCeWysclcLwDldy8DOKXVNS+H+p6raf2na6HqS6lviXUZVtpYmeMgeUzk5LZfAXB7jipr/AMIa1rUloda1+2mjhWZJUt9OaEsskTR5RvNJRsMST8wJAwF5zh/8KnvhG7L4gtTPLFJHI7aWdpzFHEjBRMMELECeeSTjaOKLu+oa203/AKt/X9LY2fDsSwJZaf4eu2hudv8AosNu/wBlclmLtj7nMRJPXK+3G5qvirR9J8NSa7NfW8tiqFo5I7iMLOeyozMFLEjAGeTWBoXgTUdMe/8A7Q1bT76O9t543jTTXiG6WV5ST+/YlQXIxwcY+apL3wNfXnhWy0t9cVrq2Mwa6ntDMrpKrow2M5OQr4DM7Hj5i2TlPmUNN/6/4f5lK3P5f1r/AMD/ADNuz8U6TdqCb23t983kxCW5izK+xWKgBidw3YKnB4PGMEyQeJ9BuZraK21vTppLsuLdI7uNjMV+9sAPzY746VyLfDTUJ7d4rnxBCpln8ySW2sZIn2GKONoxmYrhvKB+ZWx1ABAIi074VXNjNp7vrcMyWc4uCj208nmOMDdmS4chinyk5IwBgKMg099PIhc3Ld7nYnxPozon2PUrO9mmR3t7e2uY2kuNg+YRjd8xHT274q9YX0Gp6fBe2jFoZ0DoSpU49CDyCOhB5BrgrX4aXOma5ba2+pnUpLMFlstkyhghcxrHm5xkb2GZfMHPG0V1PhfTtT0rT/s2otamPHmKsIbckjszyKSeCoLAAgDgcijp/X9f15ju+a3Q3K5v4cf8ks8Kf9gWz/8ARCV0lc38OP8AklnhT/sC2f8A6ISgo6SiiigDm7H/AJKnrv8A2BdN/wDR99XSVzdj/wAlT13/ALAum/8Ao++rpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8Uf8jF4M/7DUn/pvvKyPEuq+JLbVNXXTP7S8yG3Q2FvBYCSCZSB5khk8tv3q/NtTcoOF4bNa/ij/kYvBn/Yak/9N95Wd4r8b6joWrjT7LS7d2ke3WGW7nkjE3mTJG23EZU4D9m3DqVxjcmrtLuHQ5WPxF42hu4muLnXDCu0R50BnE6G4kQSShINyt5W1ioKkEDgZILbu98WT28NxeS684EUCmE6Ws6SMt6A7lfswIIjwwJRDgZA4rYj+K13dTJFY+H4pGuGVrfzL8oGjYzKC/7olHDQsCmDgHOSeKG+KsktvaiXQYmN1PDG8BvCxWCZYSJP9Xg4NwispI9i1KOu2tn+fT+v00T+Jrvr92pgJ4o8cS+GVubC51q9d1hkW5/slDmQJI0kYVYfnjbbHhwBy5w/G2p31DxdYyzPCus3d1/pg86bSt728RvEx5T+TyfIyyoSQSoGDgCrWkeM9Xs9Ns7bSfD2k2ZkitDDYw3ZitUWaeVOAsG5W+Tn7w5zjg51LTxvqd/oUJig+yTtpK6lFcXMm/7QygM0fESoRjglSGHXaBgl3Xx9F/l/lr/wdxpt8vXR/wCX336/kZGieKfFlrrUEniKTWmsUlxKraG+xoPLmIlZkhyrfJCSueC7AjsOs8U6jq32nS/7ClvTb3kcgb7JbFiCVyjszRMqgehZD/vdK09d8QvpPhM6zbWf2p2WIx25dl3GRlAHyqzH73RVZj0AJwK4uT4ja1p2pEahpQW5vLKC4i0ua5Ea2x23DyL5vlBixSEYVl+9kZAyQpq6d9LCi9E11X9fn+XzxoNd8f2+luvma8zw2a48zSPMYjy4ysgPlZaQyF0ZCCQBnAxuL5fFPjN7S6htJfEbTzGRbWd/D7J5IWZhG7BrfB3ptyCB2Pycmurf4jSrBcT/ANjGOGLyZAZ5ZFIgkUnznxEQEGMblLKM/MUw2M7/AIT7WNwUWcZtg6GSb7YPOUtfm32r+42MgA7gNjvn5qppuSXfT+v6/wAiY2jGyd9n+n9f1fC1K68YS3mpOs3iD7RcW0r2ka6XlLdjZRlTHJ5JMbGTeuN457ZOTu6NqmuQ+JlgC6tJbSajtmeTSTA06GGLbJI/2cKQCrgncjcAfNwK7Lw3rz69YTzT2os54J2hltizF4yADhgyKQcEHoQeCCwINcVN8Y2RMQ+HZ7iW4KtZRwSSStNGTKPnVImZHzA42BWHIywGSC9pL0X6f1/Wj5W42vtf/IPEN1exeIbm5tlvJL2HVPKP2fT/ALU8Ft9jYxso8tyg81j8wAySQcjIqHw/4g8R3l/BbeIZfEAshhml/sBgZ2aGImKQeR8sYYzDIAPABb1t6n8Thpt/cFvDirqMcTyGO4maGY20atIxJaLqQCVUEqTu+ZSrAQaj8R9YuYY47LT4bGZ7xFt2S7EvnKl3FDIkgaL92GEqkEZI59BmYx1Ue9l/wf1fn3G9fe/re/8AwPT7zL03VvFui6LpNno9nq5VbVfKtJNJZY48W0oEbExAp++SPhiD8390iqNrfa5p17enTI/ESyzO8i3j+GSJCZJbYseLfaNyiTcBgfICQG5rqh8WJTLJGmiI5WyM67bxjidTGGhOIs5/fIQU3k5A25IFKPilqEM8UGoeFpraX7Ibm4O64ZLbIcx72+zjaG8vByA4LKAjc4d/e5/X9f8AL5/cEldJbf1/wbfgZ9h4m8RXPijRbW61bU7SzQhbs3GkNGbgmaVEDn7MQhcCPktEOflDbvlPGWoa7/al/pl7a6tf6aZpGhSHSGuI8bYHiIaOInKuJsHPGPm52mtXw1qdv4h8Ty6/qWlW8FzBpauEeGKWW1dZp45Ak2wOQfL6E49hk1T0/wAea3NqEks1qZopp99taW90kuENmZlQlYdxz1IHzBuhdeCaLfpf8X+emgnZu3p+V/1V/Mh1nXvGSaVJJpMmpi+a/dJ0n0qQRWsY3+X5ey2kaVGwm4jcefvR9q8eueNX/s6RLnXmM2oTLOsmjhUWATiNBj7OGX92wcMxHQ9eQNS6+LLQs32fR4rhY49sjC8ZNs5hklVADFkpiJlLYBDcbeDiK++I+p21/DdT2MdvZ2aS/bLe3uvOaZ/swmVQphDYAZPmBHJYbTgGp0tr03/r5fj56jei13/4b9f6sZel3ni6ysoLonXbi5trbT2vQ+lIJ7oEyLNEJGhG7YWVupIG7nkmuk8LXnjEeOLjTvEMzS2EFoAJHtmUTOFj/eK6wLGCSZAV80nphFwSbvhPxpqXiXVntLnQP7MSG2WeVriaVZBueRF2xvCjFT5RILbTgjjtXYVrqpNvrf8Ar5Ba+l/63CiiipLCiiigArm/hx/ySzwp/wBgWz/9EJXSVzfw4/5JZ4U/7Atn/wCiEoA6SiiigDm7H/kqeu/9gXTf/R99XSVzNrIkPxP1+SV1RE0TTmZmOAoE19kk1qWniTQ797RLHWdPuWvVZrVYbpHM4XhimD8wHfHSgNjSoqBL60kv5LGO6ha7iRZJLdZAZEVsgMV6gHBwfY1PQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHN+KP+Ri8Gf9hqT/ANN95VTxTqvhDSNWhXXLHTri+vI2DGUW4kEaKZAXMjKQmY+CflDAZI61b8Uf8jF4M/7DUn/pvvK5vxX4Uh8U+JL6w03xbptreunmzWEtutxPFmB4C2BKrKpSXIGMbueckFdUUrdTWvx8NXF1Dq6eFQfPWW7iu/sxImKkhpAf4yu7k84z2qrZn4ax6lfW39k+HdPksVSXzJYLWNZY9isJUIPKAMo3HGPyrF1vwhqukatZ30er2t7qN9dwQRebaomwI3mfdkuF8xVCthEO7HqQSbFz8Jb9rCezsvENpDHNH5W6XSi7BTbmBh8syjuWHAA4GDQr2v8AL8v6/Az1clF/13/U3lPw1nju5lPhWRIole6kH2YhIy+5S57LvO4E8Z561WZ/hpLp7RWGpeG7KEw+W72M9tETB95o9y9IyByBjj0rL8T+ANbke91S0vxqN1NHHEtvDbbHRQ8LHYzXCAAGIkBWQjeSG3Dca9j8PdW1OG2uU1fR7NYNsZtI9MabymijlhClvtJ5AlYsuWwwxuOMla8t1v8A1/X3oau9/wCtF+v5XOh8WWPh2HQV0i7ja00/Vp5J3uIFgaJXVTOzOJtyYYRseVK8c461R0S3+HyWF1Z3Wl6Va/YSElbU4rUGVUVJhICpKlF85SMYVc4AAxVu7+H91Lpunw2mteXcW4YzyXEc9xHIxt3hzHG0+IRiQnapxwK5lPhm51LUYbrxtYi8vFt4poLa2eBt8axtBkC4LggQsflKsQz4IwCKWkmlt+v/AA39IS1Sb+f9fezttSj8GxLDc6hZaI8OoN57XMq24RxGhcSksRuCjuNxG7PAyRS3/DObybQJ4YlSZJpY1WOBkKowaQ5A28Nhj7jPY4iv/BEt74e0zQ9M1mxtJdKjkSX/AEWSYESxPHna0+9eHYjc7E461Sk+F15cxzLda9DmSOSNTb2Lw7QwgwQRNkENbqcgjgkDBwQvtO2y2/r7g1sr/M2BqHw+0CW3voLvQrBhHmFraWNMpO6jcFTqrMq/NjHHXrTUn+H+oRy2dzF4dDalMZZLSY2rm7ZWYCUqCQ+djEE5Iwc4IIGbF8MJ4Y7dLfWIbcQ+W7pFbTss0qTpKHYS3Dk8pjOdxzyxAAqvL8MtdbzWt/FFlBKxzFKukOWiP2h58j/SOu58fgKHfS3d/d/w49bX6/qbdungrUr+0tNP0fSdQg1EPeJd20FvLA8kJVclgeXG8YODjnkVnwx/DnR5LqLVdW0W+m1C9lmll1FrZmMiNvZCwUD92TwG5XPWrfhvwJeeH9Ss7g6tbTxQNctJGtiyGRpvLyQxlbGGjzyGJ3fjVLUPhne3djdW8GuwwCdbmNEayeSOGKaNUKqGm3AjbkfNtHQKBQ+lu39fp9wLXR9/w11/ruNm074aanol5FYnw9plo862v2+y+xBXkO1tgOGUkngo6888EHl+iwfC/wDsmKOC58OX6Wfm23nXAttyE7zImAoCAgOdqhV2gkDFXIfBGq23iSTWoNbsxcNMJAj6cxQKYUidcednJ8tSGBGORhs1nXPwx1IyB7DxDbQsH3Yl01pAQHnZQcTL0FwwPqQp45BJXS93+tv+CCu9/wCmbml3fgCxme70Wfw3bSG3dnmtHgQ+SrEsSy/wBs57A0+Xw54Ei08apPo3h1LPAlF29rAI8Ho28jHO4857+9YK/Cx/tkNzNqkE7x2UduQ8NyirIkfliVFS5VVOAOxYHo4rT1bRddT4c6xo2+PV520/7NZ+UoikkYx7Tv3vt+9yORx1yeS5W1/rq/8AgBC7tfS//A/4JIR8O51gQ/8ACMSL9jkjhX/RyPsy58xVH/PMYOQOBg5pQnw8na0uQvhiQsfsdrLi3OSq48pD7KxG0dAenNYh+Geo3WoQ6pPrsa3O83DQtYfu45WjeNtqrNhQVcZ5YkoPmwas6B8PtY8P6qL+31/T5HMSwOjaSwUxiKKPj9/kH9ypznHJ4PGFr1/p6/187i16f1t/Xyt5lqytvhkUQaSPC8YkIkU2TQRl/JYSZBTBIQgN6Dqa05fHnhhHijh1zTriSZEliSK8i/eI0gjDKzMFI3HscnGACeK5U/Ca7IsJP+EgVbm1s/sxmit5owGBkMcqItwFDr5p++H9tuakg+Fl3a2bw2uuW0ZkkWRs6cxUFbr7SAB52cZLLyTwQe3LV7pPa/8AX6f1s3pqv6/4Y6i08c+Gr6KS4ttasHtI0R2uvtkQjG52QA5bcDuUjkAHsSc43wQQCDkHoRXno+Gd8sLxLrtuALOO1hcWMivEY5JGVwyzjnEpUjoe4IJWu8tI7iK2CXc6TyKT+8WPZkZ4yMnnGMnoTzgdKOg3voTUUUUAFc38OP8AklnhT/sC2f8A6ISukrm/hx/ySzwp/wBgWz/9EJQB0lFFFAHNWXPxS13/ALAunf8Ao6+rlptH8Uf8IrHp1vpF5Bc6VYSWsM9tfRRtcuZI9rRMJAVXahJ3lD2wa1b7w1oviL4na0uuaTY6g0OiWAhe7tI5jDumvcld6kDoO3OBmvItDt9Nt7jSrzXPDlvLYpZajd3PmaLpYS9FuflEflxb1wODkJk4x3qbrms+36P/AII9dkdvZaV41XxVbTy6LrA0+ESwSNNqcPmyRGaVoj5i3Bc7FdOG64OegzWi0P4iNoUdqINdikWJd5l1iMym5MAUSCQTn90sq5ZDwQ2Qrcis6DXvCrtZyXPwj0G1tZo45JXmtUjkCvOIQ0cb2ymRTvVgSVyM+nLTqvhe/uIYLD4b+F4GXWIbOVvIglDwtG8mQVhIyQhGBkejHqDSK+f66/i/8tiLpycl6/h/kttvvNu18JePLfxBOl1c6ncaVtuPmTWpPMlIBeIrmUbctJsx8vEeW4Irsvh7ba5Z6bdweIbfUYm8yJoTqF2lw7ZhjEmGWRyB5gc4JA5446eS3Wr+HL1tNvdK+H/huARzM1zZSW9sY7mBrRrhCZfILI4C/dA68EkHNV9RudBe6nurHwjpNvbwteF7U2Fkd6LZpOhVjakoRuzgh+SclhjFJ8vMuy1+/f1d/wBNLC0cl3e39eVj6Qorwc654PVdQjh+GHhu4ksoLeVCUt/33mSrEdxWAhWDNnAz77TxXS6No+gXnjO48Oar8L/C1lcW0K3EksEMcyGJgQrKTbpk7gVIOMYJ5oHzK1/61PU6K+dNQvdAk8T3ktp4I0KHSIVWKOFLK0Ejst8tu0h3Wzbc8jbk5XkFT03tT1LwdpG9L74YeHEuYZpvOt/Ih3xwRhCXOYOXIkUhBwR/FSi1KKa63/AbdpOPY9torwjVrrw//wAIlcXVr8NPDFpdXV1dWFi6xQNteBZS8rbrbAAEWVGG3E4OBzVS01/wsumyIvws0fUZrK2tfPvH06KGKSaUQ5BYQFFz52QM5O1uFGCXH3nZeX4g2la/n+Dt/XofQVFedaL4Y8M3uv3elax8OPDGnTW8SyoY7aKbz1IGWXMK5UMSuc54GQMiuh/4Vx4I/wChN8P/APgrg/8AiaOlwTTOkorm/wDhXHgj/oTfD/8A4K4P/iaP+FceCP8AoTfD/wD4K4P/AImgZ0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAHSUVzf/CuPBH/AEJvh/8A8FcH/wATR/wrjwR/0Jvh/wD8FcH/AMTQB0lFc3/wrjwR/wBCb4f/APBXB/8AE0f8K48Ef9Cb4f8A/BXB/wDE0AdJRXN/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNAB4o/5GLwZ/wBhqT/033lYXivT/EN14g1WTR9N1FVeztUgube4ijWZ43lZkyJ45FH7wc8cqchh8rbv/CuPBH/Qm+H/APwVwf8AxNH/AArjwR/0Jvh//wAFcH/xNHW476NdzkdS0HxHfRGO80vWpro6q0z3Nvq6CMQASeX5IMymMgMqnCqSQSSetZR0j4lXdvdTGDVrGS4iiSWBtQSXJQ4LRhbpdrMDuO14xwR/veh/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNTyq/8AXoS1f+vO55/e6N48+03vkWviSdyjGGddWhijdvs8W3939p+X98jEgDGCRkgkVv8Ahyz8Tf2zbTa9puuLaC4uGhjbVIz9n3TMyNMFnPmJ5bKoXL7Sp+Xoa6H/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iatOzTFyrl5TB17TfE015q5s7XVpnkuImjkt9UEMctoCm+GJfNXypeH+faM/wB8Z4wxoPjX+2LLz7HVZN1tDDdXseoxICqpdDbJiUM5Bmi52nlGIPAJ7r/hXHgj/oTfD/8A4K4P/iaP+FceCP8AoTfD/wD4K4P/AImo5Vy8v9f1+vqxpWk5f1r/AF/VkcZpOieLbGSwgh0/Wore2ayJjn1RXibbGFlBYXO4AEE42sp5+UnBHqkMjSwq7wvCx6xyFSy/XaSP1rnv+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mrbbd2KMVFJI6Siub/4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDiaRR0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSUVzf/AArjwR/0Jvh//wAFcH/xNH/CuPBH/Qm+H/8AwVwf/E0AdJRXN/8ACuPBH/Qm+H//AAVwf/E0f8K48Ef9Cb4f/wDBXB/8TQB0lFc3/wAK48Ef9Cb4f/8ABXB/8TR/wrjwR/0Jvh//AMFcH/xNAHSVzfw4/wCSWeFP+wLZ/wDohKP+FceCP+hN8P8A/grg/wDiaPhx/wAks8Kf9gWz/wDRCUAdJRRRQBw1/bavdfE3Wl0i/wBNtIv7DsBcLqGnvdLIDNe4A2zR4H3s5znI6Y55nSdKfMd9Fp3hPSrGCF5rbVZ/CKwweVxuZWF7mMEN/EFyMnpXc2say/E7X43GVfRNOUj2M19VO48E6nd+HP7FuPEKm1thF9gZbEB0MTq8ZmO/EuCgGFEeQTnnBC6/1/Xp8w7HFr4b0608TWesp4z8BQfZbPFpZDRIlt4VJMnnRj7VuVjhjuDYwDWotrYwP5K+JPhvGySJJsGhKCrgjY2PtnBBkGD1+cY61Yi+Feo2t7FNaa9YhA0ckiTaUz5dZZpTtInG1S07fLg4AUZ7mpD8IdZjsZLWTxPpzo8LRB/7GcOM2yW+c/aOyxg/UntxTXW/Tb77ku99B97plhAk1hqOvfDeJbW586W3n8PqBDOwJ3spvPlcgE5PJGavH4fz6kxvmXwHdm5zKbg+Ey/m7xy277V82R371G3wqu11SO+g1633Q3TXEKy6ezgb5lmkViJQWG9RtPG0Ej5utdr4b0qXQvDOn6VPcpdPZW6wGZIjGHCjAO0s2OAO5oivdu9x682mxyZ+Ht8YWiKeCDG2Ayf8Ik204IPT7V6gH8BVy08OeNLXU7q+bxTok8twFRfM8PyAQxrnEabboHbkk/Nk5PXGAOzooCyPPrn4cXd5fPe3kPgae7kfe88vhEtIzepY3WSfepx4I1cRJGJPBojjn+0In/CKvhZcY8wD7Vw2P4utd1RRsPc4WTwNq0umNpsr+DHsWlMzWreFXMRkPVyn2rG73xmom+Hl86FHj8DspjWIg+EmIKKcqv8Ax9dAQMDtXf0UbAchb+G/E9pfT3trqXhWC6uAFmnj8NyrJKB0DMLvJxnvVv7D43/6GHw//wCCGf8A+TK6SigDm/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MrpKKAOb+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkyukooA5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TK6SigDm/sPjf8A6GHw/wD+CGf/AOTKPsPjf/oYfD//AIIZ/wD5MrpKKAOb+w+N/wDoYfD/AP4IZ/8A5Mo+w+N/+hh8P/8Aghn/APkyukooA5v7D43/AOhh8P8A/ghn/wDkyj7D43/6GHw//wCCGf8A+TK6SigDidUufG+m6jo1r/bfh+X+1L1rTd/Yk48rFvNNux9r5/1O3HH3s9sHM1bxJ430nX49LY21z5gLLdQeH/3RVQpcgNqIchQwzhT3AyQa6XxR/wAjF4M/7DUn/pvvKs6not7eeJtM1S2v7eCKyimjaCS1aRpDIAMhxIu3G0cbTnnpUu/QOhzUfie+mGYviP4HcbGkytgx+VRlm/4/ugHJPap4tb1edY2h8feDZFlEhjKaa53hPv4/03nb39O9Zt18KtSu9P063fxJb77C3aGMnTmKAssqlgnncErNzySSi8gcVYi+G+rRyyyJ4lhtpHDgTWVhJE4Bh8sA5nKnBAYErkc4K5NPXUHurEo8SagRER8RfBJEyeZGRp7fOvPzD/TeR8rc/wCyfSmy+JNXt52S68deD7eMRpIs8un7UkDgsMf6dn7o3ZIAIIIJ5xRg+FGqWlwjWviDTlhWZZvLfSHbkXBuMA/aOBubHfgevNIfhTrA+xhPEmn7bW2SAK2jud2yKaMH/j444nY49QKf2b9Ra81uhryazrMLXKy+PfByNaFFuQ2mODCX+6H/ANN+XPbPWnSarrkTzpL468Ho1u6xzK2luDE7fdVv9N4J7A9az/8AhV+oPLc3Fx4gglu5oFhS4+wyI0W0gqVKzg4HzADOMHBDZbcD4VTRXF/Pba2qzXU5miuZIp2mt9zs7BcXAj5LtwEC4JDB8mhdLi963mXdQ1jX9JvvsuqeNPCdkwjEha40to8AkgDDXwbna2DjHynnim3OvarZMFvPiB4Lt2MSzgS6a6kxsQFfm9+6SQAehzVvxL4N1PXPEVpqVnrFnax26xBobjT2nLlJPMzuEqAZIAxisu0+G2sWPh+bSbXxDY+VcfZmlaTSWY74VjUEYnGFKxJwc4O455wFG7WvcfX7v+CWZNe1WGKWSb4g+C444VRpHbTWAQP9wk/beA3b17VJNq2t24nNx478HxC2ZEn36W6+Uz/dDZvflJzxnrVLUfhZLe6lqlzFrSxx6i7F0khmkwjnLxkGcJtJwflRTkDcWGQY7/4UT31n5Da4saq0TJEkM6RFljdHLBbgN84c5CMgzyQ2Tki21qg6l231fxNd+J5tCtfE/h2a7gt/PlMWjOwj5A2sBfblb5geQAQeCa1/sPjf/oYfD/8A4IZ//kyqGgeB9Q8PastxaaxavaosqJBJYMXVZJVkYGTzcnkMASOARnODns6rSy/rr/kJXu7/ANaf5nN/YfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZXSUUijm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPhx/wAks8Kf9gWz/wDRCV0lc38OP+SWeFP+wLZ/+iEoA6SiiigDlohGfiT4iE6eZGdC0/emwvuHnX2RtGc/TvXnPhC1vvDHhy9On6TqenX2oW8KWzafoskSxhZWDPKjROPNXcSSy/OgXaOuPSLdGk+JniBI5WhdtD04LIgBKHzr7kZBGR7giuWsfFusadpiz6pqV1qFzocdwmrQCCJftMvnCOEkJGWUEZYbBnA6Mah2u/T8P6/PTcHsvUxl8R/EOfQ5LqKTV0u0e3imin0dokizDmR0AtXdx5q4O0OMMfughl9js3lexge4x5zRqZNqkDdjnAIBHPqM1wI+I+uNY3N8fCsUFrYxwy3n2u/kglijdiGcRtb5woVm+baSuDjJwNi+8X39pY6PcDTLRV1FZJZDcXzRrbxohk3E+USfkBJGBg8c9atySTb7/d/X9bEq0mrf1/wTrKK82T4q332Jbifw7HH5cN1NcoL52KCBkHyAQ5fcJVIBCkcgjI57PwzrM+v6BDqF3p0+mzSM6tbzo6kbWIyN6I204yCVU4I4FO11cfMjWooopDCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8Uf8jF4M/wCw1J/6b7yuA+IOiy3vijxLLa6SksMumWkc+/w7PdtdsJWJWKRMDcAY8nD9BwNprv8AxR/yMXgz/sNSf+m+8rntf1XxJbfEW6ttLvNRksrezgu/IRLUWyH98WSVjGZgH8oAFc7SxJ7KZdk02OzlGS/rdGDceIfGEGrTRXF1qGk6b9u8i2hstKaSQQ7Zdnlq9rtPyqh2q0jAg52j5Q631bx5fXiLqkmuWEXmWjTRwaaCYmWRRLtdYiGRg27GXwAecBgL2seMzqEltqkmj2tyulXDFbSaSORXY20cyyLI0RaN1EhA2++TzxoS/EPUZLedX0dLV4rlId8V+G3EXgt5PvQnjJBHGSCfukA01pJJ76f5/wDBMm1OLa0W339v66HO2t54iVbe4uF1prYCyItX0ImMsLuTzXMQgyrBQj5AU8gjtjvfB2tXV7YLZa094NT/AHjbrm2aLzEVgu9cxR8ZIwCoP1HJ55viteQ6H9vuNAgWb93ILePUGctCyuWcN5P3l8tjg4BGPmBOKfN471DVY2sH8O6e8VxeizZLm8MkcsRuXgk3L5X+xwOQd3PTBF/Kur/O39ff8iTS9++it+F0YsOseMhuh0Z9R8iOwuAhTTYjFLOu50kVlhCgsVKFc8k9FJBLrfxT4vPiGV93iF7VLoCK2m0FljlRp2ABcQAgCMqc7hjAzzkHa1fxnP4L8QX9s1l9o0aGGIQRQlUNs3kSvsRFTLKRCe5IJGARwEtPijePJu1Pw8umwIsZme5upI3QSNKisI3hViuYickA7SDjqKjzvt+r/r+rFa8ln/VtDlra88R2d7Ne29jrFxqFxcee73Hh/biT7GykgiIAbXBQHcCQQCWBBPSS+IfEVn4k0gxXGpTeH1tfNurq+0uVZZiC/mB0jtfkYAJtyYgeeHzxGnxL1q+hZl0S3s0ihka4AviZEZZ44wULQkEFXzhlB5xxirFl8QNbkl1GW70eFltfO8mO1undXRLowlnUQF1IC5ypYEc4Ha7q6f8Aw2lyVa0tb9Pm/wCv8hvjyeX+2bXUNLs76cyaTIPOttKe5DgzwMqMPLYcqJOCMgZIweap6jqXj2007UhbT6hNJaXZiEz2SjzIncskiBLd2bYmxThH5LcZGR2HivVry38E/wBp6NOsdwzW7xshVlcNIgK5ZSNpDEZxnnIrmZPive+bLFb+GJJZLaM/an8+UQwuCQR5ohKbeDgkhicfKAchOyfL2v8Anf8AzX9Id1a762f6f1/wC1oOqeJ5/C2v31xPqNxqMJKWtvNppgVcIDuiV4kdxuLAbs52gdc55XTrrWtJ88abDrQbF5IlxN4eeORi1xG4IKWzBWdN2QFwSBlQ3TodQ+K13ZuLdNFtnulFxHOEv2ZYJo1lKjPlYZG8h+chhg5WrukeNtWvNU/s59Ntm1CWZB5bX+2CNPs8UrlGEO4n95wpBJ5+YDo0uaV10X/Av+v47BKNlyy73+7/AIexzuo+IfHgu7rYus2seQCkOkrN5KeZD5bIwibezI0u9fm2lf4eCa+o3vi201y/vbSHVptSSCS0Ez6XhY4VuE2skkdu4cmP58bXwxYBRyo7bXPHU+h+JJ9Pk0pZrO3gimkuVusPh1lIAj2YPMJH3u+faqWkfEPUtajb7L4cFvLFbvdSrfXEtuGiH3Gj3wBnyeDlVA9Txmbrf+W/5f5XHJfYfW3/AAP0H+ANV168kvX8T3OoySebFBBG+lvBD/qFd3UtCj43iQZfgcDqRnuq87t/iheSXVvDN4dUtMiApb3pkcSSQPPEoUxruBVMFh0bgBsE0+H4i3DLd3hsA8MKQeYouHMVuGaYO7/uBIhBj2tuGBxnZhjWr3t8hKStfvqeg0VzHjXVtT0m20q40UrJJJfLG9u7qiXCGNztLlGKjIByozxXPH4rXU995OneGppod1vH9pmlliiWSUxAKz+SU/5bKRhiSFbIGBmIvmfKt/6/zKbSav11PSKK8zv/AIrXqROun6LayS/ZJH3vesUinQ8xtiPkY+YMp5GMhcitzSvFeo3uuHSlsIGuBcz+eZb7CxRRsi5jxEC5+YHaQMc5fpQmm+Vf1Ylzilf+tTsKK858V+M9a8NeI9RuWiiuNPsbeIwWKXQRrossjuzfuGIZVicgBwvy89eCfxtqcGpC7RS9tG12sllJMgRljeAK4cRbgQsjHbyMnBJ4IIvm/H8Cm+Xc9Gorzi4+Kd5BHcyjQIZIbfcrFL2R2Z/tT2ygIkBJBZQeMnBOASAD3GiajJq+h2l/PZTWMtxGHe2nRleI9wQwB/MA+wprVXQ3o+V7/wBf5l+ub+HH/JLPCn/YFs//AEQldJXN/Dj/AJJZ4U/7Atn/AOiEoA6SiiigDh72PWm+J+svomo6fYrHolgZ/tmnyXW4ede427Jo9uOc9c5HTHPJweKdVvLI3k0ekxWWt3ENu91N4ZUxXgkDKruRqB3KAmCG+ZQRlRXWXuu22jfE/WVuU1Bmn0SwEbWWmXF5tImveWESNt6jG7GecdDXB3Hh60ubefOqataXNxeW91M+n+CdRt42aINlwgBxKxflwf4R8tS73+789fw/p9Dpp5/lp/X9O9FFp4sr+20nxf4A0S1mEcM95p+kQRLdIVLGLIvCcbQwOQpxkqe46bVrK+3add674i8D5J8uwmvdBbJLjG2JmvOrDsvUVwV/4Z/tLc1zrd+JC8DL5fgHUlQCKGSIfLnuJM8YAI4FbevWOn654Z0PSGvtcgGlQLE8q+Dr8mYrswR+7ygynK5IOfYGq9e6+7qT72no/v7F+Cwsbf7VPZ6/8N0NhC6XDw6AoNvGfkZWIvPlU42kHA4wam8L6pqH/CEWOqaZr3hTQtGnZlgil0E26K24jAC3uzJIJ4Jz1rkD4TtG1O+vG1jV83E7XMSr4I1EbJDcrcDfx86grtx8uR3Fb1tDZ2/gGy8O/a9WNxaXDTR348G6kpjJZmyigfKw3EZJZSMgqQSKI35U3vp/wQd+ZpbamjrHjjUNIsprn/hN/Cl6LaVI7mOz0su9uGkEe9wb8bVVjgntWm2u6siQO/xA8GKtxC1xCx01wJYlGWdf9N5UAHJHAxXA3Phe0k1PUrm31jWo47uQywxyeCtRcxMbpLj5iAN43LjAC8H251NH0vS9GlvDDf8AiF49SsXtr9D4Rv8A53Z5H3xny/3YBmb5Tu4xz3M3lyX6/wDA/wA/67V9ry/S+/8AX/D70ni/UFu7K2i8feD7h72doIzBpbuA6oXO4i944x75ZfWrA8Sag0cEi/EXwSUuSRAw09sSkEKdp+2/NgkDjuQK4XS/DNvpqKx1nV5ZlkkbcfA2obCr2q2+NjAg4CKecg8gjmqt34LtJ7OGCHW9ZXy5Lh2eXwRqLkmYxlsdMYMfHXg1X2rdCLyttqelT6xrVstw1z488HRLbSrBOZNMdfKkbojZvflY9geaY+v6pFcT28nxB8FpNbhmmjbTmDRBQCxYfbcjAIznpkV58/grRMXzwahr6XFzcyyrNJ4T1STbHKJQ8bIw2HHnyFSqrgnJ3ZObK+GtLg8Sy6jb32sSWrxuotLzwbqUhy0UUZJdQuf9SpGACCTzS1/D8bf5/wBdXTvfT+tf8v66HYa14o1fQLOwu9R8beFY7fUH2W0x0hxHJ8pbO9r0LtwOucZI9adD4m1V7GO5uPHfg613wxzNHNp/MavjbkrflecgAgkHPBNZOrNaalpHh+3W/wBeF5opJ+0z+EdQkE5MLRHKBFxw+fvHp361jWmh2llpMVjDqOqKIrKO1Ei+CdTDM6ABZz/00AUAEY44bcAAK0u/X8A109Pxv/kdouv6o0k8a/EHwWXt0d5lGnNmJVOGZh9t4APBJ6UzxD4g1/w14Yl17UPFvhprJYvMjMejvm44yFjLXwVmI6DPNcHq3hDT9V1bUbpta8QxxXfmPGi+D9REkcjvE5YuqjI3QrwApwTyDg1ra9pWkar4P0rRNPn1rT206Ca3Dnwlqc8bLLG0b4RxuBw2QS7Y96h35L9f6/4A4/Frt/w3/BOi07xNrmoTeV/wmHha3kZ0jjjm0z55HZFcKFW/LBhuA2sAfQEYJlk8R6jFAJ5fiJ4JSIytCJG09gpdfvJn7b94dx1FchZaPbW2svfy6nqxaSSBmeHwVqUcyrHEsbIr8gK4QZBVsdRyAQaJoOm6Ne6ZcDUNcn+w3kdwVbwbqCiRI7cwIvCcNtJJfnJxwAMVel/u/wCD/X9OFzcuu/8Aw/8AwDo08Z6q3iHUdJbxl4YQ6ZAk91dvpLCCPcxXYW+3fK4I5DAdRV1vEOpJLPE/xD8FLJb/AOuQ6cwMXIHzD7bxyyjnuw9a88uPBenzy3GdY10QsFWBR4O1NXULO8o3um0vnzHUldh6HIxzv2dlplloutWEMmqEajNDLAz+D9UP2Xy4kjXB++xGxSG3Ag561Eb8t3v/AMH/AC/Ip35rLb/gf5ndx2vjSWNZIvEnh10cBlZdCmIYHoQftlO+w+N/+hh8P/8Aghn/APkyobTxtpdvZwwyw+IZnjjVGlbw1fguQME4EGBnrU3/AAnmkf8APn4g/wDCc1D/AOMVbtfQFdrUPsPjf/oYfD//AIIZ/wD5Mo+w+N/+hh8P/wDghn/+TKP+E80j/nz8Qf8AhOah/wDGKP8AhPNI/wCfPxB/4Tmof/GKQw+w+N/+hh8P/wDghn/+TKPsPjf/AKGHw/8A+CGf/wCTKP8AhPNI/wCfPxB/4Tmof/GKP+E80j/nz8Qf+E5qH/xigCjf+HPGOo3umXU/iTQ1fTbprqEJoUwDMYZIcNm75G2VjxjkD6FU8M+JYtUm1KPUfCiX9wgjmul8NSCWRR0Vn+15I4HBNWJfiLoMEkMc8WuRvcOY4Vfw9fgyNtLbVBh5O1WOB2UntUv/AAnmkf8APn4g/wDCc1D/AOMUAc9J8MppVCy2ngN1ByA3g8kA4x/z9egH5UD4ZTCMxi08BhCu0qPB5wRndjH2rpkA/Wuh/wCE80j/AJ8/EH/hOah/8Yo/4TzSP+fPxB/4Tmof/GKAMFfhtcqu1bfwKBgDA8IHoAQB/wAfXoSPxNPg+H1/bStJbJ4IikbG54/CTKThg45F1/eAb6jNbf8Awnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8JzUP/jFAGVdeCdYv7572+l8G3N05Baebws7uxAKgljdZOASB7E1n2Pwy1fTtdk1O11LwugNsttFaDwvthtkBYnywLgFd29t3ODnpXS/8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xQG5it8P9Qe2Fu6+CWgAIER8JsVAO3Ix9qx/Av/AHyPQUSfD/UJpppZl8EySTqVldvCbEyAnJDH7VyCeea2v+E80j/nz8Qf+E5qH/xij/hPNI/58/EH/hOah/8AGKAMw+DteezuLSW98Ky21zMJ5YJfDkrxs4xhtpuyMjav5Vl6p8LtS1LT5raC88J6bJKhj+1WXhQLMqs2XUFrhhhuc8c5NdP/AMJ5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/Cc1D/4xSsGiMlPA+sItuBN4NP2aMRQn/hFWHlrzwuLr5RyeBgcmmDwDqQUqP+EKCl0kI/4RNuWQbUb/AI+uqjgHsOlbP/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxT8xWRl3fgvWb/AFJdQvpvB1zeoVK3M3hZ3kUr93DG7zxnj0qufh5fG3SAx+BzDGXZI/8AhEm2qX+8QPtWBnHPrW5/wnmkf8+fiD/wnNQ/+MUf8J5pH/Pn4g/8JzUP/jFKyGZaeC9ajaJo5vBytDAbaIr4WcbIT1jH+l8If7o4qEfD/UFACr4IAAUADwm3RTlf+XrsScelbX/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wnNQ/+MU/MDKPgrW3tFtZrvwnPAk73KRz+G5ZFSVySzgNdnBJZunqazNW+FmpapaLAl74UsMGINJZ+FdrPHGwZYW3XBBjyoyvtXUf8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xQBlP4I1eVt0kng128oQ5bwq5PlhSoT/j6+7gkY6YJFNXwLqqSrKjeC1kSc3KuPCrgrKesgP2r73A+brxWv/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xR1uHSxk3XgbVr69mvL1/Blxcz482eXwq7vJgYG5jdZOBxzUcfw+1CJ2eJfBCM4cMy+E2BYOMOD/AKV/EBg+o61tf8J5pH/Pn4g/8JzUP/jFH/CeaR/z5+IP/Cc1D/4xQBhwfDy+tvtH2aPwPD9qjMU/l+EmXzkPJVsXXzA4HBrSsfD3inS4RDpmqeF7OIKFCW/hyWNQAMAYF2OAKtf8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xQAfYfG/wD0MPh//wAEM/8A8mUfDj/klnhT/sC2f/ohKP8AhPNI/wCfPxB/4Tmof/GKPhx/ySzwp/2BbP8A9EJQB0lFFFAHMW4c/E3xAISBIdD07aT2PnX2K5SFH0zww1zoHh7UrbxNBDGmo3hsG81izxiZwzDbcybQzLjePlxxnaertt//AAs7X/KZVf8AsTTtpZcgHzr7GRkZ/MVz3hP4hareaJqep67Bb3UFjFG3+g2xtXMrEgxBZ5SH42EPuAbdgZqbpNvy/r/g99A7f1/X/D9DEXxH43F5BDeXOvwq6xhXg0AyBkMk6mRiICEfyxA5U4wxxtxlaqxeMPHE1tLKW8RxziEutufDcgXcLeN9oJt+8wkTr0PH8LV1s/xj0K1006hcWOow2ZEWyeUwRq5ki80KN0oIOzJwccqQMkqD3lvcR3VrFcQHdHMgdDjqCMirSs2/6RLs2jyW78Q+On1t1LazaWb3hSX7Po3mCCLzQIzGTCxcNEWZiclWUA7c7T6R4VvbzUfCWl3eqRzR3stqhuFmgaFxJj5soQCvOeMVrUUo6R5R297mCiiigYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfij/kYvBn/Yak/wDTfeVxXiTSEPxfk1oaNM9vZxWcs93b6TK9wWVpMmGVVO7AaMOi5ZlPH3CK7XxR/wAjF4M/7DUn/pvvKqavr2t2mpeJIbSbTxFp2lxXlqJbR2bexkyHIlG4fuj0C/e9uTXmTXQHZwcXs9PxRy2neIvF91IZblNZNnLqEbJbTaS0cwt34MRP2faQpBznYcH75x82r8MLu+stPTSdQh1NIFhh+ypc6VJAsBIk3RhvLUbQEX7xzlsZ5ApdT+J8tiJIU8Pamxi+0RyX223MStDgO4j+0BmUEg4yDg8ZOa1NS+Iljpek3uqT6XqMlhaTtb/aE8kCdlLCTy1aUMQhRs8AnBKhhzSjbdPT+rf8P6+ZNm35r/g/1byOuori1+IsMl4wGlahBaRG5DXE4twkxhBLKreeCvrl1AI6kdui8Pa5b+JNCt9Us4poYp9w8q4ULIhVirKwBIyCD0JprUfMmaVFFFAwooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArm/hx/ySzwp/2BbP/wBEJXSVzfw4/wCSWeFP+wLZ/wDohKAOkooooA5WP/ko/iP93JL/AMSLT/kiba7fvr7hTkYPocj6iua0q18GX2maM40bWLG0ubWWRZLvU3T7NHBJu/fn7QT8rtlSd23P8PSursf+Sp67/wBgXTf/AEffVnz/AA7Sa2123XU5Ei1Ji9qqxlfsRZ/MfBVgTukG44KkcAEHmpd76f1/VwexnQad8LtPjWxg12ytzcyRSwqPEcgkDBcRmJvO3J8rYGwjKkDkV2EniPQLG2tjca3p8MUxMcDzXifvSp2kBmb5iDwepz1rjU+H19pXhzV7NJ4tQa/hiit0tLdomt5VZmWYyT3EhbDvvPJbjjJ4rodR8KXVwujR6bqi2UemRSR7mtzLIxaIxhlbeApGSeQ2TVSbs7CV21zF5PF/hqRIHj8Q6Uy3IZoGW9jIlCnDFfm+bB646Vo2V7a6jZx3en3MN3bSjdHNBIHRx6hhwa8+g+FNykMkE2uQmGW2uoXENi8b7p/LLOH84kYaIH1OTznmuw8K6D/wjfh+LTmljmdXeR5YxKA7OxYn97JI+STk5c8+nSmrW/rz/wCAK7NiiiikUFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAc34o/5GLwZ/2GpP/TfeVh+J9S8PDxkY9a0DVXktI7dZtQhnVLcxyyFYhKizBpV3hhho2wcnGDmtzxR/yMXgz/sNSf8ApvvKyPEPw5m1/wAZHW31DT4lCQJEW0wvdWwidnzFP5o2MxYgnZ0wMd6X2kD+CXoQ3+m+Brm0SC3WbVo726Zn+w6u7shuQcszecCI3KYwDjPIHBIbBZfDzVdKje8nW0F5F/aD2N5rDxvGJFKM5QS4XdvYMRwxY5JzUkXw81a21Vru28QWfl+bCyRy6YzFUjllkVdwmGT+9IJx2HFZ9r8HHS2a3vNfWaNoXz5dkUYStbm33AmRvk2EHZz8wzuA4ojazuv+Gtt/XZeotebT+n1/r19DWg8K+AZhb6dDeeezy3Pkw/27O7yOQFmx+9JYjHI52nng1o2moeDfCST26a7Y2KwyeXNHd6tu8p2LSYIkc7WO5m9SPYDFPSPA2oafrFvqE+tQyyR3U1xN5Fm8RmEmT5ZHnMuAzEglSQOARkk0YPhjcWfir+1rTWIPL/tD7b5c9tPLJtLOxjBNx5ajMjEFYx755y1fT8QezsvT8f8AgfedQ3jTwuioz+JNIUSIJEJv4huU9GHzcg4PPtTU8Z+H5r+W0g1eyklt2dbgC6jHk7FDMWBYHADDJAIGecVw+pfDzX7fxHYz6dfQ3VvLMY5HawUi0i23OCwacGQ/6SR8o7A44wb9/wDCu4uoFtLfXkhs0laVFazLSgmONFy4kAODECfl5BI96Wr/AK6/19/kKV00l8/69Tr4fFfh64uLaCDXtMlmulD28aXkZaZTnBQA5YHa3I9D6VestQs9StRc6ddwXcBJAlglDrkdRkHFcFD8MdQtrwXEGu2O95VmmWTS2Ks/2hp22gTDapLYxzgDqa6HQvD2paTYvpt1qEF3YSJLysciyRFiNqqXdyVC5+8Sc9MDgGtn31C75rdDQHifQTBFMNb03yppzbRyfa49ryjgxg55b/Z61FB4x8M3QBtvEWkzAzeQDHfRNmTGdnDfewOnWuY8PfDW78NT2tzp2sWzXUBkR5Li1mmE0TrGuG8y4YhwIUG5SFxxsFUP+FSX0ssE15r1nNJDM8hWOwmgjlDMrHeI7lSxHlxhQTsCoo2cZpsetv68/wDgHc2vizw7fSKllr+l3LvnasN5G5bC7jjB7Lz9Oauafqdhq1it7pV7b3tq+ds9tKsiNjg4ZSRXntl8LdatJYH/AOEmsQ0AjCSQ6QyOoRJlBBM5G79+xzjGQOOtdD4Y8KX3h+xuNNmvrW5sbrzZJGit3ikEr7ckZdsj7x5Ockcnmk762+Qapr8S/P438KW0YkufE+jRISyhpNQiUEqcMMlux4Poap6p8RvC+mO0Q1a1vLhVSR7e1uI3dI2ZB5hBYAKBIrdc7ckA1heH/hpN4XvPthvItUhitJ4XtFt5TNdB1jUZkmuWUNiFFx8q47KOjk+G94+h2NvDqi20qWoinF3bm5Zv30coBYSLyBGE75H05Oq/rv8A8D7+gm3bT+tjrpPFXh6KOKSXXdMRJoTcRs15GA8Q6yA55X36Uw+L/DQglmPiHSvKhXfLJ9tj2xru2ZY7uBuBXJ78Vw198Hrm+Mzya7b+ZNDNFk2c4SMv5uGWNbkJkLMwywbPbbU7/DDWpZmkl8S2C+a0pmWDSZI1kWR4mZT/AKQTj90BjPIY5ou/6/AetkeiSXltFZG8luIktVTzDOzgIFxndu6Yx3rJfxv4UjmihfxPoyyzbfKQ6hEGk3AFcDdzkEYx1zWevhK/uPAk3hjUdRg8uOGKC0urWJ42CoqYZxvznepPysOMYIPNYifD6+0rw5q9mk8WoNfwxRW6Wlu0TW8qszLMZJ7iQth33nktxxk8U38TS2Euayv8zduPiT4Ug1KOzTWbOcm4+zzyxXMZjtX2O48xiw258thxnkYOK1rnxPoFnNJDd65psEsRUSJLdxqyFgSoIJ4yASPXBrldS+GtxczD7Dq8EEAKsI7ixMxLC1e3yW81c5D7umcjrzVJPhTf292bu112z+0+bFMr3FjPKqsrK7KE+1BApZQcKoPqx61Otxtu10dqPFfh5ghXXtMIkmWBCLyP5pGAZUHPLEEEDqQa1q8vi+EuqLYw2UviW0a1iihTyk0plDtEPldv35ywPPpye+CPUB71YK/UKKKKQwrm/hx/ySzwp/2BbP8A9EJXSVzfw4/5JZ4U/wCwLZ/+iEoA6SiiigDm7H/kqeu/9gXTf/R99XSVzdj/AMlT13/sC6b/AOj76ukoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5vxR/yMXgz/ALDUn/pvvK5Xxbrviaz8XXNppl1rkdoSgU2uhtcRopgkLMsggYEhxFwSeWIwe3VeKP8AkYvBn/Yak/8ATfeVleIviJdaPr93ptjoEt8tnErzXDPJHGhIDYLiJkAx0y2ScDGDuqJdrhdJXZyt9rXiDULOS01iz1u8tpLZ5TG+hSECXfA8ONkOcrmUeo288jNVr067Nb63Z6pP4lnE4lCsNDMpRPtvEaOLY7kaLBKksMegGK6l/iDfyXxtBp8cN3IHto41v1MInErIx8wwkgALkEjknaUBrM0v4r6m2k20f9hy6lcRWdq1xeuzwxNNKsTHLrCY1yJcjBySD8oGCaVpq66fje/9X9COWycW+qKllqPi+2Menw/2vptkt3Hb7LTQ0C2ieaygRYhKmMw7XLEHawwSudlR2vinxrHNtEviC7aPaFS58POiyuZJlwzCBQF2CFywIGT1xkV0cfxJ1WO+Ftf+HbaPbOYZHg1MyBdtwkDsMwrnBlUgcZG7pgZfp3jm91vxJY28MS2duNSe2bypRNHeQm2lkSQFo1ZTmMcD82BBpJc0Vrvrf7v6/wCGYaJtfL06/wBf8MXvAGuapfaWLbxPJKdUcvKiSWssTCIFRgl4IQSGbHC9Mctya5GHTtS0iO8g8OWWp2my7tHe9isHjnmDSsXjlBVlmIzlpkGCDhidpNbt78TbvT2vluNAVjDO8Fr5FzJMZ3WZYvmVISyj51Pyhz1GOMmwnj/U7jQbvVrbw9HHFbNBC1ve3rQziaQx7kZPKOwL5nUnJx90Dmi6mlKPl+a/4H9OwaJOm31/r+v8rnPaJqfxEu/scuo3N8i3U0lq8Udhg2rkIyyOZLaPKriUZAK42Dcx5NOfxJ8QkS5a4k1SGVHnMcFpo0k+GWNiiljahdpdUA2s/wB5vnPGNq4+JGo315FZ2tkthKL5IkkS4EqzbLuO3njcNGCgzJlSOSMH5fu1pWnxCv57H7VPoUMCQ3Qs7xvtcjLbShmDhiIfugBDuOFO/kjGTW6Ul6fl+rt+HYNIvXpv+On3f12n0bWvEk+oalusnuraO4Rg94ktoqQtuJES/Z98jqAMqcgnGHGSo48L4g0W1jh8O6PcWlhf3VxdfZ4dKyLrzLshluFMe6IC3IZc7TkbewU9r4c8XXOo6jBY3loYxObgrPLMW3Ok0imNCsSo2AnchsdQeWNOx1XV7/xhplw+rzQ6fdvfA6ekUPl7YG2KS5Qvk8scMB0HY5l2du39bjUtLef9fn/lY4fTtb8X6T4YsNNsm8RRPa2IZEHh2RgCLUFYiTARgSrt67sMcnoRv6r4h8ZbrwWK6usH2r5bqDSixjUxyGNFieEMRvCK5w+Ach1ydmpf/Ey5sJtTRtFhmFi67WgvHl86OUxi3kASEkhzI3ChiPLbG44FUj4k8SarqdvHYXVzpcmoEJHZ3lug+zO9pM4B3Rh8CSJW+YZ5ORjAFSvO77/8P/X4horL1/r07fgW/A2teJrrXpYPEbaowkjnJjuNLMUMDLIoUJIIlDZUtjLHIUEdyaMeo+MpzY51DUYRcXsthKWs4k42iQXEayQK+FVZAFKnJI5YDceus/Et1cWWssdNP2vTGZVtQz+ZMADtYjywRuxxtDg9ielcpcfEKYTXV+3hjTpr3T7B7yKYXr7ja7W8zDm3BU+ZGEKHHPJxipTTsvL89fy+aWvQUV07v/gW+/8AHTqYU+reLdU8J3Wm6ifEFyLq3HnSP4f+cM0Uo8oIYQpUsse44JG48qDlZjrfjVdHebSpdeEayyRQRSaLtaMrCrQpseAOY3csjOegVeV5at3VPH2rSrbW1nZxWN5HfQpeYu1cCNrpYdq7ovn3AnONpX1PGWwfFW8d7Nbjw/BGZ0gkkCagzFFnkMURGYhu+dTu6bQQfm5AFb4r76fdb+v61NNH/L+v9Ixj4o8aQ6pIrya+/l3Lbof+EfdotouUUKrrB8ymJpDuDE4RTnru6f4feIddu0ktvGRljv55WNvC1nMmwKoLrvMEaEAn5cF8j+N8ZrPi+Ldwmnx31/4fWG3kgWYeTemVvmtzOg2iIZ4RwfTjAOcDc8N+KdQ1bVrQX9lNZJqNrNKlpPEyNA0MioxBdUdkcOrDcgPHvgXFNe49/wCv8n/W5puu5yTah48tLpbaCbWJA1/Psd7BZA4N0RsdjHhIxAQ6NkAnIycBaii13xlthWe01i+1K1kkaF7vRVELZtH8tgyxgoxfAblQC5TJAzXReLvHV1oniKFLeP8A0Cwkf7cFkXzJ/wDRJZggQoTj5AdwYc5GDziqnxP1qWEyx+FI4ljjjklW7vZrdiHmMQKK9uGIzggsFyCfTmI/Dy/1/Whc9Hzvrr/wDtPDUzXGgwSSXeoXbkZaXUrT7NMT1wY/LTGOn3fxPWtWvNLv4s3dlpt1cT6BCJ4F3pAuoMfOCvMsoU+VwV+zuwyACOpU8Uy7+IuuxrdTR6ZZgxrem1T7YdkgheJQZR5W4H94T8rY9c5BF3u9PP8AAn4Ur/11PTqK4nQvGd/c3tnaalpywm6u7q3knNyZI45I5HURowhUN93gPsbGMbyGx21HS5Wza7BXN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJSA6SiiigDm7H/AJKnrv8A2BdN/wDR99XSVzdj/wAlT13/ALAum/8Ao++rpKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOb8Uf8jF4M/7DUn/pvvKqeMtP8G6itzD4gv8AS9Mv2tcPeO1stzHBuAOGlVsISdpyMfNjvVvxR/yMXgz/ALDUn/pvvKztZ+Hg1bxTd6v9ujCXVuYmgnilkCMYzGWVRKsfKnB3RsfRhUvfYCreX/w5ttSstNOn6DeMbZ1aRFswlrbxP8xcsy4QOD8qg4IJxwcPaD4eXuqJaN4c0OciO3FtcNbWhjmjlLlPKYn5gDG52jnjIBqrJ8M9YuLaK2ufFMMsNuhFuTphDpidJo9zCXDhTGoORlvmJbJyFtfhjqVjOr2niG2jHmxTMDprE7klmlbb+++UFp2wMHaAo5p62v1v+v8Al/w+uk66/wBdF+v9d5bt/hSkrXQsvCl3dXSyzq0cVoWuCjAt+8bC7txH3mHP0ONOBvh3AV1G3PhiI27NMLlDbgxMG2s28dCGYgnPVsd6wYvhRfRWVzEPEMBmuYJ4XlbT3OfNSEMxBmyWzBuyTzuP1qzqfw1SXTNQ87W1t1a5+2ROY5Io7Xq0oJSVH2szMxw644GTg5Holb+tf8tQ1b2NnWND8Jabpl1qs3hbTbtJR+/MNjAzSrI4LElsBgSdx55x3NRz2Pw7Z7mO5tfDBa2MdrcLJHb5iI/1cTA9MYG1T6cU23sX1vwVdaJpetaQwhEdvBPaI06RRhEYB083O4jkfP0Knnvkf8KruFeWSHXUSUM32Sb7Gwkt0eRpGyyyje2XYAn5dpIZXycvaSXT+v6/rVXk436/1c6Y6X4Q1CS/ufsWiXMkcoN7N5MLlJI+hkODhl7buRWPBqfhO4vNK0KN7XxRcXrNfpOXtZsYbm4PKjgjA8tSRt4HBqzF4QGoeH9esH1kTWmsFvKa1Q7bbOQcbnfcd3UDavGAo5ynh3wZqGh68NRm1e1uVkSY3MUdgYt8kjKxZD5pCD5F+Uhj97nniY35lfa342/zt/WqJXcdF/w3/DX/AK0cWh6p4At1m1O0t9E0O5t7iS1mMq28E0TmRkIYqeN7ISOfmxTf7N+H+parJBqcWiX1zNdyrb21+badg+f3ghU5YZfJZeu7PAzWPqHwm1O/S4gbxJax2t19o8+NNMYGQSySvhj5/IUy5AI6qp9q0tP8DeINJ1qXVbfXNMuJViuRbwyaZIih5fLOWYTnIBiXoBwT7YcdWr+f9fMuW9o9zYuE8M2N7c6Zq19YT3GpIkY068eAF4huCRJFgbl+9gEHvzxxk6JL8NpdPtvElrp3h3S3hZIxNNDbRTWkmMLGzLnY+MAAHp0qbxH4e1XXvF9oiqLfTlsx9puzDHIrusySCNMyBkOUB3bGGPQ4IyB8J78QQqfEFr5kMSxKRpZ2ONkqPuUzHOVmOORggdRkUk5Wv1/yb/r8fWetktP81f8AP+u3TWmqeB2F3bWdzoaC9vGtrmJTEv2m4AG5GH8b4xxyahhi8GK0ts+oaTPa3H/Evi06R7fyIwnLQJGAM88lTk/QACsVvhNgRxRa1i2UvG8clpvZoWeOTAbf8sgaMYfGMHG3IBpn/CtFvNcW7j16GZbG73NZBZzFCMxyKm1bkEMCqsA5ZACMIBimun4/1/W9vVXlrden9fd/W2tDafDC8s0jt7fwlPbST+WiolsyNK4B2gDgswAOOpAHpVeHV/hxHNp9lFD4eiuIoy9pbg2qmGGQtueM7tu0hWJCEnHUc1V0/wCGeqWM1q58QWmbYQhXh06SKTEbFiM/aCpDbuQysOAcZANPtPhtqVrc2Ux16zkMLQmZTpjYlEUsrgL+++XImIJO7oD7Uav7x62fp+P/AA34k4g+F+niGWz07wr5bq0xltorQCOMRsxk7ErtBGVBPPpkibRrP4f6s0X9h3ekXcDBRa2lnPEI4PLZZT5caY2ncUdu/wB3PGBVYfDOVNNtrGLWUEUEkwBe0LMIHheGOJT5gxsVzyc5PYVp+GPDMul63qF9MHRpIYoF3KoSR1ULJMiBmKhwkQwTn5PzafvN/cJ30TX9f1r/AMEkkvfAes6lFdS3Ph2/vcmOKZpIJZMqNxVTyeAScDoDms9bD4Vxaek0dp4QW0vkZEZYrXZcKh3MowMOARkgZwRmqD/C27lNhLLr0f2i0EgLxW00aktK0qOqLcAblZzgv5g4HyirWhfDq90KeWS31q1cXSSR3anT2+dWOSUJlJVtxYkndnIyMjNR71np3/r5/gU27/1/Wn9WCxh+Fsti17a6f4VisVESC6MNqkZMg3Knqp5+6wB54zWtaWHgXWL6eKwtfD1/dwq6TpDHBLJGG+RwwGSAdu0567cdq56b4XajOqGTxBa74oooo8aYShVbdoHDKZju3KxIxjaf7wyKt6F4E1rwzexzaZrGn3EaF08q4sHVjG8qM2XEpywVMA7cZ5xjir+2107/ANf1+se9yp21Oos/C+gafPHNp+h6bayxMzxvBaRoyM33iCBwT3PetSiig0Cub+HH/JLPCn/YFs//AEQldJXN/Dj/AJJZ4U/7Atn/AOiEoA6SiiigDm7H/kqeu/8AYF03/wBH31dJXDX3hrRfEXxO1pdc0mx1BodEsBC93aRzGHdNe5K71IHQducDNeTeE20S0s9S1LX/AA7peoQWFhJPJbXmh2UbTt55jR4DDCMx4BD7gSDjA9Z5lezE9Fc+kqK8MsdZ8IXHiWw0q8+E2i2Qu/JDyTWcUbxNIJsZjeBTjMJ5OMhgcDpVfTZ/C/iXxHoUdn4J8P6bC2rPZXcCWFrcJcRm1MyHf5QII4+6cdcFhg1aTbt/Xb9ROSSv8/wb/RnvdFeH6tq3gzTdV1myi+GHhu5bTWiEbLHB++DziE5xCQhBOcZPodp4rOn1DwzrOpeH7bSPAPh/TxLeW39oM1lbP8skssflKGh+YExElgUI4681MWpcrXV2/r+vxHKSjzX+zufQNFeO6o3hDTvHreG1+GnhqUeaIkuTBCpJa3eYEp5BwP3ZU8nqDz0rBn1TQLe3sdWufhb4bS3vNHbUILSL7OwdfMiX582gKsPM4wxU85HcOPvbf1o3+jBtLf8ArWx9AUV4ha6v4Kur3R7YfDHw4r6jdSWkmYrcmGRZJIwQBFllJjPJ29eNxBAWyn0S4s9BvJvhJ4VjttecxWbR7JCJOcK4+yjaCFYg5PTnFJO+wOSR7dRXiXi6y8O2nj3S9D0bwV4dhhjvYY72V9Ptv33mxSusYUwsQP3eS4IIPGDzVXSdR8KHw7aXF38NdBM1zbwNaNdQW4a7eSRI8lktwgVWfDMBkcfJ8wyRakrrvYG7O3lf9D3eivDodX8H3Fnc30Pwu8N/YrXTIr+V2ih35kZ0CBRAQfnQjduxtOfas3w7f6Ak6aXqnw50XVNRmvrxWaDS4mS2ijl2KN0dvgqpwC7BeOeTxQ2k7P8AqwN2V/61Vz6DoryPQLTw5qy+H5774X+F7Cz1yPzIp/Lik2ZTcqY+zgFyAxxkDA4JOQO4/wCFceCP+hN8P/8Agrg/+JqmmtwTTOkorm/+FceCP+hN8P8A/grg/wDiaP8AhXHgj/oTfD//AIK4P/iaQzpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaAOkorm/8AhXHgj/oTfD//AIK4P/iaP+FceCP+hN8P/wDgrg/+JoA6Siub/wCFceCP+hN8P/8Agrg/+Jo/4Vx4I/6E3w//AOCuD/4mgDpKK5v/AIVx4I/6E3w//wCCuD/4mj/hXHgj/oTfD/8A4K4P/iaADxR/yMXgz/sNSf8ApvvK4zxPBrGteNdb07wrf6gLy2hikcxayY4bctC+EMXmZDMwjIwoHBJIyQ3Z/wDCuPBH/Qm+H/8AwVwf/E0f8K48Ef8AQm+H/wDwVwf/ABNLqmB5zrMfiGxtdV1PX4tf0qzt455YJ319Y497Tq0S/JcddrMuGG3oOQBWi2k+Mrbyri3s9du7aV45Et01pWkgiWaQ7HZpgrMY5FGQzA7eWJVSe1/4Vx4I/wChN8P/APgrg/8AiaP+FceCP+hN8P8A/grg/wDiaXLol2Fbfz/rQ4zR7Dxhol7omoXmn69cQ2lgP7RhOqC5aeTy5N4KPOVLbxHt2jo3XsOg8W2viO68T6Pd6Na37WVsu+dbe8WNZQ2Q0ckbyKrYBBBwec8jGDp/8K48Ef8AQm+H/wDwVwf/ABNH/CuPBH/Qm+H/APwVwf8AxNOa59/68vQLWTXc86svD3juLSbSG00/UdI8uS2WcRzQPI/l20Ue4BLpAVDRtwzEEMPkboINdGqac2mWusXfiGxmu767lkgj1sedNEJlMSRD7WnJjO3apcjn92Thh6Z/wrjwR/0Jvh//AMFcH/xNH/CuPBH/AEJvh/8A8FcH/wATVN3lzP8Ar+rBbS39df8AMxPB9j4hg1GybxDp+tbI7by4nl1RHSAhn3ecomPmsylMMfMI/wBk5zgafDrurahqF54futUu7Wy1KVJQNZLrcbLtT5catL8u2LzVIbaDuXrgEd1/wrjwR/0Jvh//AMFcH/xNH/CuPBH/AEJvh/8A8FcH/wATU21T/rcLe7Y81lh13S7O3m8Ux+IrSVp7O0gjPiMJ9rcllkVNtzgsw28vtPBPBzVi40L4hWtmbcwa5fOyPia21pF2l44doy0yElXSTJx/FxkMQPQv+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mhK1/P/AIAuXX+vMw9Ct/EGh+KtRuryw1mXSpljggga/wDtYU+YqrIA8zMPlYlzx908HALYXjFNc1XxXr9h4PuNUnv7eCN2W11oRRwF4XG3ymlG1i3lsCAAME5GSG7n/hXHgj/oTfD/AP4K4P8A4mj/AIVx4I/6E3w//wCCuD/4mi2iXYpaNvv/AF/X3nDaxofjO2kuINJsvENzbSCRoWTXBvj3xwkKTJcA5WRJe5A3YXIJw7UPCHiS5uLhbOHXokt5Ls6fLLrrllLQR+WS3nlivmK4w2fvdMZx2/8AwrjwR/0Jvh//AMFcH/xNH/CuPBH/AEJvh/8A8FcH/wATR1uTyrQ5zQrfxdbeI1vL3TNXa0El05gn1CNwqMXaMLi4IZjlV2suFwMOoHzejg5AJGPY9q5v/hXHgj/oTfD/AP4K4P8A4mj/AIVx4I/6E3w//wCCuD/4mn0S7Dtq33Okorm/+FceCP8AoTfD/wD4K4P/AImj/hXHgj/oTfD/AP4K4P8A4mgZ0lFc3/wrjwR/0Jvh/wD8FcH/AMTR/wAK48Ef9Cb4f/8ABXB/8TQB0lFc3/wrjwR/0Jvh/wD8FcH/AMTR/wAK48Ef9Cb4f/8ABXB/8TQB0lFc3/wrjwR/0Jvh/wD8FcH/AMTR/wAK48Ef9Cb4f/8ABXB/8TQB0lc38OP+SWeFP+wLZ/8AohKP+FceCP8AoTfD/wD4K4P/AImj4cf8ks8Kf9gWz/8ARCUAdJRRRQBwepwa1P8AEjXf7EubCNRoVj58N5p7XRnHnXuFUCaIDuOSQcjpjnldIia707SJI9O8LadZ3dvdTIbnwnHGlki4WXzAL47N2QDjOejYr0Kx/wCSp67/ANgXTf8A0ffVnz/DtJrbXbddTkSLUmL2qrGV+xFn8x8FWBO6QbjgqRwAQeal3u7dv6/P8A7HLiy0K31CzceIvhdFeKqC0b+wUEgBGUCf6ZnGCMY9eKujSbXSXsrwa58ObJjIfsc//CPiMl1wh8tvtg5HC8cjpVhPh9faV4c1ezSeLUGv4YordLS3aJreVWZlmMk9xIWw77zyW44yeK6HUfCl1cLo0em6otlHpkUke5rcyyMWiMYZW3gKRknkNk1TbSbX9f1/XUmN9L/1/X9dDkJrLTdQUPceIvhrdLqO5w0mgq4ucNljzefPhhknnkVesfBDX9nY3emyeAbm2hG+ymt/Cu9I/m3ZjYXWB83OR3pIPhTcpDJBNrkJhltrqFxDYvG+6fyyzh/OJGGiB9Tk855rsPCug/8ACN+H4tOaWOZ1d5HljEoDs7Fif3skj5JOTlzz6dKcbJf15hq90c/eeC9Z1HUl1HUJvB11eqmxbmfws7yBcEY3G6zjk8e5qCX4e39xDFDOngiWKGLyY0fwkxVI87tgBuuFzzjpmu/opFdbnAwfD/ULZY1tl8EQrH9wR+E2ULznjF1xzz9afD4M8T2stgtjrvh2zsrAs0On23hto4A5z8+Bc5BG5uhA+YkgnBHd0UCsjh9Q8Fazq1/HfarN4NvbuIAR3Fz4WeSRAOQAzXRIqC3+H1/aW81vap4IghuI/Kmjj8JMqyJnO1gLrBGecGu/ooGcQvg3XEaYpceD1M8AtpSPC7jzIgMCNv8AS+VA/hPFVovh3e28cccEfgeJImZ41TwkwCMwwxAF1wSAAT3Ar0CigDibfwfrtpJavaXPhCB7NCls0fhd1MCnPCYu/lHJ4Hqa0vsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDm/sPjf/AKGHw/8A+CGf/wCTKPsPjf8A6GHw/wD+CGf/AOTK6SigDidUufG+m6jo1r/bfh+X+1L1rTd/Yk48rFvNNux9r5/1O3HH3s9sGHWNY8U6HqmlafeeINEM2qzmGEx+H5iEIH3nJvRgZKrnnlgK2PFH/IxeDP8AsNSf+m+8rO8UeArvxLqkt8+tC2lh8g6aEimC2zRyCRjIqzKs24gdQNuBjnJJ1Xbr6A9nbcjm1vWLe9ls7jx94NiuoTiWB9MdXj+Utypvcj5QW57AmorbxFql5I0dt4/8HSMLgWwA0qT5pSoYIv8ApvzEg54z+hqxJ4F1NtOezj1y1RFv5L6Bv7OJKNLv8wN+9+YfvX29CPlzuxzlp8JZyth9p1uGc2ku4r9mmiSVSsIYER3CknMCkZJUZ5VsA0R1euwpX+z5/rb9DRu9a1jT7qa2v/H3g22uIF3zRTaY6PGvHLA3uQPmHJ9R60069qoFyT8QPBY+yKXuP+Ja/wC5UHBL/wCm/KM8ZPepfEXgC68QXupTtq8cC3T27wIlvKrRGIMMO8cyMwYO33ShHHJ5zmx/C7UoZMW/iCzt4fnURxabIDsbyMoWNwSVxbhTzkhjzUpye43ui7Dq/ieX+0XbxL4fittPiSZ7t9EfyZImTeJFYXx+XAPJx09OazdL8aazqulG9i8W+GIm2rIttLpy+a0bMFR8DUCAGJAG4g54wDxW74a8F6h4c0m7sU1e1nWSyitLZvsDJ5XloVDMPNO/rnA29OtYcvwr1aZklk8TWz3EdmLSN30xyqIBFwF8/gZhzjPV2PPGK+010/4f/gfiT71l31/S36/cWrHxNrl4Jln8YeGLCeC4e3kt7vSWSQMruoOBfHhvLYj1APoatWmsa1qElvHYePPB1y9zu8hYdMdzLt+9tAvfmx3x0qnN8N9Ya6kuoPEdlHPJc/aG3aUzJxO0yjHng8GRweefl6YOVt/hld2Vxo15b6tbzXek2Edqomt51ikeIP5UmxJ1APznO4P3xtzRHa7/AK0/zKl8TUduhYutX8T2PiS30W98TeHrae6h823kl0V1SY7tvlrm+3F++MdPxpya3rEkUcsfj7wa8ck5t0ddMchpR1jB+28sP7vWrPiLwdqWv6laXy6pZ2kkMESMjWLTfOk8cxKt5i4BMYGMd85rnl+DkwukuptfS5nE/mymW3nVZvliBLiO4UsxMKNySuc/KeMJXtr5/np+Au/9dP8AM1rXXtVvpFSy+IHgu5d87Vh013LYXccYvey8/Tmq48W3bXVpbr8RvBTSXqk22NNcibDbcKftuCdxxgcnn0NVrL4W61aSwP8A8JNYhoBGEkh0hkdQiTKCCZyN379jnGMgcdasWnwvurS2dI9bgEjhm3CwbHmGWKUNgykkb4uQTkhuoIyWvi12E72Vh1x4p1KFoY08feDJp7hkWGBLDDy7m2jaGvxnv05ODjJ4rT0+fxPq0DzaV4w8LXsUbmN5LbR5ZFVx1Ulbw4I9Kx4fhlrEcF6j+JLJmuPs/luNKYGPyrlrgZ/f/NkuR24x+Ox4R8I6p4Uup92qW2oQXsnnXbvbOkzSCNEDBjIwJOzLZ7njHShba/1t/wAEf9f18yg3iTUEiklb4i+CVjjYI7nT2wjHOAT9t4Pyn8j6USeItTiZVfx/4O3NcraYXSpGImbpGcXvDH0NUtJ8C61eOt9fXEWmSwanLPDbTWiysYTdNP8AM6TYJbK4PG0ZG09asWfwqNpcJKNZ3mF41gza8iFWlO1zvy7/AL5hv46D5Tzmbu23/Daf8H+tx3u0um3n/X4/k6TxNqsUke7x54N8lw+Z/wCz8IhRlUg5vs53MBwDg8HBIzMNe1VohIPiB4LMbAEMNNfBBUsDn7b3VWb6AntWPH8Hr22gt4rPxBaJ5RYSPNYzztMuYcbjJdHBAt1HGFx0UVcm+GWrtskh8R2cc4be5OlMyMQ87DC+eCBi4cdecKeOQXK6Xu6sFfqSQ+KtSn8+SPx/4MNrA0aPdiwzF5jk4jyL/Ib5ehAzkYzzjU1C48TaRbLcar4x8K2MDNtWW50eWNScE4y14BnAJ/CsfUPhfqOo6c9jL4igSCWxgs5Uj09gJBFHImSPO5GZNwHQFV610GoeHtY1TQ7Wzn1CwintL6OeOUWbujxxnKqUMgIbgZO4j2py0vy9/wAP61Em7JtdPx6GZca5q9owW68f+DISY0lAk011+RzhG5vehJAB71Uh8V6xNq0lj/wmfhaMLapdxXL6S3k3ETbzujb7d8wURsTxwOelY958KtT0exFzp10usXiJbRJEsLx7GQxKZFV7kRbdkSkqVLEjAYDAGq/wv1NZnntNfso5pdruZtKZwH3zuxUCZcAm4bA5wAOTyaUttP6/r+vKu/8AXb/g/wBb2v8AhJNR8oyL8Q/BbqIXnymmu2Y0zucAXvIGDk9sU208S6veRiWLxz4QEMkyQQStpp2zu6B1VcX2d2GHykA+2MGon+FLTtCLnWlaNbeNJFS0wTKlu9uroS52JtfJTnJGcjnNvTfAWq6Z4nGtxa7ZvMQEaNtMbaUMUUbAfvshj5CEHtlgQc8UrczT2/4P9fn5E3dlp/Xb+v8Agmt9h8b/APQw+H//AAQz/wDyZR8OP+SWeFP+wLZ/+iErpK5v4cf8ks8Kf9gWz/8ARCUijpKKKKAObsf+Sp67/wBgXTf/AEffV0lc3Y/8lT13/sC6b/6Pvq6SgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDm/FH/IxeDP+w1J/wCm+8rD8Yaj4ntNZv20m8vYrS1shdqIbVDGfLKs8bPJERuddwBWQ44+UbSW3PFH/IxeDP8AsNSf+m+8rF8X+No9K1O6sdX8PQX+n2pjkEhl8xjJ5UkyERGM8gwtyCSPlIB6CW7NP+v6/MfkY97rfjbTdWaOGTVr+XyVK250kNb+Y9vK+POSEDCyCJc7v4jn2y9PvvFVnc38Ph/+3yzJd3v+laELdbqYrCU3FoFUMf3vyqVyVGeTz1tt8Q9TvLG4mh8OCCaysHvbuG+uZLdgA0ioI1aHewbyicsqYDLwTxUUXxOvG1E2cnh5TKMxbbe8aVjP9n+0Ku3ygShTjeATuyAp4Je0m+yf3f8ADr8vIh7RT/4f+k/61Ofm8SeNIHtwLjxA8TsBC/8Awj5ZpY/tCDdKFg/dt5ZlOPk+4pwM/Ne0HxZ4pTXoJdfN7FosFs3nS3WlTxtNjI3lVtsK2QDy6gg8IeDWva/EC5k8+5awRoFmgjdhcu0UCupLMxEAZSGG0hxgHqV6V3tEdFbtf+vx/rpCtLVP+v6R51421LWLLxjaJpUmrwxTQwq89joxuhGplIf955L4+XnBPVVOOuedk1z4gjTTe2kmqrcXItd63OmyBLf9wdxEa20j4MoIZQucY5TIavZ6KIrlVvO/43saNXlc8ts9W8XTWttJJea3I91dXcJiOliFolDMIX+a2AC7QDlmUknjcflrJiufEu6INdeJcJaoZpTouXmf7G/yuTb/ALwCQYwc4JweSK9oopON4tdwt7yl2PGrvVNe1CQW97puryaYsdlJDbPosmIZY5bdi6bYQV4aT5SWxsPToNzxPr3iuw8WXkWhjVLmEIq29t/ZTNblmt5TnzhF2kWIffwN5B9vSaKp6q3r+IQXL5/1/XzPG7DX/GVzdQ22oXmoXLyRxO9iNKJR4mmdZPOL20TqfLBIOFDMoC5yQYfDt/4nh0vSND+1eJLCKK1UO6aAf3ai1B8vc9uy8SLt55O4g54x7Cum2Kam+pLZW63zxiJ7oRL5rIDkKXxkjPOM4qzSavFx7/8AB/zDrc8a0O68SxCze4XVkPmDyIp9DYw2Y/s8AMirBmMCXcuFx3GOeewtPEN/d/D3UGH9pRa7a2TuVayLT7zv8tlTyVD528DywcdVB4rtaKc7yT8xQXK097Hjl5rvj+C8kiS61X7L5Fu0Uo0hpJpN5jLNtW02KwLSKQzAgAfICNxj1XW/E+p2MljdWuuXlhJp91bXMVxob4uW2zeXJgQAq3yRjAOCXHyjqfZ6KTVxxvFp32t+Fv8AI898R6xrdpqWhW2iXOoRm605pVs47EPvkR4QBJuQtGpEjBiSuMDoevOzeJfGYuZhLe69bedcS/YoBo6PIf3bFYj+5G5Q6YLDACvy2MPXrb6bYyalHqMllbtfRRmOO6aJTKiHqofGQD6Ulxplhd31te3VjbTXVoWNvPJCrPDuGG2MRlcjrjrTev4/i7/8D+tZjHltbpb8EeO6g11d6nqB1PRNTnuEiukaRNBmIZvPt3iAZIsSY2uVYZOFznudKLXPGN/4sGnm68QWFjdX5CTLowP2eHbMMGRrfYBuWEgtnh+rAZr1qkZVdCrqGVhggjIIpW91LsrfqNRs277nMeBJtcudKnk8RXclxPFO1qpZI1DmJijSgIoxvYE45wAOnNdRUVraW9jaRWtjbxW1vCoSOGFAiIo6AKOAPapap7jWgUUUUhhXN/Dj/klnhT/sC2f/AKISukrm/hx/ySzwp/2BbP8A9EJQB0lFFFAHDXseuv8AE7WX8P3tjbFNEsDKl3YNcmX99e7QuJogvfqTnI6Y5wvD3j7xHr9wI5NS0/SVe2kuo5dQ0EiN4432Odyag4XDf3se2a3b7XbfRvidrQuI75nn0SwEbWmmXF4FImveWEKNjqOpGecdDjz6w8JafYaLf6fBqutRLqkLx37QeDNSj8595eOUDBKupJBOTuXA4IzU3d/l+Ov9f1dD20O9i8RalPex2cHxD8FSXUqCSOBNOYu6bd24KL3JGOc+nNFv4i1G8ERtPiJ4JnE0vkxGLT2bzJMZ2Li95bHOBzXnmk6Ylr41ANvrttpNjHaypcDwvqL/AGueNpWO0uXkRd0uSG3buQCK0m8PaVLoehadNqOvZ0yJreaSPwfqA8+MzJN8oKHy33RqN2W78dMUt/K/4d/69fIi8u3T8f6/y8zov+E31JfEt7os3jXwtDJYxo81xJpREIZ2KiLd9uyJMj7pA7VZv/FeoabpzXtx4/8AB7RC1a7QR6W7NLEvVkAvfmHGMjvXDN4SsvOuWj1jWlRvK+zBvBWolozHdG4UucDzOWZTgLkY6Y5s2HhyxsfDOoaIusa80Go6YtjcN/wht+DvUMEkX5OBhuV5yRkEcipV3DXf/h/+B/Wpf2/L/hv+D/W/UW3ji8uLiWGT4g+C7do1DqJrNcyIUD7go1AkAA87gOhPTmtqG78SXIujb+M/Ckosji62aRI3kcZ+fF78vHPPauI/sjTZtbbU7zUNfMrX8F2Rb+EdRiyqQeS8RJRvlcdfT3q54dstA8PHxCUTWrw6y0mPtPhbVHCI7O/lupG1lDSN91Uzk5yTmqe2nb8dP+D93oTG+l/L9b/15m+PEWot934ieCT8objT26EkA/8AH70JBH4Gq58XagNQ+yf8J94PyLQ3jS/2W/lrEG27i323HXP5VzsEemPqtkt9aeIrprHTri2e8ufC9+be681spGYtpdhGC33znn7xJJFLUfDVhqVsUn1jxD5htIoDIPCWpghorgzRkEAOFG7bjcWIAO/PNLW/z/DX/gf1qPW33fpf9TtJ/FF7azGK5+JHgeGQEApJYMrDIBHBvu4YfmPWtC8ufEunyW0eoeMvCtq92/l26z6RIhmb+6gN78x9hXlWp+BrK9MkdpqupWdo0YjSD/hB9Ul8sC2+z4DM2SAuSM5IOOTXUeKILDxLHoiNe63bf2WkYcjwdft5zJJG+c+WGVf3X3ckcg9VBqtLr1X3dRa2+X49DfPiLVPsV3dx+P8AwZLDZruuGTTmIi5IG4/bsLkgjkjkVmHxzrsfhPRvEdzr+jW2matKkaTT6GyC33Zw0pN/gLx1BbqK5K18IWlrfXV2us6uZZJhPCP+EI1EKri4ef5xj5xmRlx8vAXnjnfSC1g+H+ieHbe/1hbrR50mjvH8G6iySbCxAMW0Ho397tUe9y363X3dRu/M0ttf+AdGfEGprM8TfELwUJI4vOdDpzZVNu7eR9t4XaQc9MHNSNrOsrKYm8e+DhILf7UUOmPkQ4z5uPtv3MfxdK4dfDejpoOp6Sl/4gWG7tLO3glXwlqKywtbncGLBBuBbJwNuOx70WvhzR7TUre5SbVGgt7V7ZbJ/BmptEVeII24kF26ZG5iQOM4Aw3dXt/W/wDwAV9L/wBbf8E7Ox1/XNT159I07xn4XurtLVbsiHRpHBjZioIIveeR+GR6isu18eate6/c6VaeK/Dcr29wlu040seUzMjOdpOoZbbtIKgbge2Mmo/D7WOj6pc3l1e+IL03emRWMw/4RTUUbMbOQ6sYycYkIwcngEsTnPLad4Tg0+6tT/bGpT21rJA6wyeBNSy4hieJFY9DlXO7jk9MdKHe+n9a/wCX5i1t/XZfrc9DXXtVdLd0+IHgtkuldoGGmuRKE+8V/wBN+YDvjpWbrPjm/wBH0A6uPHHhO/t/NWFFstMMjSuSPlTN+AxAYMQDnHOK5+XQ7CW4s5X1XX/3G3cn/CIaiVASV5YlTK5RQXwcliwAGR1qHU/Den33hnRdMt9T1qCbTNPbT3mfwXqLpKhdH3BNo2NmNedx6nj0a137/hr/AMBfO/Qbvey/r+v6sdvc+IdTsvM+2/EHwXbGKXyZBNpzJ5cmN2xs3vDY5x1xVywuPE2qiU6X4x8K3ohbZL9n0eSTY3odt6cHjpXnum+GtJ0zV47+G81p3XVl1FjJ4S1VmdQZG8rn5FAaZyCqjGeQx5rsvD2u6dolxqTuNakivLjzo7eDwpqMSQZ+9gGNsliSTjAz0AySRba/1t/wfuFrf+vP/gfebn2Hxv8A9DD4f/8ABDP/APJlH2Hxv/0MPh//AMEM/wD8mUf8J5pH/Pn4g/8ACc1D/wCMUf8ACeaR/wA+fiD/AMJzUP8A4xQUH2Hxv/0MPh//AMEM/wD8mUfYfG//AEMPh/8A8EM//wAmUf8ACeaR/wA+fiD/AMJzUP8A4xR/wnmkf8+fiD/wnNQ/+MUAUb/w54x1G90y6n8SaGr6bdNdQhNCmAZjDJDhs3fI2yseMcgfQ17vwPq9/ftfX0ngy5u2ILXE3hV3kOBgZY3WeASPoa0ZfiLoMEkMc8WuRvcOY4Vfw9fgyNtLbVBh5O1WOB2UntUv/CeaR/z5+IP/AAnNQ/8AjFAGI/w9v5LWG2kTwQ0ECMkUTeEmKxqxywUfasAE8kDrU48Ga0JBIJ/BwcW4tQ3/AAiz5EI/5Z5+1/c/2elan/CeaR/z5+IP/Cc1D/4xR/wnmkf8+fiD/wAJzUP/AIxQBix/D/UImBiXwShBjIK+E2GCn3D/AMfX8Pb07VrQ6V4ytovLt9c8ORJkttTw/MoyTknAvO5JP41J/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR9h8b/8AQw+H/wDwQz//ACZR/wAJ5pH/AD5+IP8AwnNQ/wDjFH/CeaR/z5+IP/Cc1D/4xQAfYfG//Qw+H/8AwQz/APyZR8OP+SWeFP8AsC2f/ohKP+E80j/nz8Qf+E5qH/xij4cf8ks8Kf8AYFs//RCUAdJRRRQBzFvDHcfEzxBDPGskUmh6cjo4yGBmvgQR6VxdpoOo6Fpd1Do+h+XdeForiHS5vs3+uWaUMGjO1izLGMHCtlj0J4rodQ0ey1P4l63NqEuoxra6HYOPsOo3FqSPOvSc+S67vu8ZzjnGMmuR0q50o6LZa/4h8RPYWGoQPeQ6efEmpJdiBVY/Lm6PmtkDOFXHI5qHu9en+dv1t8w3svP+v0LlpqnjW60jVL6fWtWgn0u2iuRCdKWGG6ALGRA89rGxYooGRtwzE4xgDotZu/ENnB4fjW71dp5UmlvRY2Mcu4iMusZcwsifNhATtyD3PI4geJfhxrgsYLiDxXdW9zJGweTXbqaKGQTiNSxF0eQ5UgrnqCDwcXdP8T+CtYEI0RPGWovPemyjjt/EVzkv5ZkUnddgAFVY8kEYIYKatrmWnf8Ar8X/AFqSrLrt/wAP+jJLXXPH0lsiCfWJLmK1vJV8zSBEtwymMwq7G3AB2tIOApJQcZ4PoPgi61W88J2s2vuZL1mcMzQyRMV3nbuV4oju24yfLUE8gYrzafVNHuvFFjpGknxJA41WOxvkv9dvwxR0lIePbdfKcxHhhnHbkGoPFmsaZo/iaTTdLPiOW3sorn7dctrd9IFljgEwWMfbE3EAgsDgEHAYGkpLl/rprf8AFILPmtf+ndfo/ke30V5I+qeF4LWV5IfGUkkbxRKieILtWuGdC/yKbvIAVWOWwMDgt3jj1vwnPY3t3bW/jSS2tZIYUnHiC62zyzBDEiD7XklhKp5Cgc5Ip97f1/w9x8ysn3PX6K8G0jxr4VTSbJPEUviQavNaTXUkFp4gvVACGXCgPd53FYm7lQRgsMrnsNFg0LWdUt7A2fjKxluLQXaG78R3QBjOcH5btiTwM4BxuGcE4p27f1v/AJMXMlv/AF/Vz0mivIL7XvB+n3mo2s0HjZptPuIYHRddvA0nmyGNWUG6B27l74JBBAIINUW13QtT1nw3a+HP+EleDU7iFbuW516/AgSVJGVMi6yJP3ZPRlxnnpSXvWt1aX3jk+W9+mv3HttFeVavqHg/Q9evdK1F/F8ctnatc+Z/b19smC7cqn+k5J+dQCQFJyM5Bxzmn+LNGttPkk8SWHi4XH2m6RUs9eu/3ccU6xAOGvT8+ZEztJBzxSTT2G9N/T9T3iivFH8S+Fowt2Y/GRtGtRJ5A1q780P9p+zkbvtuOH4Ix7hj0qSHX/DM1xJKieMHtvskUywjW7tXUtK8RLSG92gBkIIIAGOGbIFNa29bCutfL+v1PZ6K8es9Q0ubXrjTZdJ8ZyM2pS2No0HiS5IYxxqzlibwY6sc4xjA61Wu/EGgMyw6Tp/jKe7XU47CSCXxDdo/zIz7gGuwOVQ4DFSD1AqeZWT72/G3+aC618r/AIX/AMme1UV4lp/ivwfLoyXVy/i+dls2nkli1u8jVnWIytEFN4xD7BuxuI/2s8Vu2c/hW+8I3niCIeMFgspvJmgfX70Sg/Lz/wAfO0DDAklgAM5xg1T0bXb/AIYL7eZ6hRXidzrWj2uuLZtH4oaNr9IJN2vXim3iNqZy24XjBzgZyAOMjBIGdaw1PwXqnhB/ENhc+KZ4BdLZrbx+I7xpXmZlCIMXWznevJYAZ5xg0b/h+NrfmHMtP67/AOR6tRXkOp654Q0ia+ivofGaPYwPJKF8QXbAuiI8kQIu8F1WRSf4TzgkisnW/FGgjR4JfDsfil717oRyxXmu3223QXCwuXxdjqWwu0tz1GM0LVpLr+oNpK7PdKK8Em8S6eijy7fxU8SQzyXFwNZu/wBxsuhCAYzqAyBhgSrEklSABkVtXXiLwZatcjZ40m8idIUMWvXh8/dMYd6ZuhlRIpU5we4BHNK6svP/AIYG0m0+h3vij/kYvBn/AGGpP/TfeVyXjPVvEGm+MLr+x/7YhhdIVaex0M3OR5Nwdu8QNuAk8rucFz0BNLoFt4R8YX9itrB4qJFsuoW9xda/dgR7gU+X/SS27DMpKgjDEbuTXWf8IHpH/P54g/8ACj1D/wCP05Rew00zgJPFHjBikUd7raXbiZreFtFCm4fy4HRSrQgiMSPIhbIwOrZw1WG1Px9d6ygmfVreGK/H2iKKwURx4eQIiP5ZMkLL5ZZsnBJyy9B1svwx8NT6hBfzjWJLy3VlhuX16+MkQb7wVjNkA98datf8IHpH/P54g/8ACj1D/wCP0mr28v6/r+rzyu1r/wBf1/Xbzqz8T+P0a3k1STV1++7w22iSyjIeDEbsbROMNNynG0D5iRuOrfa940XTrN7CTUvtcl4y3y3OlyCO1I+6kfl2ztJEcH5ue37xK7D/AIQPSP8An88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8fp9v663/AOB/Tucp0EEy3EIkQOBkjDxshyDg8MAe3Xv1qSub/wCED0j/AJ/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/H6CjpKK5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfoA6Siub/AOED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH6AOkorm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+gDpKK5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfoA6Siub/AOED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH6AOkorm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+gDpKK5v8A4QPSP+fzxB/4Ueof/H6P+ED0j/n88Qf+FHqH/wAfoA6Siub/AOED0j/n88Qf+FHqH/x+j/hA9I/5/PEH/hR6h/8AH6AOkorm/wDhA9I/5/PEH/hR6h/8fo/4QPSP+fzxB/4Ueof/AB+gDpK5v4cf8ks8Kf8AYFs//RCUf8IHpH/P54g/8KPUP/j9Hw4/5JZ4U/7Atn/6ISgDpKKKKAOGvrrWrT4na0+iabY3yjRLAzi7vZICoE17jaEhlL55446DGc8cv4XEGvSXf9heFNFkDQsXtbrWtQijSObKs0UM1mFVWwwJjUA4IzXUX3iTRvD/AMTta/tnV9N0559EsPs4v7xLcSlZr3OCx7ZGcA4yK8/sJNKs/Ddzpb+KvA1yNRijS8+0+IFm2BJCTGheM5jZScAgeWxJAOeIe706f18g7ep083w8vLiSzkuPCOlytYoiQGTxlqLbFR96jmDkBgCAc4wPQVbtfCOrWX2EWvhPR0TT7lrq0j/4Sy+KQSMCDtU22AuCRtxt5PHNecLo2iSaHJb3Pi3wQl2Ht186DXoS9zFHD5RV3kgfYchHHyvyo5BAavZLP4g+Crexghk8aaCzRxqjFtXhYkgY5ORn64H0rTv6/wDBuTbW1un/AALf10OZt/AF3aapDqNt4M0SO6hmFwjDxZfYEgLkMV+z7TjzH6joxHSjWPAF5r2pz6hqXg7RmubjPmtD4tv4FfcgRiVjt1XJUBSccgYNdZ/wsfwR/wBDl4f/APBpB/8AFUf8LH8Ef9Dl4f8A/BpB/wDFVNkV1ucxceCdRuoWjuvCGjTArGgeTxZfM8apnaEc225ANzDCkZDHOc09fB2pJp17Yp4N0Fba+ljmmjXxPeDDxhQjIfs2YyoVcbNuNo9K6T/hY/gj/ocvD/8A4NIP/iqP+Fj+CP8AocvD/wD4NIP/AIqmKyOSt/h9eWlq9vbeD9IiiktntJFXxhqA8yJixKMfs+WGWYjOcZOMVr2+keJLW8srqLw1o5lsIfItvM8U3kixrtC8K1sV3YGNxG7rzzWt/wALH8Ef9Dl4f/8ABpB/8VR/wsfwR/0OXh//AMGkH/xVH9f197+8LL+v68l9xyE/w7uLhrln8FaIrXUgllaPxZfIWYSNKDlbcYw7MwxjBNOtvh7dWdzp9xa+DNFik04obYr4tvgFKbtpYfZ8ORuYZbPBI6cV1v8AwsfwR/0OXh//AMGkH/xVH/Cx/BH/AEOXh/8A8GkH/wAVQtNhvW7fU5m98FX+oapeajeeCvD8t1eq6TufE12A4ZVVuBa4HCJ0AxtBHPNZ8nwukljCSeDtMZQztz411LJLsrMSfIycsqsc9wDXbf8ACx/BH/Q5eH//AAaQf/FUf8LH8Ef9Dl4f/wDBpB/8VRa2wPXc4v8A4VlL5Ji/4Q7SyhTZg+M9ROB5gl4PkcfvBuz1zU1t8PbyziljtvCOlok0BtpB/wAJlqJ3xFmYocwcgl2JHfJrrv8AhY/gj/ocvD//AINIP/iqP+Fj+CP+hy8P/wDg0g/+KoA52Dwlq1tq6alb+EtFiuY53uE2eKr0RiRkCM3l/ZtnKgDGMVWh8A3dvEI7fwXocIEyTho/Fd6rLIgZVYMLbIwGYcHocV1f/Cx/BH/Q5eH/APwaQf8AxVH/AAsfwR/0OXh//wAGkH/xVKyYrJbHHw/DiWC3MEXgfQVja2a2K/8ACVXp+RlKn/l2+9tO3f8Ae28ZxxWhpvhfXNH0W60rTfDOl29pdyebNt8X35kZsAZEht944UDgiug/4WP4I/6HLw//AODSD/4qj/hY/gj/AKHLw/8A+DSD/wCKp738x9vI5WLwFdwSrJF4J0FWWVJVH/CUXuAyRGJePs2MeWdu3oR1Bq5/wjOtHwx/wjz+E9El0wEFYZfFN47R4IK7Ha2LpggY2kYxxit7/hY/gj/ocvD/AP4NIP8A4qj/AIWP4I/6HLw//wCDSD/4qgVkcveeBb3UJrqW78E6BI93AbeZv+EnvBuQhVPS24YhFBYfMQACTVN/hnLJaJbt4L0jYrtJuHjHUA7MzBzucQbm+ZQ2CTgjI5rtP+Fj+CP+hy8P/wDg0g/+Ko/4WP4I/wChy8P/APg0g/8AiqBnHN8N7hrQWx8G6T5W10OPGOoBnDyeYwZvs+Wy43ck81LcfD+6uhdeb4K0IG6lWaRo/FV6jblcuCpW2BQbyWwuAWOTzzXWf8LH8Ef9Dl4f/wDBpB/8VR/wsfwR/wBDl4f/APBpB/8AFUBY4+LTdb8I6t4bh0vwtosRlnk0+2WXxLeXCxIYJZmVd8GI8+SMsAxONuOdy6+p+Ote0e/Wz1DSdBjm2q77dYunWFWJCtI62RWNSQQC5AODUHiPx94Pn17wnJB4s0ORLfVpJJmTUoSI1+w3S7mIbgbmUZPdgO9ZXiDXtAvb3WotL8a+EDY6/bLb3b3OrxiS2wpQsijIkyp6EpgjOTnFJt3BJHYXGreM7W0luZvD2g+VEhdtmt3DnAGThVsyT9AM0lrrHjK9s4bq10Dw+8M8ayRt/bs43KwyDg2eehryh9P0BL/UJB428Jajb3F15nkX2uwiK5j/AHgVZEWLcGj3qVLPJnYoG0YxVt9P0qJxNeeKvBGozB4GMdx4jhWJljIyhAti54BUFmb5WICgHFF3+RMm1su57P8AbvG//QveH/8AwfT/APyHR9u8b/8AQveH/wDwfT//ACHXjX2PTW8N/wBlnxT4Bj/1EhkXX0YtPHEyCXJiyrbthyOSFxkAYPsafEbwSI13+MvD+7AzjVYTz/31VNbjTY77d43/AOhe8P8A/g+n/wDkOj7d43/6F7w//wCD6f8A+Q6P+Fj+CP8AocvD/wD4NIP/AIqj/hY/gj/ocvD/AP4NIP8A4qkMPt3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6P+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAD7d43/6F7w//wCD6f8A+Q6Pt3jf/oXvD/8A4Pp//kOj/hY/gj/ocvD/AP4NIP8A4qj/AIWP4I/6HLw//wCDSD/4qgA+3eN/+he8P/8Ag+n/APkOj7d43/6F7w//AOD6f/5Do/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KoAPt3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6P+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAD7d43/6F7w//wCD6f8A+Q6Pt3jf/oXvD/8A4Pp//kOj/hY/gj/ocvD/AP4NIP8A4qj/AIWP4I/6HLw//wCDSD/4qgA+3eN/+he8P/8Ag+n/APkOj7d43/6F7w//AOD6f/5Do/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KoAPt3jf/oXvD//AIPp/wD5Do+3eN/+he8P/wDg+n/+Q6P+Fj+CP+hy8P8A/g0g/wDiqP8AhY/gj/ocvD//AINIP/iqAD7d43/6F7w//wCD6f8A+Q6Pt3jf/oXvD/8A4Pp//kOj/hY/gj/ocvD/AP4NIP8A4qj/AIWP4I/6HLw//wCDSD/4qgA+3eN/+he8P/8Ag+n/APkOj7d43/6F7w//AOD6f/5Do/4WP4I/6HLw/wD+DSD/AOKo/wCFj+CP+hy8P/8Ag0g/+KoAPt3jf/oXvD//AIPp/wD5Do+HH/JLPCn/AGBbP/0QlH/Cx/BH/Q5eH/8AwaQf/FUfDj/klnhT/sC2f/ohKAOkooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==" /></p><p><br />* The frequency reflects data from long-term treatment with a high dose (150 mg/day). Clinical trial and<br />epidemiological data consistently point towards an increased risk of arterial thrombotic events (for example<br />myocardial infarction or stroke) associated with the use of diclofenac, particularly at high doses (150 mg daily)<br />and in long term treatment (see sections 4.3 and 4.4 for Contraindications and Special warnings and special<br />precautions for use).</p><p><br />Reporting of suspected adverse reactions<br />The National Pharmacovigilance Center (NPC):<br />Fax: +966-11-205-7662<br />Call NPC at +966-11-2038222, Ext 2317-2356-2340<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Symptoms<br />There is no typical clinical picture resulting from diclofenac over dosage. Over dosage can cause symptoms<br />such as headache, nausea, vomiting, epigastric pain, gastrointestinal bleeding, diarrhoea, dizziness,<br />disorientation, excitation, coma, drowsiness, tinnitus, fainting or convulsions. In the case of significant<br />poisoning acute renal failure and liver damage are possible.<br />Therapeutic measures<br />Management of acute poisoning with NSAIDs, including diclofenac, essentially consists of supportive measures<br />and symptomatic treatment. Supportive measures and symptomatic treatment should be given for complications<br />such as hypotension, renal failure, convulsions, gastrointestinal disorder, and respiratory depression.<br />Special measures such as forced diuresis, dialysis or haemo-perfusion are probably of no help in eliminating<br />NSAIDs, including diclofenac, due to high protein binding and extensive metabolism.<br />Activated charcoal may be considered after ingestion of a potentially toxic overdose, and gastric<br />decontamination (e.g. vomiting, gastric lavage) after ingestion of a potentially life threatening overdos</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group<br />Non-steroidal anti-inflammatory drugs (NSAlDs).<br />Mechanism of action<br />Rumafen is a non-steroidal agent with marked analgesic/anti-inflammatory properties. It is an inhibitor of<br />prostaglandin synthetase, (cyclo-oxygenase).<br />Diclofenac sodium in vitro does not suppress proteoglycan biosynthesis in cartilage at concentrations equivalent<br />to the concentrations reached in human beings.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Absorption<br />Absorption is complete but onset is delayed until passage through the stomach, which may be affected by food<br />which delays stomach emptying. The mean peak plasma diclofenac concentration reached at about 2 hours<br />(50mg dose produces 1511&plusmn; 466 ng/ml ).<br />Bioavailability:<br />About half of the administered diclofenac is metabolised during its first passage through the liver (&quot;first-pass&quot;<br />effect), the area under the concentrations curve (AUC) following oral administration is about half that following<br />an equivalent parenteral dose.<br />Pharmacokinetic behaviour does not change on repeated administration. Accumulation does not occur, provided<br />the recommended dosage intervals are observed.<br />Distribution<br />The active substance is 99.7% protein bound, mainly to albumin (99.4%).<br />Diclofenac enters the synovial fluid, where maximum concentrations are measured 2-4 hours after the peak<br />plasma values have been attained. The apparent half-life for elimination from the synovial fluid is 3-6 hours.<br />Two hours after reaching the peak plasma values, concentrations of the active substance are already higher in<br />the synovial fluid than they are in the plasma and remain higher for up to 12 hours.<br />Diclofenac was detected in a low concentration (100 ng/mL) in breast milk in one nursing mother. The<br />estimated amount ingested by an infant consuming breast milk is equivalent to a 0.03 mg/kg/day dose (see<br />section 4.6).<br />Metabolism<br />Biotransformation of diclofenac takes place partly by glucuronidation of the intact molecule, but mainly by<br />single and multiple hydroxylation and methoxylation, resulting in several phenolic metabolites, most of which<br />are converted to glucuronide conjugates. Two phenolic metabolites are biologically active, but to a much lesser<br />extent than diclofenac.<br />Elimination<br />The total systemic clearance of diclofenac in plasma is 263 &plusmn; 56 mL/min (mean value &plusmn; SD). The terminal halflife<br />in plasma is 1-2 hours. Four of the metabolites, including the two active ones, also have short plasma halflives<br />of 1-3 hours.<br />About 60% of the administered dose is excreted in the urine in the form of the glucuronide conjugate of the<br />intact molecule and as metabolites, most of which are also converted to glucuronide conjugates. Less than 1% is<br />excreted as unchanged substance. The rest of the dose is eliminated as metabolites through the bile in the faeces.<br />Characteristics in patients<br />Elderly: No relevant age-dependent differences in the drug&#39;s absorption, metabolism, or excretion have been<br />observed, other than the finding that in five elderly patients, a 15-minute iv infusion resulted in 50% higher<br />plasma concentrations than expected with young healthy subjects.<br />Patients with renal impairment: In patients suffering from renal impairment, no accumulation of the unchanged<br />active substance can be inferred from the single-dose kinetics when applying the usual dosage schedule. At a<br />creatinine clearance of&gt; 10ml/min the calculated steady-state plasma levels of the hydroxy metabolites are<br />about 4 times higher than in normal subjects. However, the metabolites are ultimately cleared through the bile.<br />Patients with hepatic disease: In patients with chronic hepatitis or non-decompensated cirrhosis, the kinetics<br />and metabolism of diclofenac are the same as in patients without liver disease.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None stated.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Core: -<br />Microcrystalline cellulose (PH101)<br />Lactose (100 MESH)<br />Maize starch<br />Povidone (K30)<br />Magnesium stearate<br />Enteric coat: -<br />Eudragit L30D-55 (Methacrylic acid copolymer)<br />Triethyl citrate<br />Titanium dioxide<br />Purified talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>None known.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Three years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30 &deg;C.<br />Store in original package in order to protect from light.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Each (transparent PVC-PVDC film/ Alu) blister contains 10 tablets</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder and Manufacturer
Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O.Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing
authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                10-2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>